DDI-MedLine.d79.s0|23-31|indinavir|drug
DDI-MedLine.d79.s0|34-54|IDV ) , didanosine does|brand
DDI-MedLine.d79.s0|40-49|didanosine|drug
DDI-MedLine.d79.s0|67-98|IDV exposure , despite persistent|brand
DDI-MedLine.d79.s1|29-37|indinavir|drug
DDI-MedLine.d79.s1|43-52|didanosine|drug
DDI-MedLine.d79.s1|101-109|indinavir|drug
DDI-MedLine.d79.s1|145-154|didanosine|drug
DDI-MedLine.d79.s1|171-179|indinavir|drug
DDI-MedLine.d79.s2|12-20|indinavir|drug
DDI-MedLine.d79.s2|51-52|pH|drug
DDI-MedLine.d79.s2|127-135|indinavir|drug
DDI-MedLine.d79.s2|160-168|indinavir|drug
DDI-MedLine.d79.s2|193-202|didanosine|drug
DDI-MedLine.d79.s3|15-16|pH|drug
DDI-MedLine.d79.s3|48-56|indinavir|drug
DDI-MedLine.d79.s3|74-83|didanosine|drug
DDI-MedLine.d79.s5|0-8|Indinavir|drug
DDI-MedLine.d79.s5|87-96|didanosine|drug
DDI-MedLine.d115.s0|12-27|cyclophosphamide|drug
DDI-MedLine.d115.s0|30-40|doxorubicin|drug
DDI-MedLine.d115.s0|43-53|vincristine|drug
DDI-MedLine.d115.s0|60-69|prednisone|drug
DDI-MedLine.d115.s1|0-30|BACKGROUND : The feasibility and|brand
DDI-MedLine.d115.s1|111-133|HAART ) is still unknown|brand
DDI-MedLine.d115.s1|182-207|HIV ) -related malignancies .|brand
DDI-MedLine.d115.s2|16-21|impact|drug
DDI-MedLine.d115.s2|44-71|HAART on the clinical course|brand
DDI-MedLine.d115.s2|135-155|HIV-NHL ) , the authors|brand
DDI-MedLine.d115.s2|210-238|HIV-NHL who were treated with|brand
DDI-MedLine.d115.s2|244-259|cyclophosphamide|drug
DDI-MedLine.d115.s2|262-272|doxorubicin|drug
DDI-MedLine.d115.s2|275-285|vincristine|drug
DDI-MedLine.d115.s2|292-301|prednisone|drug
DDI-MedLine.d115.s2|304-334|CHOP ) chemotherapy regimen plus|brand
DDI-MedLine.d115.s2|323-329|regimen|brand
DDI-MedLine.d115.s2|336-356|HAART with a group of|brand
DDI-MedLine.d115.s2|392-423|CHOP chemotherapy or a CHOP-like|brand
DDI-MedLine.d115.s2|425-431|regimen|brand
DDI-MedLine.d115.s2|440-455|cyclophosphamide|drug
DDI-MedLine.d115.s2|458-468|doxorubicin|drug
DDI-MedLine.d115.s2|471-480|teniposide|drug
DDI-MedLine.d115.s2|487-496|prednisone|drug
DDI-MedLine.d115.s2|503-513|vincristine|drug
DDI-MedLine.d115.s2|520-528|bleomycin|drug
DDI-MedLine.d115.s3|0-25|METHODS : All patients were|brand
DDI-MedLine.d115.s3|112-138|April 1988 to December 1998|drug
DDI-MedLine.d115.s4|0-34|HAART was included with combination|brand
DDI-MedLine.d115.s5|41-61|reverse transcriptase|drug
DDI-MedLine.d115.s5|82-89|protease|drug
DDI-MedLine.d115.s6|0-25|RESULTS : The two treatment|brand
DDI-MedLine.d115.s6|89-91|NHL|drug
DDI-MedLine.d115.s6|110-134|HIV status , and treatment|brand
DDI-MedLine.d115.s8|48-53|Health|brand
DDI-MedLine.d115.s8|133-169|CHOP-HAART compared with the patients|brand
DDI-MedLine.d115.s8|184-198|CHOP alone ( 33 %|brand
DDI-MedLine.d115.s8|222-232|P = 0.001 ) .|brand
DDI-MedLine.d115.s9|118-145|CHOP-HAART group than in the|brand
DDI-MedLine.d115.s9|147-153|control|brand
DDI-MedLine.d115.s9|189-198|P = 0.03 ) .|brand
DDI-MedLine.d115.s10|21-66|CHOP-HAART patients developed severe autonomic|brand
DDI-MedLine.d115.s10|91-94|none|brand
DDI-MedLine.d115.s10|103-141|CHOP patients developed neurotoxicity (|brand
DDI-MedLine.d115.s10|142-152|P = 0.002 ) .|brand
DDI-MedLine.d115.s11|54-76|OI ) rates and mortality|brand
DDI-MedLine.d115.s11|110-140|CHOP-HAART patients than in the|brand
DDI-MedLine.d115.s11|142-159|CHOP patients ( 18 %|brand
DDI-MedLine.d115.s11|184-196|P = 0.05 ; and|brand
DDI-MedLine.d115.s11|225-235|P = 0.001 ) .|brand
DDI-MedLine.d115.s12|24-58|CHOP-HAART patients was not reached|brand
DDI-MedLine.d115.s12|92-117|CHOP patients was 7 months|brand
DDI-MedLine.d115.s12|120-129|P = 0.03 ) .|brand
DDI-MedLine.d115.s13|0-30|CONCLUSIONS : The combination of|brand
DDI-MedLine.d115.s13|32-58|CHOP plus HAART is feasible|brand
DDI-MedLine.d115.s13|42-66|HAART is feasible and may|brand
DDI-MedLine.d115.s13|101-117|HIV-NHL patients .|brand
DDI-MedLine.d115.s15|4-9|impact|drug
DDI-MedLine.d115.s15|45-79|HAART treatment on patient survival|brand
DDI-MedLine.d141.s0|12-18|cadmium|drug
DDI-MedLine.d141.s0|24-27|zinc|drug
DDI-MedLine.d141.s1|16-22|cadmium|drug
DDI-MedLine.d141.s1|25-28|zinc|drug
DDI-MedLine.d141.s2|106-111|metals|group
DDI-MedLine.d141.s3|38-41|zinc|drug
DDI-MedLine.d141.s4|12-18|cadmium|drug
DDI-MedLine.d141.s4|24-27|zinc|drug
DDI-MedLine.d141.s7|109-110|P .|brand
DDI-MedLine.d111.s0|35-41|ethanol|drug
DDI-MedLine.d111.s0|61-71|therapeutic|brand
DDI-MedLine.d111.s0|88-92|serum|group
DDI-MedLine.d111.s1|40-46|ethanol|drug
DDI-MedLine.d111.s1|66-76|therapeutic|brand
DDI-MedLine.d111.s1|93-97|serum|group
DDI-MedLine.d111.s2|0-12|Acetaminophen|drug
DDI-MedLine.d111.s2|15-23|lidocaine|drug
DDI-MedLine.d111.s2|26-38|phenobarbital|drug
DDI-MedLine.d111.s2|41-49|quinidine|drug
DDI-MedLine.d111.s2|52-63|theophylline|drug
DDI-MedLine.d111.s2|70-77|valproic|brand
DDI-MedLine.d111.s2|111-115|serum|group
DDI-MedLine.d111.s2|120-130|therapeutic|brand
DDI-MedLine.d111.s3|87-97|therapeutic|brand
DDI-MedLine.d111.s4|70-97|acetaminophen/phenobarbital .|drug
DDI-MedLine.d111.s5|0-75|acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen|drug
DDI-MedLine.d111.s5|28-99|lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic|drug
DDI-MedLine.d111.s5|107-158|quinidine/lidocaine , theophylline/acetaminophen , and|drug
DDI-MedLine.d111.s5|160-167|valproic|brand
DDI-MedLine.d111.s6|5-9|serum|group
DDI-MedLine.d111.s6|55-59|serum|group
DDI-MedLine.d111.s6|143-151|phosphate|brand
DDI-MedLine.d111.s7|24-36|phenobarbital|drug
DDI-MedLine.d111.s7|39-47|quinidine|drug
DDI-MedLine.d111.s7|54-65|theophylline|drug
DDI-MedLine.d111.s7|82-92|therapeutic|brand
DDI-MedLine.d111.s7|112-116|serum|group
DDI-MedLine.d111.s7|127-133|ethanol|drug
DDI-MedLine.d111.s7|172-176|serum|group
DDI-MedLine.d111.s9|0-12|Acetaminophen|drug
DDI-MedLine.d111.s9|40-51|theophylline|drug
DDI-MedLine.d111.s9|62-66|serum|group
DDI-MedLine.d111.s9|136-146|FDF ] , 11.0 %|brand
DDI-MedLine.d111.s9|219-229|FDF , 13.7 % )|brand
DDI-MedLine.d111.s10|0-11|Theophylline|drug
DDI-MedLine.d111.s10|38-50|acetaminophen|drug
DDI-MedLine.d111.s10|100-109|FDF , 8.8 % )|brand
DDI-MedLine.d111.s11|0-12|phenobarbital|drug
DDI-MedLine.d111.s11|73-82|FDF , 8.5 % )|brand
DDI-MedLine.d111.s12|0-7|Valproic|brand
DDI-MedLine.d111.s12|36-48|phenobarbital|drug
DDI-MedLine.d111.s12|98-108|FDF , 21.2 % )|brand
DDI-MedLine.d111.s13|87-93|ethanol|drug
DDI-MedLine.d111.s14|15-27|acetaminophen|drug
DDI-MedLine.d111.s14|34-45|theophylline|drug
DDI-MedLine.d111.s14|48-60|phenobarbital|drug
DDI-MedLine.d111.s14|67-79|acetaminophen|drug
DDI-MedLine.d111.s14|86-93|valproic|brand
DDI-MedLine.d111.s14|105-117|phenobarbital|drug
DDI-MedLine.d64.s0|53-62|paroxetine|drug
DDI-MedLine.d102.s0|13-21|estradiol|drug
DDI-MedLine.d102.s0|27-38|progesterone|drug
DDI-MedLine.d102.s0|84-97|noradrenaline .|drug
DDI-MedLine.d102.s1|4-6|aim|brand
DDI-MedLine.d102.s1|78-86|estradiol|drug
DDI-MedLine.d102.s1|96-107|progesterone|drug
DDI-MedLine.d102.s1|128-162|noradrenaline in rat thoracic aorta|drug
DDI-MedLine.d102.s3|22-25|corn|drug
DDI-MedLine.d102.s3|45-53|estradiol|drug
DDI-MedLine.d102.s3|96-107|progesterone|drug
DDI-MedLine.d102.s4|145-158|noradrenaline .|drug
DDI-MedLine.d102.s5|70-78|estradiol|drug
DDI-MedLine.d102.s5|109-145|noradrenaline compared to the vehicle|drug
DDI-MedLine.d102.s5|178-186|estradiol|drug
DDI-MedLine.d102.s5|196-220|pD2 values = 7.86+/-0.09 ,|drug
DDI-MedLine.d102.s6|80-118|noradrenaline when compared to vehicle-|drug
DDI-MedLine.d102.s6|139-150|progesterone|drug
DDI-MedLine.d102.s6|183-207|pD2 values = 7.77+/-0.12 ,|drug
DDI-MedLine.d102.s7|48-78|pD2 values for noradrenaline in|drug
DDI-MedLine.d102.s7|63-99|noradrenaline in aortic rings without|drug
DDI-MedLine.d49.s0|15-25|clindamycin|drug
DDI-MedLine.d49.s0|31-40|gentamicin|drug
DDI-MedLine.d49.s1|41-51|clindamycin|drug
DDI-MedLine.d49.s1|57-66|gentamicin|drug
DDI-MedLine.d49.s2|191-201|clindamycin|drug
DDI-MedLine.d49.s3|0-9|Gentamicin|drug
DDI-MedLine.d49.s3|50-60|clindamycin|drug
DDI-MedLine.d49.s5|116-125|gentamicin|drug
DDI-MedLine.d49.s6|16-26|clindamycin|drug
DDI-MedLine.d49.s6|32-41|gentamicin|drug
DDI-MedLine.d49.s7|155-165|clindamycin|drug
DDI-MedLine.d49.s7|230-239|gentamicin|drug
DDI-MedLine.d49.s8|16-26|clindamycin|drug
DDI-MedLine.d49.s8|32-41|gentamicin|drug
DDI-MedLine.d216.s0|17-56|S-ketamine is unaffected by itraconazole|drug
DDI-MedLine.d216.s0|45-56|itraconazole|drug
DDI-MedLine.d216.s0|83-93|ticlopidine|drug
DDI-MedLine.d216.s1|51-85|S-ketamine with the cytochrome P450|drug
DDI-MedLine.d216.s1|71-85|cytochrome P450|drug
DDI-MedLine.d216.s1|88-117|CYP ) 2B6 inhibitor ticlopidine|brand
DDI-MedLine.d216.s1|93-125|2B6 inhibitor ticlopidine and the|drug
DDI-MedLine.d216.s1|107-117|ticlopidine|drug
DDI-MedLine.d216.s1|127-155|CYP3A inhibitor itraconazole .|drug
DDI-MedLine.d216.s1|143-154|itraconazole|drug
DDI-MedLine.d216.s2|87-126|S-ketamine after pretreatments with oral|drug
DDI-MedLine.d216.s2|128-138|ticlopidine|drug
DDI-MedLine.d216.s2|162-173|itraconazole|drug
DDI-MedLine.d216.s3|0-10|Ticlopidine|drug
DDI-MedLine.d216.s3|104-111|infinity|brand
DDI-MedLine.d216.s3|114-124|AUC ( 0- ) )|brand
DDI-MedLine.d216.s3|134-141|ketamine|drug
DDI-MedLine.d216.s3|164-175|itraconazole|drug
DDI-MedLine.d216.s3|220-230|S-ketamine .|drug
DDI-MedLine.d216.s4|13-34|norketamine AUC ( 0- )|drug
DDI-MedLine.d216.s4|25-37|AUC ( 0- ) to|brand
DDI-MedLine.d216.s4|39-46|ketamine|drug
DDI-MedLine.d216.s4|94-104|ticlopidine|drug
DDI-MedLine.d216.s4|107-119|P lt ; 0.001 )|brand
DDI-MedLine.d216.s4|110-111|lt|brand
DDI-MedLine.d216.s4|125-136|itraconazole|drug
DDI-MedLine.d216.s4|146-158|P = 0.006 ) as|brand
DDI-MedLine.d216.s5|7-17|ticlopidine|drug
DDI-MedLine.d216.s5|23-34|itraconazole|drug
DDI-MedLine.d216.s5|185-194|P < 0.05 ) .|brand
DDI-MedLine.d216.s6|40-70|S-ketamine should be reduced in|drug
DDI-MedLine.d216.s6|91-101|ticlopidine|drug
DDI-MedLine.d189.s0|11-39|CYP inhibitors on precocene I|brand
DDI-MedLine.d189.s0|39-66|I metabolism and toxicity in|brand
DDI-MedLine.d189.s1|200-219|I , and inhibitors of|brand
DDI-MedLine.d189.s1|221-235|cytochrome P450|drug
DDI-MedLine.d189.s1|238-250|CYP ) enzymes .|brand
DDI-MedLine.d189.s1|243-249|enzymes|group
DDI-MedLine.d189.s2|64-87|LC MS ) detection methods|brand
DDI-MedLine.d189.s2|67-92|MS ) detection methods with|brand
DDI-MedLine.d189.s3|79-115|CYP inhibitor , 1-aminobenzotriazole (|brand
DDI-MedLine.d189.s3|94-123|1-aminobenzotriazole ( ABT ) and|drug
DDI-MedLine.d189.s3|116-151|ABT ) and isoform-specific inhibitors|brand
DDI-MedLine.d189.s4|36-56|I in rat liver slices|brand
DDI-MedLine.d189.s4|118-122|major|brand
DDI-MedLine.d189.s5|76-86|glutathione|drug
DDI-MedLine.d189.s5|179-193|I are reported .|brand
DDI-MedLine.d189.s6|10-45|I induced hepatocellular necrosis in|brand
DDI-MedLine.d189.s7|0-28|ABT decreased the toxicity of|brand
DDI-MedLine.d189.s7|40-63|I , increased exposure to|brand
DDI-MedLine.d189.s8|24-51|CYP inhibitors tested for an|brand
DDI-MedLine.d189.s8|77-102|I metabolite profile , only|brand
DDI-MedLine.d189.s8|104-118|tranylcypromine|drug
DDI-MedLine.d189.s8|172-185|2A6 , 2C9 , 2Cl9|drug
DDI-MedLine.d189.s8|177-190|2C9 , 2Cl9 , and|drug
DDI-MedLine.d189.s8|182-195|2Cl9 , and 2E1 .|drug
DDI-MedLine.d189.s8|192-195|2E1 .|drug
DDI-MedLine.d189.s9|39-73|CYP inhibitor effectiveness was ABT|brand
DDI-MedLine.d189.s9|71-125|ABT > diethyldithiocarbamate~tranylcypromine > ketoconazole|brand
DDI-MedLine.d189.s9|75-126|diethyldithiocarbamate~tranylcypromine > ketoconazole .|drug
DDI-MedLine.d189.s9|114-125|ketoconazole|drug
DDI-MedLine.d189.s10|0-10|Furafylline|drug
DDI-MedLine.d189.s10|16-29|sulfaphenazole|drug
DDI-MedLine.d189.s10|52-60|quinidine|drug
DDI-MedLine.d189.s10|92-102|I toxicity .|brand
DDI-MedLine.d189.s11|113-135|I and therefore may not|brand
DDI-MedLine.d189.s11|175-187|I metabolism .|brand
DDI-MedLine.d189.s12|80-100|CYP activity in an in|brand
DDI-MedLine.d184.s0|0-10|Amphetamine|drug
DDI-MedLine.d184.s1|71-78|dopamine|drug
DDI-MedLine.d184.s2|88-98|amphetamine|drug
DDI-MedLine.d184.s3|62-67|saline|brand
DDI-MedLine.d184.s3|90-99|P ) 1 to P11|brand
DDI-MedLine.d184.s3|97-125|P11 and raised to adolescence|drug
DDI-MedLine.d184.s4|49-59|amphetamine|drug
DDI-MedLine.d184.s4|74-79|saline|brand
DDI-MedLine.d184.s4|103-121|P35 to P47 and were|drug
DDI-MedLine.d184.s4|110-133|P47 and were placed into|drug
DDI-MedLine.d184.s5|55-65|amphetamine|drug
DDI-MedLine.d184.s5|144-154|amphetamine|drug
DDI-MedLine.d184.s6|40-50|amphetamine|drug
DDI-MedLine.d184.s7|84-109|P32-39 ) with amphetamine (|brand
DDI-MedLine.d184.s7|97-107|amphetamine|drug
DDI-MedLine.d184.s7|122-127|saline|brand
DDI-MedLine.d184.s7|178-181|P40 .|drug
DDI-MedLine.d184.s8|148-158|amphetamine|drug
DDI-MedLine.d184.s8|203-213|amphetamine|drug
DDI-MedLine.d184.s9|10-47|D -like receptor sensitivity appears|brand
DDI-MedLine.d184.s9|92-102|amphetamine|drug
DDI-MedLine.d143.s0|21-31|clopidogrel|drug
DDI-MedLine.d143.s0|37-58|proton pump inhibitors|group
DDI-MedLine.d143.s1|29-50|proton pump inhibitors|group
DDI-MedLine.d143.s1|56-66|clopidogrel|drug
DDI-MedLine.d143.s2|46-67|proton pump inhibitors|group
DDI-MedLine.d143.s3|19-28|omeprazole|drug
DDI-MedLine.d143.s3|34-44|clopidogrel|drug
DDI-MedLine.d143.s3|82-102|AUC ) to clopidogrel 's|brand
DDI-MedLine.d143.s3|90-100|clopidogrel|drug
DDI-MedLine.d143.s3|203-212|omeprazole|drug
DDI-MedLine.d143.s3|217-242|CYP2C19 , a cytochrome P450|drug
DDI-MedLine.d143.s3|228-242|cytochrome P450|drug
DDI-MedLine.d143.s3|245-256|CYP ) enzyme .|brand
DDI-MedLine.d143.s4|0-11|Pantoprazole|drug
DDI-MedLine.d143.s4|41-51|clopidogrel|drug
DDI-MedLine.d143.s5|27-48|proton pump inhibitors|group
DDI-MedLine.d143.s5|80-90|clopidogrel|drug
DDI-MedLine.d143.s6|50-60|clopidogrel|drug
DDI-MedLine.d143.s6|70-115|CYP2C19 inhibitors omeprazole and esomeprazole|drug
DDI-MedLine.d143.s6|89-98|omeprazole|drug
DDI-MedLine.d143.s6|104-115|esomeprazole|drug
DDI-MedLine.d143.s7|3-6|date|drug
DDI-MedLine.d143.s7|97-118|proton pump inhibitors|group
DDI-MedLine.d143.s7|124-134|clopidogrel|drug
DDI-MedLine.d201.s0|21-48|CRM197 , a specific inhibitor|drug
DDI-MedLine.d201.s0|53-75|HB-EGF , in T-cell acute|brand
DDI-MedLine.d201.s1|4-14|therapeutic|brand
DDI-MedLine.d201.s1|65-84|T-ALL ) remains poor ;|brand
DDI-MedLine.d201.s3|85-101|HB-EGF ) , a member|brand
DDI-MedLine.d201.s3|110-112|EGF|drug
DDI-MedLine.d201.s4|4-6|aim|brand
DDI-MedLine.d201.s4|56-85|HB-EGF is a therapeutic target|brand
DDI-MedLine.d201.s4|68-78|therapeutic|brand
DDI-MedLine.d201.s4|91-111|T-ALL , and to further|brand
DDI-MedLine.d201.s4|172-206|HB-EGF , cross-reacting material 197|brand
DDI-MedLine.d201.s4|209-216|CRM197 ) .|drug
DDI-MedLine.d201.s5|32-57|HB-EGF in T-ALL cell lines|brand
DDI-MedLine.d201.s5|42-62|T-ALL cell lines , and|brand
DDI-MedLine.d201.s5|88-114|CRM197 on these cells alone|drug
DDI-MedLine.d201.s6|18-42|EGFR and EGFR ligands was|brand
DDI-MedLine.d201.s6|27-56|EGFR ligands was determined by|brand
DDI-MedLine.d201.s6|32-38|ligands|group
DDI-MedLine.d201.s6|74-110|RT-PCR and real-time quantitative PCR|brand
DDI-MedLine.d201.s6|108-111|PCR .|brand
DDI-MedLine.d201.s7|39-50|TUNEL assay .|brand
DDI-MedLine.d201.s8|0-31|HB-EGF was strongly expressed by|brand
DDI-MedLine.d201.s8|33-53|T-ALL cell lines , and|brand
DDI-MedLine.d201.s8|78-105|HB-EGF and EGFR was enhanced|brand
DDI-MedLine.d201.s8|89-120|EGFR was enhanced by doxorubicin|brand
DDI-MedLine.d201.s8|110-120|doxorubicin|drug
DDI-MedLine.d201.s9|0-28|CRM197 induced apoptosis , and|drug
DDI-MedLine.d201.s9|62-106|CRM197 plus doxorubicin enhanced cytotoxicity|drug
DDI-MedLine.d201.s9|74-84|doxorubicin|drug
DDI-MedLine.d201.s9|113-128|T-ALL cell line .|brand
DDI-MedLine.d201.s9|124-128|line .|drug
DDI-MedLine.d201.s10|27-59|HB-EGF is a promising therapeutic|brand
DDI-MedLine.d201.s10|49-59|therapeutic|brand
DDI-MedLine.d201.s10|72-77|T-ALL .|brand
DDI-MedLine.d195.s0|13-20|piperine|drug
DDI-MedLine.d195.s0|25-33|ibuprofen|drug
DDI-MedLine.d195.s1|0-7|Piperine|drug
DDI-MedLine.d195.s1|10-25|CAS 94-62-2 ) , an|brand
DDI-MedLine.d195.s1|50-61|Piper nigrum|group
DDI-MedLine.d195.s1|67-68|P .|brand
DDI-MedLine.d195.s2|40-46|enzymes|group
DDI-MedLine.d195.s2|49-77|CYP isozymes ) responsible for|brand
DDI-MedLine.d195.s3|39-46|piperine|drug
DDI-MedLine.d195.s4|21-28|piperine|drug
DDI-MedLine.d195.s4|112-120|ibuprofen|drug
DDI-MedLine.d195.s4|140-150|acetic acid|drug
DDI-MedLine.d195.s4|210-218|ibuprofen|drug
DDI-MedLine.d195.s5|0-8|Ibuprofen|drug
DDI-MedLine.d195.s5|80-87|piperine|drug
DDI-MedLine.d195.s6|44-52|ibuprofen|drug
DDI-MedLine.d195.s6|77-84|piperine|drug
DDI-MedLine.d195.s6|141-149|ibuprofen|drug
DDI-MedLine.d195.s7|41-48|piperine|drug
DDI-MedLine.d195.s7|90-98|ibuprofen|drug
DDI-MedLine.d27.s0|117-126|picrotoxin|drug
DDI-MedLine.d27.s0|174-181|diazepam|drug
DDI-MedLine.d27.s0|184-214|phenazepam , phenibut and amizyl|drug
DDI-MedLine.d27.s0|196-203|phenibut|drug
DDI-MedLine.d27.s0|242-253|phentolamine|drug
DDI-MedLine.d27.s1|17-26|picrotoxin|drug
DDI-MedLine.d27.s2|34-43|picrotoxin|drug
DDI-MedLine.d9.s2|65-98|prediction of abnormal handling of|drug
DDI-MedLine.d9.s3|38-40|now|brand
DDI-MedLine.d9.s3|74-82|verapamil|drug
DDI-MedLine.d9.s3|85-94|nifedipine|drug
DDI-MedLine.d9.s3|100-108|diltiazem|drug
DDI-MedLine.d9.s4|106-110|blood|group
DDI-MedLine.d9.s5|45-53|verapamil|drug
DDI-MedLine.d9.s5|59-67|diltiazem|drug
DDI-MedLine.d9.s5|87-96|nifedipine|drug
DDI-MedLine.d9.s6|20-22|now|brand
DDI-MedLine.d9.s6|100-110|therapeutic|brand
DDI-MedLine.d9.s7|68-73|impact|drug
DDI-MedLine.d61.s1|0-9|Amiodarone|drug
DDI-MedLine.d61.s1|29-33|serum|group
DDI-MedLine.d61.s3|34-40|digoxin|drug
DDI-MedLine.d61.s3|93-99|digoxin|drug
DDI-MedLine.d61.s3|140-149|amiodarone|drug
DDI-MedLine.d61.s4|7-16|amiodarone|drug
DDI-MedLine.d61.s4|56-62|digoxin|drug
DDI-MedLine.d61.s6|0-6|Digoxin|drug
DDI-MedLine.d61.s7|0-6|Digoxin|drug
DDI-MedLine.d61.s8|0-9|Amiodarone|drug
DDI-MedLine.d61.s8|51-55|serum|group
DDI-MedLine.d61.s8|65-80|triiodothyronine|group
DDI-MedLine.d61.s8|105-111|thyroid|brand
DDI-MedLine.d61.s8|172-178|digoxin|drug
DDI-MedLine.d61.s9|21-27|digoxin|drug
DDI-MedLine.d61.s9|58-67|amiodarone|drug
DDI-MedLine.d61.s9|93-97|serum|group
DDI-MedLine.d85.s0|0-11|Misonidazole|drug
DDI-MedLine.d85.s0|80-84|CCNU .|brand
DDI-MedLine.d85.s1|24-51|CCNU is given exclusively by|brand
DDI-MedLine.d85.s1|184-204|CCNU , either alone or|brand
DDI-MedLine.d85.s1|246-257|misonidazole|drug
DDI-MedLine.d85.s3|0-30|AUC for total nitrosoureas were|brand
DDI-MedLine.d85.s3|14-25|nitrosoureas|group
DDI-MedLine.d85.s6|51-74|CCNU was 1.45 times less|brand
DDI-MedLine.d85.s7|0-11|Misonidazole|drug
DDI-MedLine.d85.s7|53-82|CCNU by dose modifying factors|brand
DDI-MedLine.d85.s7|85-102|DMF ) of 0.58-0.71 .|brand
DDI-MedLine.d85.s8|55-66|DMF of 0.74 .|brand
DDI-MedLine.d85.s9|0-11|Misonidazole|drug
DDI-MedLine.d85.s9|42-63|CCNU pharmacokinetics .|brand
DDI-MedLine.d85.s12|12-31|AUC , with the extent|brand
DDI-MedLine.d85.s12|100-111|MEC ) chosen .|brand
DDI-MedLine.d85.s13|36-61|AUC was reduced by factors|brand
DDI-MedLine.d85.s13|83-101|MEC values of 1 and|brand
DDI-MedLine.d85.s14|98-131|CCNU cytotoxicity by misonidazole .|brand
DDI-MedLine.d85.s14|119-130|misonidazole|drug
DDI-MedLine.d81.s1|117-121|DER ) .|brand
DDI-MedLine.d81.s2|71-77|ethanol|drug
DDI-MedLine.d81.s2|117-126|disulfiram|drug
DDI-MedLine.d81.s2|147-153|ethanol|drug
DDI-MedLine.d81.s3|58-64|ethanol|drug
DDI-MedLine.d81.s3|142-148|ethanol|drug
DDI-MedLine.d81.s4|58-64|ethanol|drug
DDI-MedLine.d81.s5|4-8|blood|group
DDI-MedLine.d81.s6|47-53|ethanol|drug
DDI-MedLine.d81.s6|97-103|ethanol|drug
DDI-MedLine.d81.s7|71-77|ethanol|drug
DDI-MedLine.d34.s0|16-21|cobalt|group
DDI-MedLine.d34.s0|27-30|iron|drug
DDI-MedLine.d34.s1|34-39|cobalt|group
DDI-MedLine.d34.s1|45-48|iron|drug
DDI-MedLine.d34.s1|177-190|trace elements|group
DDI-MedLine.d34.s3|58-65|elements|group
DDI-MedLine.d34.s4|0-5|Cobalt|group
DDI-MedLine.d34.s4|47-52|cobalt|group
DDI-MedLine.d34.s5|53-56|iron|drug
DDI-MedLine.d34.s7|11-14|iron|drug
DDI-MedLine.d34.s7|58-63|cobalt|group
DDI-MedLine.d34.s7|81-86|cobalt|group
DDI-MedLine.d34.s8|141-146|cobalt|group
DDI-MedLine.d34.s9|28-31|iron|drug
DDI-MedLine.d34.s9|53-58|cobalt|group
DDI-MedLine.d34.s10|48-55|elements|group
DDI-MedLine.d34.s11|27-32|cobalt|group
DDI-MedLine.d34.s11|67-70|iron|drug
DDI-MedLine.d34.s11|108-113|cobalt|group
DDI-MedLine.d34.s11|118-121|iron|drug
DDI-MedLine.d34.s12|15-18|iron|drug
DDI-MedLine.d34.s12|193-223|ABSTRACT TRUNCATED AT 250 WORDS|brand
DDI-MedLine.d34.s12|202-224|TRUNCATED AT 250 WORDS )|brand
DDI-MedLine.d34.s12|212-224|AT 250 WORDS )|brand
DDI-MedLine.d34.s12|219-224|WORDS )|brand
DDI-MedLine.d11.s2|126-134|psoriasis|group
DDI-MedLine.d11.s2|148-156|arthritis|brand
DDI-MedLine.d11.s2|196-207|inflammation|group
DDI-MedLine.d11.s3|178-180|now|brand
DDI-MedLine.d11.s4|74-88|corticosteroids|group
DDI-MedLine.d11.s4|104-115|azathioprine|drug
DDI-MedLine.d11.s4|118-129|methotrexate|drug
DDI-MedLine.d11.s4|132-147|cyclophosphamide|drug
DDI-MedLine.d103.s0|0-8|Magnesium|drug
DDI-MedLine.d103.s1|36-44|magnesium|drug
DDI-MedLine.d103.s1|75-83|magnesium|drug
DDI-MedLine.d103.s1|144-152|magnesium|drug
DDI-MedLine.d103.s1|193-201|magnesium|drug
DDI-MedLine.d103.s1|230-238|magnesium|drug
DDI-MedLine.d103.s1|302-310|magnesium|drug
DDI-MedLine.d103.s2|22-30|magnesium|drug
DDI-MedLine.d103.s2|60-63|sole|brand
DDI-MedLine.d103.s2|98-106|magnesium|drug
DDI-MedLine.d103.s3|94-102|magnesium|drug
DDI-MedLine.d103.s3|140-148|magnesium|drug
DDI-MedLine.d103.s3|184-192|magnesium|drug
DDI-MedLine.d103.s3|260-268|magnesium|drug
DDI-MedLine.d103.s3|314-320|control|brand
DDI-MedLine.d103.s3|336-344|magnesium|drug
DDI-MedLine.d103.s4|19-27|magnesium|drug
DDI-MedLine.d103.s4|77-85|magnesium|drug
DDI-MedLine.d103.s4|102-110|the first|brand
DDI-MedLine.d103.s5|19-27|magnesium|drug
DDI-MedLine.d103.s5|62-65|easy|brand
DDI-MedLine.d103.s5|110-118|magnesium|drug
DDI-MedLine.d103.s6|37-45|magnesium|drug
DDI-MedLine.d103.s6|86-94|magnesium|drug
DDI-MedLine.d103.s6|104-112|diuretics|group
DDI-MedLine.d103.s6|140-149|vitamin B6|brand
DDI-MedLine.d103.s6|175-183|vitamin D|drug
DDI-MedLine.d103.s6|192-199|selenium|drug
DDI-MedLine.d103.s7|58-68|therapeutic|brand
DDI-MedLine.d103.s7|107-115|magnesium|drug
DDI-MedLine.d103.s8|79-87|magnesium|drug
DDI-MedLine.d103.s8|155-163|magnesium|drug
DDI-MedLine.d103.s9|22-30|magnesium|drug
DDI-MedLine.d103.s11|10-12|now|brand
DDI-MedLine.d103.s11|89-97|magnesium|drug
DDI-MedLine.d103.s12|0-8|Magnesium|drug
DDI-MedLine.d103.s12|55-58|care|brand
DDI-MedLine.d103.s13|10-18|magnesium|drug
DDI-MedLine.d103.s13|40-47|laxative|brand
DDI-MedLine.d103.s14|41-48|laxative|brand
DDI-MedLine.d103.s14|54-60|antacid|brand
DDI-MedLine.d103.s14|88-96|magnesium|drug
DDI-MedLine.d103.s15|71-79|magnesium|drug
DDI-MedLine.d103.s15|100-111|cardioplegic|brand
DDI-MedLine.d14.s0|1-33|A pharmacological analysis of the|brand
DDI-MedLine.d14.s1|29-40|angiotensins|group
DDI-MedLine.d14.s1|89-100|pentagastrin|drug
DDI-MedLine.d14.s1|113-121|histamine|drug
DDI-MedLine.d14.s2|127-138|angiotensins|group
DDI-MedLine.d108.s0|18-24|lithium|brand
DDI-MedLine.d108.s1|91-97|lithium|brand
DDI-MedLine.d113.s0|30-38|temazepam|drug
DDI-MedLine.d113.s0|65-71|ethanol|drug
DDI-MedLine.d113.s2|29-35|ethanol|drug
DDI-MedLine.d113.s2|96-117|central nervous system|group
DDI-MedLine.d113.s3|105-113|temazepam|drug
DDI-MedLine.d113.s3|118-131|benzodiazepine|drug
DDI-MedLine.d113.s3|138-144|ethanol|drug
DDI-MedLine.d113.s5|111-117|alcohol|brand
DDI-MedLine.d113.s5|123-169|3-hydroxy-1,4-benzodiazepine on a regular basis|drug
DDI-MedLine.d113.s5|157-163|regular|brand
DDI-DrugBank.d321.s0|0-12|Dexamethasone|drug
DDI-DrugBank.d321.s0|53-63|albendazole|drug
DDI-DrugBank.d321.s0|107-119|dexamethasone|drug
DDI-DrugBank.d321.s0|158-168|albendazole|drug
DDI-DrugBank.d321.s1|0-11|Praziquantel|drug
DDI-DrugBank.d321.s1|32-43|praziquantel|drug
DDI-DrugBank.d321.s1|128-138|albendazole|drug
DDI-DrugBank.d321.s1|245-255|albendazole|drug
DDI-DrugBank.d321.s2|5-25|T max and mean plasma|brand
DDI-DrugBank.d321.s2|52-62|albendazole|drug
DDI-DrugBank.d321.s3|24-35|praziquantel|drug
DDI-DrugBank.d321.s3|84-94|albendazole|drug
DDI-DrugBank.d321.s4|0-9|Cimetidine|drug
DDI-DrugBank.d321.s4|12-22|Albendazole|drug
DDI-DrugBank.d321.s4|142-151|cimetidine|drug
DDI-DrugBank.d321.s4|188-198|albendazole|drug
DDI-DrugBank.d321.s5|0-10|Albendazole|drug
DDI-DrugBank.d321.s6|0-11|Theophylline|drug
DDI-DrugBank.d321.s6|38-49|theophylline|drug
DDI-DrugBank.d321.s6|52-64|aminophylline|drug
DDI-DrugBank.d321.s6|148-158|albendazole|drug
DDI-DrugBank.d407.s0|89-95|Campath|brand
DDI-DrugBank.d407.s1|22-28|Campath|brand
DDI-DrugBank.d407.s1|71-75|serum|group
DDI-DrugBank.d407.s1|96-105|antibodies|group
DDI-DrugBank.d392.s0|26-33|Panretin|brand
DDI-DrugBank.d392.s0|89-118|DEET ( N , N-diethyl-m-toluamide|brand
DDI-DrugBank.d392.s0|95-120|N , N-diethyl-m-toluamide ) ,|brand
DDI-DrugBank.d392.s1|43-69|DEET toxicity when DEET was|brand
DDI-DrugBank.d392.s1|62-87|DEET was included as proof|brand
DDI-DrugBank.d392.s2|142-149|protease|drug
DDI-DrugBank.d392.s2|190-206|azole antifungals|group
DDI-DrugBank.d392.s2|223-230|Panretin|brand
DDI-DrugBank.d392.s3|72-79|Panretin|brand
DDI-DrugBank.d356.s0|5-13|amiloride|drug
DDI-DrugBank.d356.s0|57-85|angiotensin-converting enzyme|drug
DDI-DrugBank.d356.s1|161-165|serum|group
DDI-DrugBank.d356.s2|0-6|Lithium|brand
DDI-DrugBank.d356.s2|43-51|diuretics|group
DDI-DrugBank.d356.s2|116-122|lithium|brand
DDI-DrugBank.d356.s3|19-25|lithium|brand
DDI-DrugBank.d356.s4|178-196|thiazide diuretics .|drug
DDI-DrugBank.d356.s4|187-195|diuretics|group
DDI-DrugBank.d356.s5|16-22|MIDAMOR|brand
DDI-DrugBank.d356.s5|42-65|anti-inflammatory agents|group
DDI-DrugBank.d356.s5|133-163|determine if the desired effect|drug
DDI-DrugBank.d356.s6|6-17|indomethacin|drug
DDI-DrugBank.d356.s6|23-49|potassium-sparing diuretics|group
DDI-DrugBank.d356.s6|62-68|MIDAMOR|brand
DDI-DrugBank.d356.s6|109-113|serum|group
DDI-DrugBank.d356.s6|158-166|potassium|drug
DDI-DrugBank.d553.s0|138-143|AMICAR|brand
DDI-DrugBank.d553.s2|104-141|EACA inhibits ADP and collagen-induced|brand
DDI-DrugBank.d553.s2|118-162|ADP and collagen-induced platelet aggregation|brand
DDI-DrugBank.d553.s2|169-175|release|brand
DDI-DrugBank.d553.s2|180-182|ATP|drug
DDI-DrugBank.d553.s2|188-196|serotonin|drug
DDI-DrugBank.d553.s2|218-227|fibrinogen|group
DDI-DrugBank.d553.s3|26-31|AMICAR|brand
DDI-DrugBank.d553.s4|21-26|AMICAR|brand
DDI-DrugBank.d553.s4|41-48|maintain|brand
DDI-DrugBank.d553.s7|41-46|AMICAR|brand
DDI-DrugBank.d143.s0|0-9|Amiodarone|drug
DDI-DrugBank.d143.s0|55-69|cytochrome P450|drug
DDI-DrugBank.d143.s0|72-92|CYP450 ) enzyme group ,|drug
DDI-DrugBank.d143.s0|119-122|P450|drug
DDI-DrugBank.d143.s0|129-147|CYP3A4 ) and CYP2C8 .|drug
DDI-DrugBank.d143.s0|141-147|CYP2C8 .|drug
DDI-DrugBank.d143.s1|4-33|CYP3A4 isoenzyme is present in|drug
DDI-DrugBank.d143.s2|0-9|Amiodarone|drug
DDI-DrugBank.d143.s2|47-53|CYP3A4 .|drug
DDI-DrugBank.d143.s3|11-20|amiodarone|drug
DDI-DrugBank.d143.s3|132-138|CYP3A4 .|drug
DDI-DrugBank.d143.s4|67-76|amiodarone|drug
DDI-DrugBank.d143.s7|46-55|amiodarone|drug
DDI-DrugBank.d143.s7|192-201|amiodarone|drug
DDI-DrugBank.d143.s8|6-15|amiodarone|drug
DDI-DrugBank.d143.s8|36-70|CYP3A4 and CYP2C8 , drugs/substances|drug
DDI-DrugBank.d143.s8|47-83|CYP2C8 , drugs/substances that inhibit|drug
DDI-DrugBank.d143.s8|143-147|serum|group
DDI-DrugBank.d143.s8|166-175|amiodarone|drug
DDI-DrugBank.d143.s9|41-48|Protease|drug
DDI-DrugBank.d143.s9|62-69|Protease|drug
DDI-DrugBank.d143.s9|103-128|CYP3A4 to varying degrees .|drug
DDI-DrugBank.d143.s10|0-19|A case report of one|brand
DDI-DrugBank.d143.s10|36-45|amiodarone|drug
DDI-DrugBank.d143.s10|58-66|indinavir|drug
DDI-DrugBank.d143.s10|118-127|amiodarone|drug
DDI-DrugBank.d143.s11|0-35|DEA concentrations were not affected|brand
DDI-DrugBank.d143.s13|15-24|amiodarone|drug
DDI-DrugBank.d143.s13|61-70|amiodarone|drug
DDI-DrugBank.d143.s13|111-118|protease|drug
DDI-DrugBank.d143.s14|0-8|Histamine|drug
DDI-DrugBank.d143.s14|26-35|Cimetidine|drug
DDI-DrugBank.d143.s14|46-74|CYP3A4 and can increase serum|drug
DDI-DrugBank.d143.s14|70-74|serum|group
DDI-DrugBank.d143.s15|18-27|Grapefruit|drug
DDI-DrugBank.d143.s15|73-82|amiodarone|drug
DDI-DrugBank.d143.s15|152-161|amiodarone|drug
DDI-DrugBank.d143.s16|0-9|Grapefruit|drug
DDI-DrugBank.d143.s16|64-73|amiodarone|drug
DDI-DrugBank.d143.s17|69-78|amiodarone|drug
DDI-DrugBank.d143.s17|88-97|amiodarone|drug
DDI-DrugBank.d143.s18|0-9|Amiodarone|drug
DDI-DrugBank.d143.s18|32-63|CYP450 enzymes , including CYP1A2|drug
DDI-DrugBank.d143.s18|39-45|enzymes|group
DDI-DrugBank.d143.s18|58-79|CYP1A2 , CYP2C9 , CYP2D6|drug
DDI-DrugBank.d143.s18|66-84|CYP2C9 , CYP2D6 , and|drug
DDI-DrugBank.d143.s18|74-92|CYP2D6 , and CYP3A4 .|drug
DDI-DrugBank.d143.s18|86-92|CYP3A4 .|drug
DDI-DrugBank.d143.s19|108-122|CYP450 enzymes .|drug
DDI-DrugBank.d143.s19|115-121|enzymes|group
DDI-DrugBank.d143.s20|81-92|Cyclosporine|drug
DDI-DrugBank.d143.s20|95-127|CYP3A4 substrate ) administered in|drug
DDI-DrugBank.d143.s20|151-160|amiodarone|drug
DDI-DrugBank.d143.s20|238-249|cyclosporine|drug
DDI-DrugBank.d143.s20|273-282|creatinine|drug
DDI-DrugBank.d143.s20|314-325|cyclosporine|drug
DDI-DrugBank.d143.s21|30-40|Simvastatin|drug
DDI-DrugBank.d143.s21|43-74|CYP3A4 substrate ) in combination|drug
DDI-DrugBank.d143.s21|81-90|amiodarone|drug
DDI-DrugBank.d143.s22|17-34|Cardiac glycosides|group
DDI-DrugBank.d143.s22|59-65|digoxin|drug
DDI-DrugBank.d143.s22|99-108|amiodarone|drug
DDI-DrugBank.d143.s22|146-150|serum|group
DDI-DrugBank.d143.s23|0-9|Amiodarone|drug
DDI-DrugBank.d143.s23|36-42|digoxin|drug
DDI-DrugBank.d143.s23|58-62|serum|group
DDI-DrugBank.d143.s24|26-35|amiodarone|drug
DDI-DrugBank.d143.s25|37-41|serum|group
DDI-DrugBank.d143.s26|43-51|digitoxin|drug
DDI-DrugBank.d143.s27|53-61|quinidine|drug
DDI-DrugBank.d143.s27|64-75|procainamide|drug
DDI-DrugBank.d143.s27|78-89|disopyramide|drug
DDI-DrugBank.d143.s27|96-104|phenytoin|drug
DDI-DrugBank.d143.s27|140-149|amiodarone|drug
DDI-DrugBank.d143.s28|65-73|quinidine|drug
DDI-DrugBank.d143.s28|76-87|procainamide|drug
DDI-DrugBank.d143.s28|94-102|phenytoin|drug
DDI-DrugBank.d143.s28|136-145|amiodarone|drug
DDI-DrugBank.d143.s29|0-8|Phenytoin|drug
DDI-DrugBank.d143.s29|20-24|serum|group
DDI-DrugBank.d143.s30|0-9|Amiodarone|drug
DDI-DrugBank.d143.s30|36-44|quinidine|drug
DDI-DrugBank.d143.s30|56-64|quinidine|drug
DDI-DrugBank.d143.s31|0-9|Amiodarone|drug
DDI-DrugBank.d143.s31|36-47|procainamide|drug
DDI-DrugBank.d143.s31|109-120|procainamide|drug
DDI-DrugBank.d143.s31|135-146|procainamide|drug
DDI-DrugBank.d143.s32|0-8|Quinidine|drug
DDI-DrugBank.d143.s32|14-25|procainamide|drug
DDI-DrugBank.d143.s32|97-106|amiodarone|drug
DDI-DrugBank.d143.s33|17-26|flecainide|drug
DDI-DrugBank.d143.s33|83-92|amiodarone|drug
DDI-DrugBank.d143.s34|31-40|flecainide|drug
DDI-DrugBank.d143.s36|15-24|amiodarone|drug
DDI-DrugBank.d143.s36|218-227|amiodarone|drug
DDI-DrugBank.d143.s37|24-33|amiodarone|drug
DDI-DrugBank.d143.s37|157-166|amiodarone|drug
DDI-DrugBank.d143.s38|94-103|amiodarone|drug
DDI-DrugBank.d143.s39|186-195|amiodarone|drug
DDI-DrugBank.d143.s41|19-28|Amiodarone|drug
DDI-DrugBank.d143.s41|114-124|propranolol|drug
DDI-DrugBank.d143.s41|129-156|CYP3A4 inhibitor ) or calcium|drug
DDI-DrugBank.d143.s41|150-156|calcium|drug
DDI-DrugBank.d143.s41|185-193|verapamil|drug
DDI-DrugBank.d143.s41|198-228|CYP3A4 substrate , and diltiazem|drug
DDI-DrugBank.d143.s41|220-228|diltiazem|drug
DDI-DrugBank.d143.s41|233-260|CYP3A4 inhibitor ) because of|drug
DDI-DrugBank.d143.s41|304-308|sinus|brand
DDI-DrugBank.d143.s41|322-330|AV block ;|brand
DDI-DrugBank.d143.s42|14-23|amiodarone|drug
DDI-DrugBank.d143.s42|119-123|sinus|brand
DDI-DrugBank.d143.s43|0-13|Anticoagulants|group
DDI-DrugBank.d143.s43|47-74|CYP2C9 and CYP3A4 substrate )|drug
DDI-DrugBank.d143.s43|58-97|CYP3A4 substrate ) anticoagulant response|drug
DDI-DrugBank.d143.s43|143-152|amiodarone|drug
DDI-DrugBank.d143.s44|40-47|warfarin|drug
DDI-DrugBank.d143.s44|54-63|amiodarone|drug
DDI-DrugBank.d143.s44|79-89|prothrombin|drug
DDI-DrugBank.d143.s44|201-211|prothrombin|drug
DDI-DrugBank.d143.s45|64-73|amiodarone|drug
DDI-DrugBank.d143.s45|107-131|CYP3A4 ( enzyme induction )|drug
DDI-DrugBank.d143.s46|21-30|amiodarone|drug
DDI-DrugBank.d143.s47|74-81|Rifampin|brand
DDI-DrugBank.d143.s47|106-112|CYP3A4 .|drug
DDI-DrugBank.d143.s48|18-25|rifampin|brand
DDI-DrugBank.d143.s48|51-60|amiodarone|drug
DDI-DrugBank.d143.s48|103-107|serum|group
DDI-DrugBank.d143.s48|127-136|amiodarone|drug
DDI-DrugBank.d143.s49|28-33|herbal|brand
DDI-DrugBank.d143.s49|66-74|Hypericum|brand
DDI-DrugBank.d143.s49|96-102|CYP3A4 .|drug
DDI-DrugBank.d143.s50|6-15|amiodarone|drug
DDI-DrugBank.d143.s50|36-55|CYP3A4 , there is the|drug
DDI-DrugBank.d143.s50|121-130|amiodarone|drug
DDI-DrugBank.d143.s50|156-165|amiodarone|drug
DDI-DrugBank.d143.s51|33-42|amiodarone|drug
DDI-DrugBank.d143.s51|45-52|Fentanyl|drug
DDI-DrugBank.d143.s51|55-86|CYP3A4 substrate ) in combination|drug
DDI-DrugBank.d143.s51|93-102|amiodarone|drug
DDI-DrugBank.d143.s52|0-4|Sinus|brand
DDI-DrugBank.d143.s52|46-55|amiodarone|drug
DDI-DrugBank.d143.s52|77-85|lidocaine|drug
DDI-DrugBank.d143.s52|88-114|CYP3A4 substrate ) given for|drug
DDI-DrugBank.d143.s52|116-131|local anesthesia|group
DDI-DrugBank.d143.s53|35-43|lidocaine|drug
DDI-DrugBank.d143.s53|126-135|amiodarone|drug
DDI-DrugBank.d143.s54|0-15|Dextromethorphan|drug
DDI-DrugBank.d143.s54|41-58|CYP2D6 and CYP3A4 .|drug
DDI-DrugBank.d143.s54|52-58|CYP3A4 .|drug
DDI-DrugBank.d143.s55|0-9|Amiodarone|drug
DDI-DrugBank.d143.s55|20-26|CYP2D6 .|drug
DDI-DrugBank.d143.s56|0-13|Cholestyramine|drug
DDI-DrugBank.d143.s56|54-63|amiodarone|drug
DDI-DrugBank.d143.s56|84-88|serum|group
DDI-DrugBank.d143.s57|0-11|Disopyramide|drug
DDI-DrugBank.d143.s57|23-55|QT prolongation which could cause|brand
DDI-DrugBank.d143.s58|0-15|Fluoroquinolones|group
DDI-DrugBank.d143.s59|61-63|TdP|drug
DDI-DrugBank.d143.s59|85-94|amiodarone|drug
DDI-DrugBank.d143.s59|101-116|fluoroquinolones|group
DDI-DrugBank.d143.s60|110-120|propranolol|drug
DDI-DrugBank.d143.s60|123-131|diltiazem|drug
DDI-DrugBank.d143.s60|138-146|verapamil|drug
DDI-DrugBank.d143.s61|9-18|Anesthetic|brand
DDI-DrugBank.d143.s62|70-78|Cordarone|brand
DDI-DrugBank.d143.s62|117-125|phenytoin|drug
DDI-DrugBank.d143.s62|128-143|dextromethorphan|drug
DDI-DrugBank.d143.s62|150-161|methotrexate|drug
DDI-DrugBank.d143.s63|149-157|Cordarone|brand
DDI-DrugBank.d143.s63|203-208|degree|brand
DDI-DrugBank.d143.s63|261-263|TdP|drug
DDI-DrugBank.d143.s64|162-170|diuretics|group
DDI-DrugBank.d195.s0|0-10|Anastrozole|drug
DDI-DrugBank.d195.s0|76-79|P450|drug
DDI-DrugBank.d195.s0|86-103|2C8/9 , and 3A4 but|brand
DDI-DrugBank.d195.s0|97-122|3A4 but only at relatively|drug
DDI-DrugBank.d195.s1|0-10|Anastrozole|drug
DDI-DrugBank.d195.s1|28-31|P450|drug
DDI-DrugBank.d195.s1|56-59|P450|drug
DDI-DrugBank.d195.s2|0-10|Anastrozole|drug
DDI-DrugBank.d195.s2|50-59|antipyrine|drug
DDI-DrugBank.d195.s3|71-80|antipyrine|drug
DDI-DrugBank.d195.s3|184-191|ARIMIDEX|brand
DDI-DrugBank.d195.s4|26-33|warfarin|drug
DDI-DrugBank.d195.s4|78-88|anastrozole|drug
DDI-DrugBank.d195.s4|93-100|warfarin|drug
DDI-DrugBank.d195.s5|55-62|ARIMIDEX|brand
DDI-DrugBank.d195.s5|68-76|tamoxifen|drug
DDI-DrugBank.d195.s5|138-146|tamoxifen|drug
DDI-DrugBank.d195.s6|15-17|arm|drug
DDI-DrugBank.d195.s7|55-82|ATAC trial , tamoxifen should|brand
DDI-DrugBank.d195.s7|67-75|tamoxifen|drug
DDI-DrugBank.d195.s7|109-119|anastrozole|drug
DDI-DrugBank.d195.s7|126-170|CLINICAL PHARMACOLOGY Drug Interactions and|brand
DDI-DrugBank.d195.s7|135-179|PHARMACOLOGY Drug Interactions and CLINICAL|brand
DDI-DrugBank.d195.s7|172-211|CLINICAL PHARMACOLOGY - Clinical Studies|brand
DDI-DrugBank.d195.s7|181-213|PHARMACOLOGY - Clinical Studies -|brand
DDI-DrugBank.d195.s8|21-31|anastrozole|drug
DDI-DrugBank.d195.s8|37-45|tamoxifen|drug
DDI-DrugBank.d195.s8|74-84|anastrozole|drug
DDI-DrugBank.d195.s8|141-151|anastrozole|drug
DDI-DrugBank.d195.s9|54-61|ARIMIDEX|brand
DDI-DrugBank.d443.s0|0-16|Uricosuric Agents|group
DDI-DrugBank.d443.s0|19-25|Aspirin|brand
DDI-DrugBank.d443.s0|55-64|probenecid|drug
DDI-DrugBank.d443.s0|67-80|sulfinpyrazone|drug
DDI-DrugBank.d443.s0|87-100|phenylbutazone|drug
DDI-DrugBank.d443.s1|0-6|Alcohol|brand
DDI-DrugBank.d443.s1|39-45|aspirin|brand
DDI-DrugBank.d443.s2|0-14|Corticosteroids|group
DDI-DrugBank.d443.s2|49-55|aspirin|brand
DDI-DrugBank.d443.s2|125-129|serum|group
DDI-DrugBank.d443.s3|0-21|Pyrazolone Derivatives|group
DDI-DrugBank.d443.s3|24-37|phenylbutazone|drug
DDI-DrugBank.d443.s3|40-54|oxyphenbutazone|drug
DDI-DrugBank.d443.s3|113-119|aspirin|brand
DDI-DrugBank.d443.s4|38-44|Aspirin|brand
DDI-DrugBank.d443.s4|116-139|anti-inflammatory agents|group
DDI-DrugBank.d443.s5|31-37|aspirin|brand
DDI-DrugBank.d443.s6|0-12|Phenobarbital|drug
DDI-DrugBank.d443.s6|25-31|aspirin|brand
DDI-DrugBank.d443.s7|0-8|Phenytoin|drug
DDI-DrugBank.d443.s7|11-15|Serum|group
DDI-DrugBank.d443.s7|54-60|aspirin|brand
DDI-DrugBank.d443.s8|0-10|Propranolol|drug
DDI-DrugBank.d443.s8|81-84|same|drug
DDI-DrugBank.d443.s9|0-7|Antacids|group
DDI-DrugBank.d443.s9|10-31|Enteric Coated Aspirin|brand
DDI-DrugBank.d443.s9|71-78|antacids|group
DDI-DrugBank.d443.s9|106-107|pH|drug
DDI-DrugBank.d11.s0|23-31|Albuterol|brand
DDI-DrugBank.d11.s0|35-43|STRATTERA|brand
DDI-DrugBank.d11.s0|160-168|albuterol|brand
DDI-DrugBank.d11.s0|180-206|beta2 agonists ) because the|drug
DDI-DrugBank.d11.s0|218-226|albuterol|brand
DDI-DrugBank.d11.s0|317-321|blood|group
DDI-DrugBank.d11.s1|0-33|CYP2D6 inhibitors - Atomoxetine is|drug
DDI-DrugBank.d11.s1|20-30|Atomoxetine|drug
DDI-DrugBank.d11.s1|64-102|CYP2D6 pathway to 4-hydroxyatomoxetine .|drug
DDI-DrugBank.d11.s1|82-102|4-hydroxyatomoxetine .|drug
DDI-DrugBank.d11.s2|32-78|CYP2D6 increase atomoxetine steady-state plasma|drug
DDI-DrugBank.d11.s2|48-58|atomoxetine|drug
DDI-DrugBank.d11.s3|21-29|STRATTERA|brand
DDI-DrugBank.d11.s3|73-96|CYP2D6 inhibitors , e.g. ,|drug
DDI-DrugBank.d11.s3|98-107|paroxetine|drug
DDI-DrugBank.d11.s3|110-119|fluoxetine|drug
DDI-DrugBank.d11.s3|126-134|quinidine|drug
DDI-DrugBank.d11.s4|3-40|EM individuals treated with paroxetine|brand
DDI-DrugBank.d11.s4|31-40|paroxetine|drug
DDI-DrugBank.d11.s4|45-54|fluoxetine|drug
DDI-DrugBank.d11.s4|61-95|AUC of atomoxetine is approximately|brand
DDI-DrugBank.d11.s4|68-78|atomoxetine|drug
DDI-DrugBank.d11.s4|157-167|atomoxetine|drug
DDI-DrugBank.d11.s5|50-64|cytochrome P450|drug
DDI-DrugBank.d11.s5|131-141|atomoxetine|drug
DDI-DrugBank.d11.s6|48-52|blood|group
DDI-DrugBank.d11.s6|64-72|STRATTERA|brand
DDI-DrugBank.d469.s0|61-68|TRACRIUM|brand
DDI-DrugBank.d469.s0|79-87|enflurane|drug
DDI-DrugBank.d469.s1|0-9|isoflurane|drug
DDI-DrugBank.d469.s2|0-8|halothane|drug
DDI-DrugBank.d469.s3|56-65|polymyxins|group
DDI-DrugBank.d469.s4|0-6|lithium|brand
DDI-DrugBank.d469.s5|0-8|magnesium|drug
DDI-DrugBank.d469.s6|0-11|procainamide|drug
DDI-DrugBank.d469.s7|61-68|TRACRIUM|brand
DDI-DrugBank.d469.s7|79-87|enflurane|drug
DDI-DrugBank.d469.s7|89-98|isoflurane|drug
DDI-DrugBank.d469.s7|100-108|halothane|drug
DDI-DrugBank.d469.s7|166-175|polymyxins|group
DDI-DrugBank.d469.s7|177-183|lithium|brand
DDI-DrugBank.d469.s7|185-193|magnesium|drug
DDI-DrugBank.d469.s7|201-212|procainamide|drug
DDI-DrugBank.d469.s7|218-226|quinidine|drug
DDI-DrugBank.d469.s8|9-14|muscle|brand
DDI-DrugBank.d469.s8|46-49|same|drug
DDI-DrugBank.d469.s9|28-42|succinylcholine|drug
DDI-DrugBank.d469.s9|160-167|TRACRIUM|brand
DDI-DrugBank.d469.s10|0-7|TRACRIUM|brand
DDI-DrugBank.d544.s0|37-44|Simulect|brand
DDI-DrugBank.d544.s0|102-113|cyclosporine|drug
DDI-DrugBank.d544.s0|116-130|corticosteroids|group
DDI-DrugBank.d544.s0|144-155|azathioprine|drug
DDI-DrugBank.d544.s0|160-180|mycophenolate mofetil|drug
DDI-DrugBank.d544.s1|40-47|Simulect|brand
DDI-DrugBank.d544.s3|6-9|body|brand
DDI-DrugBank.d544.s3|24-31|Simulect|brand
DDI-DrugBank.d544.s3|76-87|azathioprine|drug
DDI-DrugBank.d544.s3|93-113|mycophenolate mofetil|drug
DDI-DrugBank.d544.s3|146-152|regimen|brand
DDI-DrugBank.d544.s3|168-179|cyclosporine|drug
DDI-DrugBank.d544.s3|182-199|USP ( MODIFIED ) and|brand
DDI-DrugBank.d544.s3|187-216|MODIFIED ) and corticosteroids .|brand
DDI-DrugBank.d544.s3|201-215|corticosteroids|group
DDI-DrugBank.d544.s4|37-44|Simulect|brand
DDI-DrugBank.d544.s4|82-93|azathioprine|drug
DDI-DrugBank.d544.s4|111-131|mycophenolate mofetil|drug
DDI-DrugBank.d544.s5|73-80|Simulect|brand
DDI-DrugBank.d544.s5|121-158|ATG/ALG , azathioprine , corticosteroids|brand
DDI-DrugBank.d544.s5|130-141|azathioprine|drug
DDI-DrugBank.d544.s5|144-158|corticosteroids|group
DDI-DrugBank.d544.s5|161-172|cyclosporine|drug
DDI-DrugBank.d544.s5|175-195|mycophenolate mofetil|drug
DDI-DrugBank.d524.s0|0-8|Albuterol|brand
DDI-DrugBank.d524.s0|47-55|diuretics|group
DDI-DrugBank.d323.s0|21-27|MYOBLOC|brand
DDI-DrugBank.d323.s1|76-79|same|drug
DDI-DrugBank.d138.s0|72-79|ALPHAGAN|brand
DDI-DrugBank.d138.s0|143-167|CNS depressants ( alcohol ,|brand
DDI-DrugBank.d138.s0|160-166|alcohol|brand
DDI-DrugBank.d138.s0|169-180|barbiturates|group
DDI-DrugBank.d138.s0|206-216|anesthetics|group
DDI-DrugBank.d138.s1|49-53|blood|group
DDI-DrugBank.d138.s2|110-127|cardiac glycosides|group
DDI-DrugBank.d138.s3|163-170|ALPHAGAN|brand
DDI-DrugBank.d138.s3|228-247|IOP lowering effect .|brand
DDI-DrugBank.d138.s4|36-49|catecholamines|group
DDI-DrugBank.d138.s4|57-64|ALPHAGAN|brand
DDI-DrugBank.d138.s5|132-137|amines|group
DDI-DrugBank.d89.s0|0-14|Cytochrome P450|drug
DDI-DrugBank.d89.s0|21-39|CYP1A2 ) is known to|drug
DDI-DrugBank.d89.s0|48-52|major|brand
DDI-DrugBank.d89.s0|91-98|caffeine|drug
DDI-DrugBank.d89.s1|11-18|caffeine|drug
DDI-DrugBank.d89.s1|85-107|CYP1A2 , inhibit CYP1A2 ,|drug
DDI-DrugBank.d89.s1|101-124|CYP1A2 , or induce CYP1A2|drug
DDI-DrugBank.d89.s1|119-125|CYP1A2 .|drug
DDI-DrugBank.d89.s2|41-48|caffeine|drug
DDI-DrugBank.d89.s3|36-43|caffeine|drug
DDI-DrugBank.d89.s3|126-133|caffeine|drug
DDI-DrugBank.d89.s3|154-163|cimetidine|drug
DDI-DrugBank.d89.s3|169-180|ketoconazole|drug
DDI-DrugBank.d89.s3|194-201|caffeine|drug
DDI-DrugBank.d89.s3|273-280|caffeine|drug
DDI-DrugBank.d89.s3|301-313|phenobarbital|drug
DDI-DrugBank.d89.s3|319-327|phenytoin|drug
DDI-DrugBank.d89.s4|0-7|Caffeine|drug
DDI-DrugBank.d89.s4|40-49|ketoprofen|drug
DDI-DrugBank.d89.s4|63-87|urine volume in 4 healthy|drug
DDI-DrugBank.d89.s6|24-31|caffeine|drug
DDI-DrugBank.d89.s6|37-48|theophylline|drug
DDI-DrugBank.d406.s0|18-28|cefamandole|drug
DDI-DrugBank.d406.s0|39-75|cephalothin sodium , magnesium sulfate|drug
DDI-DrugBank.d406.s0|51-56|sodium|group
DDI-DrugBank.d406.s0|59-67|magnesium|drug
DDI-DrugBank.d406.s0|78-89|prednisolone|drug
DDI-DrugBank.d406.s0|113-128|prochlorperazine|drug
DDI-DrugBank.d557.s0|109-134|cephalosporin antibiotics .|drug
DDI-DrugBank.d557.s1|186-230|cephalosporin antibiotics before parturition ,|drug
DDI-DrugBank.d378.s0|106-113|MAXIPIME|brand
DDI-DrugBank.d378.s1|79-92|cephalosporins|group
DDI-DrugBank.d378.s1|106-114|diuretics|group
DDI-DrugBank.d378.s1|124-133|furosemide|drug
DDI-DrugBank.d378.s2|56-63|cefepime|drug
DDI-DrugBank.d378.s2|109-115|glucose|group
DDI-DrugBank.d378.s2|124-158|urine when using Clinitest tablets|drug
DDI-DrugBank.d378.s3|23-29|glucose|group
DDI-DrugBank.d378.s3|56-62|glucose|group
DDI-DrugBank.d121.s0|104-129|cephalosporin antibiotics .|drug
DDI-DrugBank.d121.s1|30-39|probenecid|drug
DDI-DrugBank.d121.s1|53-70|AUC for cefprozil .|brand
DDI-DrugBank.d121.s1|61-69|cefprozil|drug
DDI-DrugBank.d121.s2|50-58|cefprozil|drug
DDI-DrugBank.d121.s2|118-124|antacid|brand
DDI-DrugBank.d172.s0|49-57|celecoxib|drug
DDI-DrugBank.d172.s0|108-111|P450|drug
DDI-DrugBank.d172.s1|0-8|Celecoxib|drug
DDI-DrugBank.d172.s1|24-65|predominantly mediated via cytochrome P450|drug
DDI-DrugBank.d172.s1|51-65|cytochrome P450|drug
DDI-DrugBank.d172.s2|21-29|celecoxib|drug
DDI-DrugBank.d172.s2|68-90|2C9 should be done with|drug
DDI-DrugBank.d172.s3|31-39|celecoxib|drug
DDI-DrugBank.d172.s3|64-78|cytochrome P450|drug
DDI-DrugBank.d172.s3|85-96|2C19 or 3A4 .|drug
DDI-DrugBank.d172.s3|93-96|3A4 .|drug
DDI-DrugBank.d172.s4|36-44|celecoxib|drug
DDI-DrugBank.d172.s4|92-106|cytochrome P450|drug
DDI-DrugBank.d172.s5|99-102|P450|drug
DDI-DrugBank.d172.s6|22-30|celecoxib|drug
DDI-DrugBank.d172.s6|90-100|fluconazole|drug
DDI-DrugBank.d172.s6|106-112|lithium|brand
DDI-DrugBank.d172.s7|107-116|furosemide|drug
DDI-DrugBank.d172.s7|122-136|ACE inhibitors .|brand
DDI-DrugBank.d172.s8|12-20|celecoxib|drug
DDI-DrugBank.d172.s8|73-81|glyburide|drug
DDI-DrugBank.d172.s8|84-95|ketoconazole|drug
DDI-DrugBank.d172.s8|98-109|methotrexate|drug
DDI-DrugBank.d172.s8|112-120|phenytoin|drug
DDI-DrugBank.d172.s8|123-133|tolbutamide|drug
DDI-DrugBank.d172.s8|140-147|warfarin|drug
DDI-DrugBank.d172.s9|0-30|ACE inhibitors : Reports suggest|brand
DDI-DrugBank.d172.s9|119-134|ACE ) inhibitors .|brand
DDI-DrugBank.d172.s10|66-73|CELEBREX|brand
DDI-DrugBank.d172.s11|0-9|Furosemide|drug
DDI-DrugBank.d172.s11|130-139|furosemide|drug
DDI-DrugBank.d172.s11|145-153|thiazides|group
DDI-DrugBank.d172.s13|0-6|Aspirin|brand
DDI-DrugBank.d172.s13|9-16|CELEBREX|brand
DDI-DrugBank.d172.s13|35-50|low dose aspirin|brand
DDI-DrugBank.d172.s14|39-45|aspirin|brand
DDI-DrugBank.d172.s14|52-59|CELEBREX|brand
DDI-DrugBank.d172.s14|96-131|GI ulceration or other complications|brand
DDI-DrugBank.d172.s14|153-160|CELEBREX|brand
DDI-DrugBank.d172.s15|41-48|CELEBREX|brand
DDI-DrugBank.d172.s15|74-80|aspirin|brand
DDI-DrugBank.d172.s16|0-10|Fluconazole|drug
DDI-DrugBank.d172.s16|43-53|fluconazole|drug
DDI-DrugBank.d172.s16|65-89|QD resulted in a two-fold|brand
DDI-DrugBank.d172.s16|103-111|celecoxib|drug
DDI-DrugBank.d172.s17|42-50|celecoxib|drug
DDI-DrugBank.d172.s17|67-70|P450|drug
DDI-DrugBank.d172.s17|79-89|fluconazole|drug
DDI-DrugBank.d172.s17|96-136|CLINICAL PHARMACOLOGY - Pharmacokinetics :|brand
DDI-DrugBank.d172.s17|105-147|PHARMACOLOGY - Pharmacokinetics : Metabolism|brand
DDI-DrugBank.d172.s18|0-7|CELEBREX|brand
DDI-DrugBank.d172.s18|83-93|fluconazole|drug
DDI-DrugBank.d172.s19|0-6|Lithium|brand
DDI-DrugBank.d172.s19|69-75|lithium|brand
DDI-DrugBank.d172.s19|141-147|lithium|brand
DDI-DrugBank.d172.s19|156-179|BID with CELEBREX 200 mg|brand
DDI-DrugBank.d172.s19|165-172|CELEBREX|brand
DDI-DrugBank.d172.s19|181-207|BID as compared to subjects|brand
DDI-DrugBank.d172.s19|219-225|lithium|brand
DDI-DrugBank.d172.s20|12-18|lithium|brand
DDI-DrugBank.d172.s20|63-70|CELEBREX|brand
DDI-DrugBank.d172.s21|0-11|Methotrexate|drug
DDI-DrugBank.d172.s21|52-60|arthritis|brand
DDI-DrugBank.d172.s21|78-89|methotrexate|drug
DDI-DrugBank.d172.s21|92-99|CELEBREX|brand
DDI-DrugBank.d172.s21|162-173|methotrexate|drug
DDI-DrugBank.d172.s22|0-7|Warfarin|drug
DDI-DrugBank.d172.s22|24-32|celecoxib|drug
DDI-DrugBank.d172.s22|66-73|warfarin|drug
DDI-DrugBank.d172.s22|153-160|warfarin|drug
DDI-DrugBank.d172.s23|19-27|celecoxib|drug
DDI-DrugBank.d172.s23|71-78|warfarin|drug
DDI-DrugBank.d172.s23|97-107|prothrombin|drug
DDI-DrugBank.d172.s24|51-58|CELEBREX|brand
DDI-DrugBank.d172.s24|65-72|warfarin|drug
DDI-DrugBank.d46.s0|62-80|thiazide diuretics .|drug
DDI-DrugBank.d46.s0|71-79|diuretics|group
DDI-DrugBank.d46.s1|2-8|Alcohol|brand
DDI-DrugBank.d46.s1|11-22|barbiturates|group
DDI-DrugBank.d46.s1|28-36|narcotics|group
DDI-DrugBank.d46.s3|39-45|insulin|group
DDI-DrugBank.d46.s7|2-15|Cholestyramine|drug
DDI-DrugBank.d46.s7|21-30|colestipol|drug
DDI-DrugBank.d46.s7|40-80|Cholestytamine and colestipol resins have|drug
DDI-DrugBank.d46.s7|59-68|colestipol|drug
DDI-DrugBank.d46.s7|107-146|thiazide diuretics and reducing diuretic|drug
DDI-DrugBank.d46.s7|116-124|diuretics|group
DDI-DrugBank.d46.s9|2-16|Corticosteroids|group
DDI-DrugBank.d46.s9|19-57|ACTH : Intensified electrolyte depletion|brand
DDI-DrugBank.d46.s11|10-15|amines|group
DDI-DrugBank.d46.s11|24-37|norepinephrine|drug
DDI-DrugBank.d46.s11|80-85|amines|group
DDI-DrugBank.d46.s13|11-16|muscle|brand
DDI-DrugBank.d46.s13|52-63|tubocurarine|drug
DDI-DrugBank.d46.s13|108-113|muscle|brand
DDI-DrugBank.d46.s15|2-8|Lithium|brand
DDI-DrugBank.d46.s15|46-54|diuretics|group
DDI-DrugBank.d46.s16|46-52|lithium|brand
DDI-DrugBank.d46.s16|77-83|lithium|brand
DDI-DrugBank.d46.s17|32-38|lithium|brand
DDI-DrugBank.d46.s17|90-103|chlorothiazide|drug
DDI-DrugBank.d46.s19|219-237|thiazide diuretics .|drug
DDI-DrugBank.d46.s19|228-236|diuretics|group
DDI-DrugBank.d46.s20|16-29|chlorothiazide|drug
DDI-DrugBank.d46.s20|49-72|anti-inflammatory agents|group
DDI-DrugBank.d46.s20|140-170|determine if the desired effect|drug
DDI-DrugBank.d46.s22|37-45|Thiazides|group
DDI-DrugBank.d46.s22|100-110|parathyroid|drug
DDI-DrugBank.d366.s0|48-55|dandruff|brand
DDI-DrugBank.d366.s0|60-68|psoriasis|group
DDI-DrugBank.d404.s0|17-25|vitamin D|drug
DDI-DrugBank.d404.s0|46-60|D2 , Vitamin D3 ,|drug
DDI-DrugBank.d404.s0|58-76|D3 , Calcitriol , and|drug
DDI-DrugBank.d404.s0|62-71|Calcitriol|drug
DDI-DrugBank.d404.s0|90-103|Cholestyramine|drug
DDI-DrugBank.d404.s0|106-119|Cholestyramine|drug
DDI-DrugBank.d404.s0|174-176|fat|drug
DDI-DrugBank.d404.s0|186-193|vitamins|group
DDI-DrugBank.d404.s1|54-62|vitamin D|drug
DDI-DrugBank.d404.s2|0-47|Phenytoin/Phenobarbital : The coadministration of|drug
DDI-DrugBank.d404.s2|49-57|phenytoin|drug
DDI-DrugBank.d404.s2|62-74|phenobarbital|drug
DDI-DrugBank.d404.s2|117-125|vitamin D|drug
DDI-DrugBank.d404.s3|6-10|blood|group
DDI-DrugBank.d404.s3|80-88|Rocaltrol|brand
DDI-DrugBank.d404.s4|0-8|Thiazides|group
DDI-DrugBank.d404.s4|11-19|Thiazides|group
DDI-DrugBank.d404.s4|75-81|calcium|drug
DDI-DrugBank.d404.s4|96-101|urine .|drug
DDI-DrugBank.d404.s5|63-71|thiazides|group
DDI-DrugBank.d404.s5|78-86|vitamin D|drug
DDI-DrugBank.d404.s7|11-19|Vitamin D|drug
DDI-DrugBank.d404.s7|52-55|care|brand
DDI-DrugBank.d404.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d404.s8|14-25|Ketoconazole|drug
DDI-DrugBank.d404.s8|68-74|enzymes|group
DDI-DrugBank.d404.s8|79-87|vitamin D|drug
DDI-DrugBank.d404.s9|14-18|serum|group
DDI-DrugBank.d404.s9|31-39|vitamin D|drug
DDI-DrugBank.d404.s9|133-144|ketoconazole|drug
DDI-DrugBank.d404.s10|45-56|ketoconazole|drug
DDI-DrugBank.d404.s10|63-71|vitamin D|drug
DDI-DrugBank.d404.s11|0-14|Corticosteroids|group
DDI-DrugBank.d404.s11|17-55|A relationship of functional antagonism|brand
DDI-DrugBank.d404.s11|72-80|vitamin D|drug
DDI-DrugBank.d404.s11|107-113|calcium|drug
DDI-DrugBank.d404.s11|131-145|corticosteroids|group
DDI-DrugBank.d404.s11|162-168|calcium|drug
DDI-DrugBank.d404.s12|32-40|vitamin D|drug
DDI-DrugBank.d404.s12|64-72|phosphate|brand
DDI-DrugBank.d404.s12|91-118|intestine , kidneys and bones|drug
DDI-DrugBank.d404.s12|200-204|serum|group
DDI-DrugBank.d404.s13|0-8|Vitamin D|drug
DDI-DrugBank.d404.s13|46-54|vitamin D|drug
DDI-DrugBank.d404.s14|0-6|Calcium|drug
DDI-DrugBank.d404.s15|0-8|Magnesium|drug
DDI-DrugBank.d404.s15|50-57|antacids|group
DDI-DrugBank.d404.s15|140-148|vitamin D|drug
DDI-DrugBank.d123.s0|5-14|quinolones|group
DDI-DrugBank.d123.s0|27-39|ciprofloxacin|drug
DDI-DrugBank.d123.s0|99-106|caffeine|drug
DDI-DrugBank.d123.s1|38-45|caffeine|drug
DDI-DrugBank.d123.s1|73-77|serum|group
DDI-DrugBank.d123.s2|5-14|quinolones|group
DDI-DrugBank.d123.s2|27-39|ciprofloxacin|drug
DDI-DrugBank.d123.s2|92-96|serum|group
DDI-DrugBank.d123.s2|131-142|cyclosporine|drug
DDI-DrugBank.d123.s3|0-8|Glyburide|drug
DDI-DrugBank.d123.s3|45-57|ciprofloxacin|drug
DDI-DrugBank.d123.s3|81-89|glyburide|drug
DDI-DrugBank.d123.s4|0-8|Histamine|drug
DDI-DrugBank.d123.s4|35-43|Histamine|drug
DDI-DrugBank.d123.s4|132-144|ciprofloxacin|drug
DDI-DrugBank.d123.s5|0-11|Methotrexate|drug
DDI-DrugBank.d123.s5|40-51|methotrexate|drug
DDI-DrugBank.d123.s5|103-115|ciprofloxacin|drug
DDI-DrugBank.d123.s5|168-179|methotrexate|drug
DDI-DrugBank.d123.s6|32-43|methotrexate|drug
DDI-DrugBank.d123.s7|26-37|methotrexate|drug
DDI-DrugBank.d123.s7|94-106|ciprofloxacin|drug
DDI-DrugBank.d123.s8|71-105|quinolone , including ciprofloxacin ,|drug
DDI-DrugBank.d123.s8|92-104|ciprofloxacin|drug
DDI-DrugBank.d123.s8|159-167|magnesium|drug
DDI-DrugBank.d123.s8|181-188|antacids|group
DDI-DrugBank.d123.s8|191-200|sucralfate|drug
DDI-DrugBank.d123.s8|203-207|VIDEX|brand
DDI-DrugBank.d123.s8|279-285|calcium|drug
DDI-DrugBank.d123.s8|288-291|iron|drug
DDI-DrugBank.d123.s8|297-300|zinc|drug
DDI-DrugBank.d123.s8|347-359|ciprofloxacin|drug
DDI-DrugBank.d123.s8|375-379|serum|group
DDI-DrugBank.d123.s8|385-420|urine levels considerably lower than|drug
DDI-DrugBank.d123.s9|0-9|Proquin XR|brand
DDI-DrugBank.d123.s10|66-78|ciprofloxacin|drug
DDI-DrugBank.d123.s10|144-151|antacids|group
DDI-DrugBank.d123.s11|47-53|aspirin|brand
DDI-DrugBank.d123.s11|108-117|quinolones|group
DDI-DrugBank.d123.s12|0-9|Omeprazole|drug
DDI-DrugBank.d123.s12|49-61|ciprofloxacin|drug
DDI-DrugBank.d123.s12|86-95|Proquin XR|brand
DDI-DrugBank.d123.s12|121-130|Proquin XR|brand
DDI-DrugBank.d123.s12|156-165|omeprazole|drug
DDI-DrugBank.d123.s13|0-9|Omeprazole|drug
DDI-DrugBank.d123.s13|43-52|Proquin XR|brand
DDI-DrugBank.d123.s14|0-8|Phenytoin|drug
DDI-DrugBank.d123.s14|19-23|serum|group
DDI-DrugBank.d123.s14|35-43|phenytoin|drug
DDI-DrugBank.d123.s14|124-136|ciprofloxacin|drug
DDI-DrugBank.d123.s15|0-9|Probenecid|drug
DDI-DrugBank.d123.s15|12-21|Probenecid|drug
DDI-DrugBank.d123.s15|66-78|ciprofloxacin|drug
DDI-DrugBank.d123.s15|121-133|ciprofloxacin|drug
DDI-DrugBank.d123.s15|138-142|serum|group
DDI-DrugBank.d123.s16|0-11|Theophylline|drug
DDI-DrugBank.d123.s16|33-42|quinolones|group
DDI-DrugBank.d123.s16|74-86|ciprofloxacin|drug
DDI-DrugBank.d123.s16|93-104|theophylline|drug
DDI-DrugBank.d123.s16|127-131|serum|group
DDI-DrugBank.d123.s16|151-162|theophylline|drug
DDI-DrugBank.d123.s18|38-42|serum|group
DDI-DrugBank.d123.s18|54-65|theophylline|drug
DDI-DrugBank.d123.s19|0-7|Warfarin|drug
DDI-DrugBank.d123.s19|10-19|Quinolones|group
DDI-DrugBank.d123.s19|89-96|warfarin|drug
DDI-DrugBank.d123.s20|52-62|prothrombin|drug
DDI-DrugBank.d322.s0|0-9|Amantadine|drug
DDI-DrugBank.d322.s0|88-96|clidinium|drug
DDI-DrugBank.d322.s1|0-8|Clidinium|drug
DDI-DrugBank.d322.s1|37-50|phenothiazines|group
DDI-DrugBank.d322.s1|53-60|levodopa|drug
DDI-DrugBank.d322.s1|67-78|ketoconazole|drug
DDI-DrugBank.d136.s0|0-6|Alcohol|brand
DDI-DrugBank.d136.s0|44-53|cimetidine|drug
DDI-DrugBank.d473.s0|74-77|date|drug
DDI-DrugBank.d473.s0|118-132|cytochrome p450|drug
DDI-DrugBank.d473.s0|199-209|clofarabine|drug
DDI-DrugBank.d473.s1|14-24|clofarabine|drug
DDI-DrugBank.d473.s1|47-61|cytochrome p450|drug
DDI-DrugBank.d473.s2|93-98|CLOLAR|brand
DDI-DrugBank.d473.s3|76-81|CLOLAR|brand
DDI-DrugBank.d12.s0|33-46|anticoagulants|group
DDI-DrugBank.d12.s1|109-116|maintain|brand
DDI-DrugBank.d12.s1|122-132|prothrombin|drug
DDI-DrugBank.d12.s1|163-169|prevent|brand
DDI-DrugBank.d12.s2|9-19|prothrombin|drug
DDI-DrugBank.d12.s2|99-109|prothrombin|drug
DDI-DrugBank.d12.s3|44-52|phenytoin|drug
DDI-DrugBank.d12.s3|57-67|tolbutamide|drug
DDI-DrugBank.d12.s5|27-37|tolbutamide|drug
DDI-DrugBank.d12.s6|125-134|lovastatin|drug
DDI-DrugBank.d12.s7|168-177|lovastatin|drug
DDI-DrugBank.d12.s8|79-89|gemfibrozil|drug
DDI-DrugBank.d12.s8|196-205|clofibrate|drug
DDI-DrugBank.d12.s9|31-40|lovastatin|drug
DDI-DrugBank.d495.s0|30-38|clonidine|drug
DDI-DrugBank.d495.s0|110-118|clonidine|drug
DDI-DrugBank.d495.s1|0-8|Clonidine|drug
DDI-DrugBank.d495.s1|66-72|alcohol|brand
DDI-DrugBank.d495.s1|75-86|barbiturates|group
DDI-DrugBank.d495.s2|0-12|Amitriptyline|drug
DDI-DrugBank.d495.s2|34-42|clonidine|drug
DDI-DrugBank.d495.s2|117-125|Clonidine|drug
DDI-DrugBank.d495.s2|171-177|alcohol|brand
DDI-DrugBank.d495.s2|180-191|barbiturates|group
DDI-DrugBank.d495.s3|9-18|analgesics|group
DDI-DrugBank.d495.s3|62-70|clonidine|drug
DDI-DrugBank.d495.s4|68-76|clonidine|drug
DDI-DrugBank.d495.s5|55-63|analgesic|brand
DDI-DrugBank.d495.s6|65-73|clonidine|drug
DDI-DrugBank.d495.s7|72-91|AV block , caution is|brand
DDI-DrugBank.d495.s7|125-133|clonidine|drug
DDI-DrugBank.d495.s7|163-167|sinus|brand
DDI-DrugBank.d495.s7|186-210|AV nodal conduction ( e.g.|brand
DDI-DrugBank.d495.s7|224-230|calcium|drug
DDI-DrugBank.d495.s8|100-111|fluphenazine|drug
DDI-DrugBank.d495.s8|122-130|clonidine|drug
DDI-DrugBank.d495.s9|23-31|clonidine|drug
DDI-DrugBank.d495.s9|99-107|clonidine|drug
DDI-DrugBank.d495.s10|9-17|clonidine|drug
DDI-DrugBank.d495.s10|23-29|prolong|brand
DDI-DrugBank.d495.s10|87-97|anesthetics|group
DDI-DrugBank.d480.s0|19-27|Clozapine|drug
DDI-DrugBank.d480.s1|55-63|Clozapine|drug
DDI-DrugBank.d480.s3|11-19|Clozapine|drug
DDI-DrugBank.d480.s4|18-42|CNS effects of Clozapine ,|brand
DDI-DrugBank.d480.s4|33-41|Clozapine|drug
DDI-DrugBank.d480.s4|120-126|alcohol|brand
DDI-DrugBank.d480.s5|43-51|clozapine|drug
DDI-DrugBank.d480.s7|59-76|psychotropic drugs|group
DDI-DrugBank.d480.s7|86-94|Clozapine|drug
DDI-DrugBank.d480.s8|74-82|Clozapine|drug
DDI-DrugBank.d480.s8|152-160|clozapine|drug
DDI-DrugBank.d480.s8|196-209|benzodiazepine|drug
DDI-DrugBank.d480.s9|0-8|Clozapine|drug
DDI-DrugBank.d480.s10|22-32|epinephrine|drug
DDI-DrugBank.d480.s10|127-137|epinephrine|drug
DDI-DrugBank.d480.s11|38-46|Clozapine|drug
DDI-DrugBank.d480.s11|72-91|CYP 450 isozymes , in|brand
DDI-DrugBank.d480.s11|104-116|1A2 , 2D6 , and|drug
DDI-DrugBank.d480.s11|109-121|2D6 , and 3A4 .|drug
DDI-DrugBank.d480.s11|118-121|3A4 .|drug
DDI-DrugBank.d480.s13|146-152|enzymes|group
DDI-DrugBank.d480.s14|52-66|cytochrome P450|drug
DDI-DrugBank.d480.s14|110-118|clozapine|drug
DDI-DrugBank.d480.s15|0-8|Phenytoin|drug
DDI-DrugBank.d480.s15|11-18|nicotine|drug
DDI-DrugBank.d480.s15|25-32|rifampin|brand
DDI-DrugBank.d480.s15|47-55|Clozapine|drug
DDI-DrugBank.d480.s15|139-147|Clozapine|drug
DDI-DrugBank.d480.s16|69-83|cytochrome P450|drug
DDI-DrugBank.d480.s16|128-136|clozapine|drug
DDI-DrugBank.d480.s17|0-9|Cimetidine|drug
DDI-DrugBank.d480.s17|12-19|caffeine|drug
DDI-DrugBank.d480.s17|26-37|erythromycin|drug
DDI-DrugBank.d480.s17|69-77|Clozapine|drug
DDI-DrugBank.d480.s18|28-36|Clozapine|drug
DDI-DrugBank.d480.s18|42-54|carbamazepine|drug
DDI-DrugBank.d480.s18|131-143|carbamazepine|drug
DDI-DrugBank.d480.s18|189-197|Clozapine|drug
DDI-DrugBank.d480.s19|50-58|clozapine|drug
DDI-DrugBank.d480.s19|91-101|fluvoxamine|drug
DDI-DrugBank.d480.s19|106-115|paroxetine|drug
DDI-DrugBank.d480.s20|66-74|clozapine|drug
DDI-DrugBank.d480.s20|97-139|N-desmethylclozapine and clozapine N-oxide ,|drug
DDI-DrugBank.d480.s20|122-130|clozapine|drug
DDI-DrugBank.d480.s20|160-170|fluvoxamine|drug
DDI-DrugBank.d480.s20|204-227|baseline concentrations .|drug
DDI-DrugBank.d480.s21|0-9|Paroxetine|drug
DDI-DrugBank.d480.s21|56-64|clozapine|drug
DDI-DrugBank.d480.s22|84-92|clozapine|drug
DDI-DrugBank.d480.s22|129-137|clozapine|drug
DDI-DrugBank.d480.s22|154-163|paroxetine|drug
DDI-DrugBank.d480.s22|166-175|fluoxetine|drug
DDI-DrugBank.d480.s22|182-191|sertraline|drug
DDI-DrugBank.d480.s23|115-123|Clozapine|drug
DDI-DrugBank.d480.s23|173-183|fluvoxamine|drug
DDI-DrugBank.d480.s24|0-30|A reduced Clozapine dose should|brand
DDI-DrugBank.d480.s24|10-18|Clozapine|drug
DDI-DrugBank.d480.s25|0-11|A subset ( 3 %|brand
DDI-DrugBank.d480.s25|86-92|enzymes|group
DDI-DrugBank.d480.s25|106-120|cytochrome P450|drug
DDI-DrugBank.d480.s25|130-133|P450|drug
DDI-DrugBank.d480.s26|84-99|dextromethorphan|drug
DDI-DrugBank.d480.s26|137-145|clozapine|drug
DDI-DrugBank.d480.s27|76-84|clozapine|drug
DDI-DrugBank.d480.s28|97-105|clozapine|drug
DDI-DrugBank.d480.s28|108-146|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d480.s29|19-27|clozapine|drug
DDI-DrugBank.d480.s29|61-75|cytochrome P450|drug
DDI-DrugBank.d480.s29|140-148|clozapine|drug
DDI-DrugBank.d480.s30|32-40|clozapine|drug
DDI-DrugBank.d480.s30|124-137|phenothiazines|group
DDI-DrugBank.d480.s30|140-152|carbamazepine|drug
DDI-DrugBank.d480.s30|164-188|1C antiarrhythmics ( e.g. ,|drug
DDI-DrugBank.d480.s30|190-200|propafenone|drug
DDI-DrugBank.d480.s30|203-212|flecainide|drug
DDI-DrugBank.d480.s30|218-226|encainide|drug
DDI-DrugBank.d480.s30|265-273|quinidine|drug
DDI-DrugBank.d146.s0|0-9|Colchicine|drug
DDI-DrugBank.d146.s0|27-43|acidifying agents|group
DDI-DrugBank.d146.s1|14-23|colchicine|drug
DDI-DrugBank.d146.s2|0-9|Colchicine|drug
DDI-DrugBank.d146.s2|43-58|CNS depressants .|brand
DDI-DrugBank.d146.s3|54-63|colchicine|drug
DDI-DrugBank.d345.s0|6-15|colestipol|drug
DDI-DrugBank.d345.s0|93-98|anions|group
DDI-DrugBank.d345.s0|120-124|acids|group
DDI-DrugBank.d345.s1|37-46|colestipol|drug
DDI-DrugBank.d345.s3|43-50|COLESTID|brand
DDI-DrugBank.d345.s4|78-85|COLESTID|brand
DDI-DrugBank.d345.s5|18-27|colestipol|drug
DDI-DrugBank.d345.s5|75-85|propranolol|drug
DDI-DrugBank.d345.s5|134-144|propranolol|drug
DDI-DrugBank.d345.s6|80-89|colestipol|drug
DDI-DrugBank.d345.s6|109-119|propranolol|drug
DDI-DrugBank.d345.s6|207-217|propranolol|drug
DDI-DrugBank.d345.s9|23-33|propranolol|drug
DDI-DrugBank.d345.s9|59-66|COLESTID|brand
DDI-DrugBank.d345.s9|111-121|therapeutic|brand
DDI-DrugBank.d345.s10|46-59|chlorothiazide|drug
DDI-DrugBank.d345.s10|156-165|colestipol|drug
DDI-DrugBank.d345.s11|18-29|tetracycline|drug
DDI-DrugBank.d345.s11|32-41|furosemide|drug
DDI-DrugBank.d345.s11|44-55|penicillin G|group
DDI-DrugBank.d345.s11|58-76|hydrochlorothiazide|drug
DDI-DrugBank.d345.s11|83-93|gemfibrozil|drug
DDI-DrugBank.d345.s11|154-163|colestipol|drug
DDI-DrugBank.d345.s12|31-68|determine the effect of administration|drug
DDI-DrugBank.d345.s12|86-95|colestipol|drug
DDI-DrugBank.d345.s13|24-28|blood|group
DDI-DrugBank.d345.s13|62-71|colestipol|drug
DDI-DrugBank.d345.s13|137-143|aspirin|brand
DDI-DrugBank.d345.s13|146-156|clindamycin|drug
DDI-DrugBank.d345.s13|159-168|clofibrate|drug
DDI-DrugBank.d345.s13|171-180|methyldopa|drug
DDI-DrugBank.d345.s13|199-204|niacin|drug
DDI-DrugBank.d345.s13|208-218|tolbutamide|drug
DDI-DrugBank.d345.s13|221-229|phenytoin|drug
DDI-DrugBank.d345.s13|234-241|warfarin|drug
DDI-DrugBank.d345.s14|120-129|colestipol|drug
DDI-DrugBank.d345.s14|168-174|digoxin|drug
DDI-DrugBank.d345.s14|180-188|digitoxin|drug
DDI-DrugBank.d345.s16|14-23|colestipol|drug
DDI-DrugBank.d345.s16|62-67|health|brand
DDI-DrugBank.d345.s16|208-217|colestipol|drug
DDI-DrugBank.d345.s17|72-80|phosphate|brand
DDI-DrugBank.d345.s17|98-111|hydrocortisone|drug
DDI-DrugBank.d487.s1|26-32|enzymes|group
DDI-DrugBank.d487.s1|42-54|phenobarbital|drug
DDI-DrugBank.d487.s1|57-65|phenytoin|drug
DDI-DrugBank.d487.s1|71-78|rifampin|brand
DDI-DrugBank.d487.s1|110-124|corticosteroids|group
DDI-DrugBank.d487.s1|155-188|corticosteroid dose to achieve the|drug
DDI-DrugBank.d487.s2|14-27|troleandomycin|drug
DDI-DrugBank.d487.s2|33-44|ketoconazole|drug
DDI-DrugBank.d487.s2|76-90|corticosteroids|group
DDI-DrugBank.d487.s3|23-58|corticosteroid should be titrated to|drug
DDI-DrugBank.d487.s4|0-14|Corticosteroids|group
DDI-DrugBank.d487.s4|64-70|aspirin|brand
DDI-DrugBank.d487.s5|40-44|serum|group
DDI-DrugBank.d487.s5|102-129|corticosteroid is withdrawn .|drug
DDI-DrugBank.d487.s6|0-6|Aspirin|brand
DDI-DrugBank.d487.s6|54-96|cortico-steroids in patients suffering from|drug
DDI-DrugBank.d487.s7|14-28|corticosteroids|group
DDI-DrugBank.d487.s7|38-51|anticoagulants|group
DDI-DrugBank.d487.s8|63-76|anticoagulants|group
DDI-DrugBank.d487.s8|107-121|corticosteroids|group
DDI-DrugBank.d487.s9|54-61|maintain|brand
DDI-DrugBank.d229.s0|35-49|Cromolyn sodium|group
DDI-DrugBank.d229.s0|55-67|isoproterenol|brand
DDI-DrugBank.d229.s1|0-14|Cromolyn sodium|group
DDI-DrugBank.d229.s1|204-208|major|brand
DDI-DrugBank.d229.s2|0-12|Isoproterenol|brand
DDI-DrugBank.d229.s3|33-47|cromolyn sodium|group
DDI-DrugBank.d229.s3|168-180|isoproterenol|brand
DDI-DrugBank.d337.s0|0-7|Warfarin|drug
DDI-DrugBank.d337.s0|40-49|daptomycin|drug
DDI-DrugBank.d337.s0|96-103|warfarin|drug
DDI-DrugBank.d337.s0|204-236|INR was not significantly altered|brand
DDI-DrugBank.d337.s1|105-110|muscle|brand
DDI-DrugBank.d337.s1|164-167|CPK .|brand
DDI-DrugBank.d337.s2|73-91|I trial in which 10|brand
DDI-DrugBank.d337.s2|120-130|simvastatin|drug
DDI-DrugBank.d337.s2|171-180|daptomycin|drug
DDI-DrugBank.d337.s3|70-77|Fentanyl|drug
DDI-DrugBank.d337.s3|226-233|Fentanyl|drug
DDI-DrugBank.d167.s0|71-77|digoxin|drug
DDI-DrugBank.d167.s1|21-47|neostgmine , physostigmine ) ,|drug
DDI-DrugBank.d167.s1|33-45|physostigmine|drug
DDI-DrugBank.d167.s1|49-81|lignocaine , quinine , procainamide|drug
DDI-DrugBank.d167.s1|61-67|quinine|drug
DDI-DrugBank.d167.s1|70-81|procainamide|drug
DDI-DrugBank.d167.s2|66-76|anesthetics|group
DDI-DrugBank.d167.s2|85-95|anesthetics|group
DDI-DrugBank.d167.s2|102-110|lidocaine|drug
DDI-DrugBank.d167.s2|113-120|procaine|drug
DDI-DrugBank.d167.s2|154-160|lithium|brand
DDI-DrugBank.d167.s2|177-187|terbutaline|drug
DDI-DrugBank.d84.s0|34-39|Exjade|brand
DDI-DrugBank.d84.s0|65-71|antacid|brand
DDI-DrugBank.d84.s1|9-19|deferasirox|drug
DDI-DrugBank.d84.s1|64-67|iron|drug
DDI-DrugBank.d84.s1|70-75|Exjade|brand
DDI-DrugBank.d84.s1|122-128|antacid|brand
DDI-DrugBank.d84.s2|23-28|Exjade|brand
DDI-DrugBank.d84.s2|71-77|digoxin|drug
DDI-DrugBank.d84.s3|14-20|digoxin|drug
DDI-DrugBank.d84.s3|25-30|Exjade|brand
DDI-DrugBank.d84.s4|34-39|Exjade|brand
DDI-DrugBank.d84.s4|45-53|vitamin C|brand
DDI-DrugBank.d84.s5|9-17|vitamin C|brand
DDI-DrugBank.d84.s6|19-24|Exjade|brand
DDI-DrugBank.d84.s6|31-41|hydroxyurea|drug
DDI-DrugBank.d84.s7|17-27|deferasirox|drug
DDI-DrugBank.d84.s7|43-53|hydroxyurea|drug
DDI-DrugBank.d84.s8|0-5|Exjade|brand
DDI-DrugBank.d84.s8|41-44|iron|drug
DDI-DrugBank.d84.s9|44-66|AUC ) of deferasirox was|brand
DDI-DrugBank.d84.s9|52-62|deferasirox|drug
DDI-DrugBank.d84.s10|0-10|Deferasirox|drug
DDI-DrugBank.d84.s11|0-5|Exjade|brand
DDI-DrugBank.d84.s11|55-59|water|drug
DDI-DrugBank.d84.s11|62-67|orange|drug
DDI-DrugBank.d84.s11|79-83|apple|drug
DDI-DrugBank.d149.s0|30-37|HUMORSOL|drug
DDI-DrugBank.d149.s0|44-58|succinylcholine|drug
DDI-DrugBank.d363.s0|120-125|muscle|brand
DDI-DrugBank.d363.s0|168-177|anesthetic|brand
DDI-DrugBank.d363.s1|14-23|desflurane|drug
DDI-DrugBank.d363.s2|5-14|isoflurane|drug
DDI-DrugBank.d363.s2|17-26|desflurane|drug
DDI-DrugBank.d363.s2|37-83|predispose to premature ventricular arrhythmias|drug
DDI-DrugBank.d363.s2|124-134|epinephrine|drug
DDI-DrugBank.d363.s2|139-144|swine .|drug
DDI-DrugBank.d285.s0|140-147|rifampin|brand
DDI-DrugBank.d285.s1|0-28|A similar association , though|brand
DDI-DrugBank.d285.s1|67-78|barbiturates|group
DDI-DrugBank.d285.s1|98-106|phenytoin|drug
DDI-DrugBank.d285.s1|116-128|carbamazepine|drug
DDI-DrugBank.d285.s1|148-159|griseofulvin|drug
DDI-DrugBank.d285.s1|162-171|ampicillin|drug
DDI-DrugBank.d285.s1|178-190|tetracyclines|group
DDI-DrugBank.d293.s0|18-24|thyroid|brand
DDI-DrugBank.d293.s0|44-56|levothyroxine|drug
DDI-DrugBank.d293.s0|88-95|antacids|group
DDI-DrugBank.d293.s0|120-129|famotidine|drug
DDI-DrugBank.d293.s0|132-141|ranitidine|drug
DDI-DrugBank.d293.s0|149-170|proton pump inhibitors|group
DDI-DrugBank.d293.s0|179-190|lansoprazole|drug
DDI-DrugBank.d293.s0|193-202|omeprazole|drug
DDI-DrugBank.d352.s0|38-44|insulin|group
DDI-DrugBank.d352.s1|28-38|anesthetics|group
DDI-DrugBank.d352.s2|23-36|diethylpropion|drug
DDI-DrugBank.d352.s3|12-25|diethylpropion|drug
DDI-DrugBank.d352.s3|76-87|guanethidine|drug
DDI-DrugBank.d352.s4|18-31|phenothiazines|group
DDI-DrugBank.d352.s4|72-85|diethylpropion|drug
DDI-DrugBank.d450.s0|20-28|diuretics|group
DDI-DrugBank.d450.s0|36-40|major|brand
DDI-DrugBank.d450.s1|0-6|Calcium|drug
DDI-DrugBank.d450.s2|0-8|Quinidine|drug
DDI-DrugBank.d450.s2|11-19|verapamil|drug
DDI-DrugBank.d450.s2|22-31|amiodarone|drug
DDI-DrugBank.d450.s2|34-44|propafenone|drug
DDI-DrugBank.d450.s2|47-58|indomethacin|drug
DDI-DrugBank.d450.s2|61-72|itraconazole|drug
DDI-DrugBank.d450.s2|75-84|alprazolam|drug
DDI-DrugBank.d450.s2|91-104|spironolactone|drug
DDI-DrugBank.d450.s2|116-120|serum|group
DDI-DrugBank.d450.s3|0-11|Erythromycin|drug
DDI-DrugBank.d450.s3|17-30|clarithromycin|drug
DDI-DrugBank.d450.s3|79-90|tetracycline|drug
DDI-DrugBank.d450.s3|105-111|digoxin|drug
DDI-DrugBank.d450.s3|151-157|digoxin|drug
DDI-DrugBank.d450.s3|196-223|intestine , so that digitalis|drug
DDI-DrugBank.d450.s4|47-53|digoxin|drug
DDI-DrugBank.d450.s5|0-12|Propantheline|drug
DDI-DrugBank.d450.s5|18-30|diphenoxylate|drug
DDI-DrugBank.d450.s5|74-80|digoxin|drug
DDI-DrugBank.d450.s6|0-7|Antacids|group
DDI-DrugBank.d450.s6|25-37|sulfasalazine|drug
DDI-DrugBank.d450.s6|40-47|neomycin|drug
DDI-DrugBank.d450.s6|50-63|cholestyramine|drug
DDI-DrugBank.d450.s6|96-109|metoclopramide|drug
DDI-DrugBank.d450.s6|141-147|digoxin|drug
DDI-DrugBank.d450.s6|191-195|serum|group
DDI-DrugBank.d450.s7|0-7|Rifampin|brand
DDI-DrugBank.d450.s7|22-26|serum|group
DDI-DrugBank.d450.s7|139-145|digoxin|drug
DDI-DrugBank.d450.s8|81-87|quinine|drug
DDI-DrugBank.d450.s8|90-102|penicillamine|drug
DDI-DrugBank.d450.s8|108-112|serum|group
DDI-DrugBank.d450.s9|0-6|Thyroid|brand
DDI-DrugBank.d450.s9|98-104|digoxin|drug
DDI-DrugBank.d450.s10|19-25|digoxin|drug
DDI-DrugBank.d450.s10|31-46|sympathomimetics|group
DDI-DrugBank.d450.s11|0-14|Succinylcholine|drug
DDI-DrugBank.d450.s11|48-56|potassium|drug
DDI-DrugBank.d450.s11|63-68|muscle|brand
DDI-DrugBank.d450.s12|37-43|calcium|drug
DDI-DrugBank.d450.s12|66-72|digoxin|drug
DDI-DrugBank.d450.s12|106-112|control|brand
DDI-DrugBank.d450.s12|161-189|AV node conduction can result|brand
DDI-DrugBank.d450.s12|194-201|advanced|brand
DDI-DrugBank.d450.s12|206-213|complete|brand
DDI-DrugBank.d450.s13|73-79|digoxin|drug
DDI-DrugBank.d450.s14|56-62|digoxin|drug
DDI-DrugBank.d450.s14|148-182|decline in glomerular filtration or|drug
DDI-DrugBank.d450.s14|230-236|digoxin|drug
DDI-DrugBank.d506.s0|3-11|phenytoin|drug
DDI-DrugBank.d506.s0|74-80|Norpace|brand
DDI-DrugBank.d506.s0|85-91|Norpace|brand
DDI-DrugBank.d506.s0|120-131|disopyramide|drug
DDI-DrugBank.d506.s1|14-25|disopyramide|drug
DDI-DrugBank.d506.s2|32-40|quinidine|drug
DDI-DrugBank.d506.s2|43-54|procainamide|drug
DDI-DrugBank.d506.s2|57-65|lidocaine|drug
DDI-DrugBank.d506.s2|68-78|propranolol|drug
DDI-DrugBank.d506.s2|127-133|Norpace|brand
DDI-DrugBank.d506.s3|26-59|QRS complex and/or prolongation of|brand
DDI-DrugBank.d506.s3|65-89|Q-T interval may occur in|brand
DDI-DrugBank.d506.s4|76-82|Norpace|brand
DDI-DrugBank.d506.s4|115-125|propranolol|drug
DDI-DrugBank.d506.s4|130-137|diazepam|drug
DDI-DrugBank.d506.s5|30-36|Norpace|brand
DDI-DrugBank.d506.s5|42-50|quinidine|drug
DDI-DrugBank.d506.s5|91-102|disopyramide|drug
DDI-DrugBank.d506.s5|142-150|quinidine|drug
DDI-DrugBank.d506.s6|0-6|Norpace|brand
DDI-DrugBank.d506.s6|26-30|serum|group
DDI-DrugBank.d506.s7|16-27|disopyramide|drug
DDI-DrugBank.d506.s7|43-54|erythromycin|drug
DDI-DrugBank.d506.s7|92-96|serum|group
DDI-DrugBank.d506.s7|116-127|disopyramide|drug
DDI-DrugBank.d506.s7|168-201|QRS complex and/or prolongation of|brand
DDI-DrugBank.d506.s7|207-219|Q-T interval .|brand
DDI-DrugBank.d506.s8|16-27|disopyramide|drug
DDI-DrugBank.d506.s8|51-67|enzyme inhibitors|group
DDI-DrugBank.d506.s9|44-52|verapamil|drug
DDI-DrugBank.d506.s9|58-69|disopyramide|drug
DDI-DrugBank.d506.s9|95-106|disopyramide|drug
DDI-DrugBank.d506.s9|176-184|verapamil|drug
DDI-DrugBank.d558.s0|34-37|None|brand
DDI-DrugBank.d558.s1|23-32|Cimetidine|drug
DDI-DrugBank.d558.s1|54-63|cimetidine|drug
DDI-DrugBank.d558.s2|0-9|Cimetidine|drug
DDI-DrugBank.d558.s2|21-47|BID ( the usual prescription|brand
DDI-DrugBank.d558.s2|76-82|TIKOSYN|brand
DDI-DrugBank.d558.s2|93-107|BID ) for 7 days|brand
DDI-DrugBank.d558.s2|136-145|dofetilide|drug
DDI-DrugBank.d558.s3|0-9|Cimetidine|drug
DDI-DrugBank.d558.s3|30-43|BID ( OTC dose )|brand
DDI-DrugBank.d558.s3|35-55|OTC dose ) resulted in|brand
DDI-DrugBank.d558.s3|75-84|dofetilide|drug
DDI-DrugBank.d558.s4|56-65|cimetidine|drug
DDI-DrugBank.d558.s5|22-28|TIKOSYN|brand
DDI-DrugBank.d558.s5|75-84|omeprazole|drug
DDI-DrugBank.d558.s5|87-96|ranitidine|drug
DDI-DrugBank.d558.s5|102-109|antacids|group
DDI-DrugBank.d558.s5|125-133|magnesium|drug
DDI-DrugBank.d558.s5|174-183|cimetidine|drug
DDI-DrugBank.d558.s5|251-257|TIKOSYN|brand
DDI-DrugBank.d558.s6|0-8|Verapamil|drug
DDI-DrugBank.d558.s6|30-38|verapamil|drug
DDI-DrugBank.d558.s7|21-27|TIKOSYN|brand
DDI-DrugBank.d558.s7|34-42|verapamil|drug
DDI-DrugBank.d558.s7|69-78|dofetilide|drug
DDI-DrugBank.d558.s7|136-145|dofetilide|drug
DDI-DrugBank.d558.s8|54-85|DIAMOND patient populations , the|brand
DDI-DrugBank.d558.s8|117-125|verapamil|drug
DDI-DrugBank.d558.s8|132-141|dofetilide|drug
DDI-DrugBank.d558.s9|0-11|Ketoconazole|drug
DDI-DrugBank.d558.s9|33-44|ketoconazole|drug
DDI-DrugBank.d558.s10|0-11|Ketoconazole|drug
DDI-DrugBank.d558.s10|91-97|TIKOSYN|brand
DDI-DrugBank.d558.s10|108-122|BID ) for 7 days|brand
DDI-DrugBank.d558.s10|151-160|dofetilide|drug
DDI-DrugBank.d558.s10|207-219|AUC by 41 % in|brand
DDI-DrugBank.d558.s11|0-11|Trimethoprim|drug
DDI-DrugBank.d558.s11|42-57|Sulfamethoxazole|drug
DDI-DrugBank.d558.s11|79-90|trimethoprim|drug
DDI-DrugBank.d558.s11|121-136|sulfamethoxazole|drug
DDI-DrugBank.d558.s12|0-18|Hydrochlorothiazide|drug
DDI-DrugBank.d558.s12|21-37|HCTZ ) Alone or in|brand
DDI-DrugBank.d558.s12|56-66|Triamterene|drug
DDI-DrugBank.d558.s12|88-115|HCTZ alone or in combination|brand
DDI-DrugBank.d558.s12|122-132|triamterene|drug
DDI-DrugBank.d558.s13|0-15|HCTZ 50 mg QD or|brand
DDI-DrugBank.d558.s13|11-42|QD or HCTZ/triamterene 50/100 mg|brand
DDI-DrugBank.d558.s13|44-78|QD was co-administered with TIKOSYN|brand
DDI-DrugBank.d558.s13|72-78|TIKOSYN|brand
DDI-DrugBank.d558.s13|89-103|BID ) for 5 days|brand
DDI-DrugBank.d558.s14|22-47|HCTZ alone , dofetilide AUC|brand
DDI-DrugBank.d558.s14|34-43|dofetilide|drug
DDI-DrugBank.d558.s17|81-90|dofetilide|drug
DDI-DrugBank.d558.s17|123-127|serum|group
DDI-DrugBank.d558.s18|7-35|DIAMOND trials , 1252 patients|brand
DDI-DrugBank.d558.s18|55-61|TIKOSYN|brand
DDI-DrugBank.d558.s18|67-75|diuretics|group
DDI-DrugBank.d558.s18|177-185|diuretics|group
DDI-DrugBank.d558.s19|28-36|potassium|drug
DDI-DrugBank.d558.s19|48-56|diuretics|group
DDI-DrugBank.d558.s19|104-131|DIAMOND trials , the patients|brand
DDI-DrugBank.d558.s19|136-142|TIKOSYN|brand
DDI-DrugBank.d558.s19|194-198|death|drug
DDI-DrugBank.d558.s19|213-228|CI 0.376 , 1.230 )|brand
DDI-DrugBank.d558.s20|28-37|Dofetilide|drug
DDI-DrugBank.d558.s21|64-70|TIKOSYN|brand
DDI-DrugBank.d558.s22|68-78|triamterene|drug
DDI-DrugBank.d558.s22|81-89|metformin|drug
DDI-DrugBank.d558.s22|95-103|amiloride|drug
DDI-DrugBank.d558.s22|137-140|care|brand
DDI-DrugBank.d558.s22|165-174|dofetilide|drug
DDI-DrugBank.d558.s23|0-9|Dofetilide|drug
DDI-DrugBank.d558.s23|51-84|CYP3A4 isoenzyme of the cytochrome|drug
DDI-DrugBank.d558.s23|75-89|cytochrome P450|drug
DDI-DrugBank.d558.s24|18-57|CYP3A4 isoenzyme could increase systemic|drug
DDI-DrugBank.d558.s24|59-68|dofetilide|drug
DDI-DrugBank.d558.s25|59-91|azole antifungal agents , protease|drug
DDI-DrugBank.d558.s25|65-74|antifungal|brand
DDI-DrugBank.d558.s25|84-91|protease|drug
DDI-DrugBank.d558.s25|105-113|serotonin|drug
DDI-DrugBank.d558.s25|136-145|amiodarone|drug
DDI-DrugBank.d558.s25|162-170|diltiazem|drug
DDI-DrugBank.d558.s25|173-182|grapefruit|drug
DDI-DrugBank.d558.s25|203-213|norfloxacin|drug
DDI-DrugBank.d558.s25|216-222|quinine|drug
DDI-DrugBank.d558.s25|225-235|zafirlukast|drug
DDI-DrugBank.d558.s25|279-285|TIKOSYN|brand
DDI-DrugBank.d558.s25|320-329|dofetilide|drug
DDI-DrugBank.d558.s26|0-9|Dofetilide|drug
DDI-DrugBank.d558.s26|34-63|CYP3A4 nor of other cytochrome|drug
DDI-DrugBank.d558.s26|54-68|cytochrome P450|drug
DDI-DrugBank.d558.s26|88-106|CYP2C9 , CYP2D6 ) and|drug
DDI-DrugBank.d558.s26|96-113|CYP2D6 ) and is not|drug
DDI-DrugBank.d558.s26|167-173|CYP3A4 .|drug
DDI-DrugBank.d558.s27|35-41|Digoxin|drug
DDI-DrugBank.d558.s27|90-96|TIKOSYN|brand
DDI-DrugBank.d558.s27|138-144|digoxin|drug
DDI-DrugBank.d558.s28|47-53|digoxin|drug
DDI-DrugBank.d558.s28|60-69|dofetilide|drug
DDI-DrugBank.d558.s29|60-66|TIKOSYN|brand
DDI-DrugBank.d558.s29|139-145|digoxin|drug
DDI-DrugBank.d558.s31|57-63|digoxin|drug
DDI-DrugBank.d558.s32|36-45|amlodipine|drug
DDI-DrugBank.d558.s32|48-56|phenytoin|drug
DDI-DrugBank.d558.s32|59-67|glyburide|drug
DDI-DrugBank.d558.s32|70-79|ranitidine|drug
DDI-DrugBank.d558.s32|82-91|omeprazole|drug
DDI-DrugBank.d558.s32|140-159|conjugated estrogens|drug
DDI-DrugBank.d558.s32|165-183|medroxyprogesterone|brand
DDI-DrugBank.d558.s32|187-193|antacid|brand
DDI-DrugBank.d558.s32|209-217|magnesium|drug
DDI-DrugBank.d558.s32|235-246|theophylline|drug
DDI-DrugBank.d558.s32|287-293|TIKOSYN|brand
DDI-DrugBank.d558.s33|59-65|TIKOSYN|brand
DDI-DrugBank.d558.s33|127-134|warfarin|drug
DDI-DrugBank.d558.s33|164-174|propranolol|drug
DDI-DrugBank.d558.s33|197-205|phenytoin|drug
DDI-DrugBank.d558.s33|208-219|theophylline|drug
DDI-DrugBank.d558.s34|121-154|examine the effects of concomitant|drug
DDI-DrugBank.d558.s34|210-219|dofetilide|drug
DDI-DrugBank.d558.s35|40-74|ACE inhibitors , oral anticoagulants|brand
DDI-DrugBank.d558.s35|61-74|anticoagulants|group
DDI-DrugBank.d558.s35|77-83|calcium|drug
DDI-DrugBank.d558.s35|118-135|cardiac glycosides|group
DDI-DrugBank.d558.s35|150-182|CYP3A4 , substrates and inhibitors|drug
DDI-DrugBank.d558.s35|187-219|CYP3A4 , substrates and inhibitors|drug
DDI-DrugBank.d558.s35|240-247|nitrates|group
DDI-DrugBank.d558.s35|271-279|diuretics|group
DDI-DrugBank.d558.s35|282-290|potassium|drug
DDI-DrugBank.d558.s35|300-308|diuretics|group
DDI-DrugBank.d558.s35|311-344|thiazide diuretics , substrates and|drug
DDI-DrugBank.d558.s35|320-328|diuretics|group
DDI-DrugBank.d558.s37|23-32|dofetilide|drug
DDI-DrugBank.d558.s37|72-107|thiazide diuretics and inhibitors of|drug
DDI-DrugBank.d558.s37|81-89|diuretics|group
DDI-DrugBank.d34.s0|94-104|dorzolamide|drug
DDI-DrugBank.d34.s0|155-183|carbonic anhydrase inhibitors|group
DDI-DrugBank.d34.s1|95-105|dorzolamide|drug
DDI-DrugBank.d29.s0|0-11|Esomeprazole|drug
DDI-DrugBank.d29.s0|56-74|CYP2C19 and CYP3A4 .|drug
DDI-DrugBank.d29.s0|68-74|CYP3A4 .|drug
DDI-DrugBank.d29.s1|45-56|esomeprazole|drug
DDI-DrugBank.d29.s1|88-100|1A2 , 2A6 , 2C9|drug
DDI-DrugBank.d29.s1|93-105|2A6 , 2C9 , 2D6|drug
DDI-DrugBank.d29.s1|98-110|2C9 , 2D6 , 2E1|drug
DDI-DrugBank.d29.s1|103-118|2D6 , 2E1 and 3A4|drug
DDI-DrugBank.d29.s1|108-119|2E1 and 3A4 .|drug
DDI-DrugBank.d29.s1|116-119|3A4 .|drug
DDI-DrugBank.d29.s2|68-96|CYP enzymes would be expected|brand
DDI-DrugBank.d29.s2|72-78|enzymes|group
DDI-DrugBank.d29.s3|41-52|esomeprazole|drug
DDI-DrugBank.d29.s3|113-121|phenytoin|drug
DDI-DrugBank.d29.s3|124-131|warfarin|drug
DDI-DrugBank.d29.s3|134-142|quinidine|drug
DDI-DrugBank.d29.s3|145-158|clarithromycin|drug
DDI-DrugBank.d29.s3|163-173|amoxicillin|drug
DDI-DrugBank.d29.s4|37-47|prothrombin|drug
DDI-DrugBank.d29.s4|107-114|warfarin|drug
DDI-DrugBank.d29.s4|120-131|esomeprazole|drug
DDI-DrugBank.d29.s5|13-40|INR and prothrombin time may|brand
DDI-DrugBank.d29.s5|21-31|prothrombin|drug
DDI-DrugBank.d29.s5|77-81|death|drug
DDI-DrugBank.d29.s6|22-43|proton pump inhibitors|group
DDI-DrugBank.d29.s6|49-56|warfarin|drug
DDI-DrugBank.d29.s6|114-138|INR and prothrombin time .|brand
DDI-DrugBank.d29.s6|122-132|prothrombin|drug
DDI-DrugBank.d29.s7|0-11|Esomeprazole|drug
DDI-DrugBank.d29.s7|44-74|CYP2C19 , the major esomeprazole|drug
DDI-DrugBank.d29.s7|57-61|major|brand
DDI-DrugBank.d29.s8|20-31|esomeprazole|drug
DDI-DrugBank.d29.s8|43-50|diazepam|drug
DDI-DrugBank.d29.s8|55-84|CYP2C19 substrate , resulted in|drug
DDI-DrugBank.d29.s8|117-124|diazepam|drug
DDI-DrugBank.d29.s9|27-34|diazepam|drug
DDI-DrugBank.d29.s10|44-51|diazepam|drug
DDI-DrugBank.d29.s10|68-78|therapeutic|brand
DDI-DrugBank.d29.s11|0-11|Esomeprazole|drug
DDI-DrugBank.d29.s12|11-22|esomeprazole|drug
DDI-DrugBank.d29.s12|81-82|pH|drug
DDI-DrugBank.d29.s12|136-147|ketoconazole|drug
DDI-DrugBank.d29.s12|150-153|iron|drug
DDI-DrugBank.d29.s12|165-171|digoxin|drug
DDI-DrugBank.d29.s13|41-48|diazepam|drug
DDI-DrugBank.d29.s13|51-59|phenytoin|drug
DDI-DrugBank.d29.s13|65-73|quinidine|drug
DDI-DrugBank.d29.s13|129-140|esomeprazole|drug
DDI-DrugBank.d29.s14|30-43|clarithromycin|drug
DDI-DrugBank.d29.s14|50-57|pimozide|drug
DDI-DrugBank.d405.s0|14-21|warfarin|drug
DDI-DrugBank.d405.s1|27-33|alcohol|brand
DDI-DrugBank.d405.s1|36-47|barbiturates|group
DDI-DrugBank.d405.s1|72-108|CNS depression when administered with|brand
DDI-DrugBank.d405.s1|110-122|ethchlorvynol|drug
DDI-DrugBank.d485.s0|0-16|Ethinyl estradiol|group
DDI-DrugBank.d485.s0|32-46|CYP3A4 ( major ) ,|drug
DDI-DrugBank.d485.s0|40-44|major|brand
DDI-DrugBank.d485.s0|48-61|3A5-7 ( minor ) ;|brand
DDI-DrugBank.d485.s1|9-22|CYP1A2 ( weak ) ,|drug
DDI-DrugBank.d485.s1|24-34|2B6 ( weak ) ,|drug
DDI-DrugBank.d485.s1|36-47|2C19 ( weak ) ,|drug
DDI-DrugBank.d485.s1|49-59|3A4 ( weak ) .|drug
DDI-DrugBank.d485.s2|0-12|Acetaminophen|drug
DDI-DrugBank.d485.s2|62-70|estrogens|group
DDI-DrugBank.d485.s3|82-94|acetaminophen|drug
DDI-DrugBank.d485.s4|0-8|Acitretin|drug
DDI-DrugBank.d485.s6|0-16|Aminoglutethimide|drug
DDI-DrugBank.d485.s6|32-67|CYP metabolism of progestins leading|brand
DDI-DrugBank.d485.s6|50-59|progestins|group
DDI-DrugBank.d485.s8|13-22|ampicillin|drug
DDI-DrugBank.d485.s8|25-36|tetracycline|drug
DDI-DrugBank.d485.s8|223-230|steroids|group
DDI-DrugBank.d485.s10|0-13|Anticoagulants|group
DDI-DrugBank.d485.s10|92-99|coumarin|drug
DDI-DrugBank.d485.s12|0-14|Anticonvulsants|group
DDI-DrugBank.d485.s12|17-29|carbamazepine|drug
DDI-DrugBank.d485.s12|32-40|felbamate|drug
DDI-DrugBank.d485.s12|43-55|phenobarbital|drug
DDI-DrugBank.d485.s12|58-66|phenytoin|drug
DDI-DrugBank.d485.s12|69-78|topiramate|drug
DDI-DrugBank.d485.s12|109-125|ethinyl estradiol|group
DDI-DrugBank.d485.s12|139-148|progestins|group
DDI-DrugBank.d485.s14|0-12|Ascorbic acid|drug
DDI-DrugBank.d485.s14|24-36|ascorbic acid|drug
DDI-DrugBank.d485.s14|39-47|vitamin C|brand
DDI-DrugBank.d485.s14|123-131|estrogens|group
DDI-DrugBank.d485.s16|0-11|Atorvastatin|drug
DDI-DrugBank.d485.s16|14-25|Atorvastatin|drug
DDI-DrugBank.d485.s16|41-73|AUC for norethindrone and ethinyl|brand
DDI-DrugBank.d485.s16|49-61|norethindrone|brand
DDI-DrugBank.d485.s16|67-83|ethinyl estradiol|group
DDI-DrugBank.d485.s17|105-114|alprazolam|drug
DDI-DrugBank.d485.s17|117-132|chlordiazepoxide|drug
DDI-DrugBank.d485.s17|135-142|diazepam|drug
DDI-DrugBank.d485.s17|183-191|lorazepam|drug
DDI-DrugBank.d485.s17|194-201|oxazepam|drug
DDI-DrugBank.d485.s17|204-212|temazepam|drug
DDI-DrugBank.d485.s18|0-13|Clofibric acid|group
DDI-DrugBank.d485.s18|82-95|clofibric acid|group
DDI-DrugBank.d485.s19|0-11|Cyclosporine|drug
DDI-DrugBank.d485.s19|80-91|cyclosporine|drug
DDI-DrugBank.d485.s20|8-19|cyclosporine|drug
DDI-DrugBank.d485.s21|0-31|CYP3A4 inducers : CYP3A4 inducers|drug
DDI-DrugBank.d485.s21|17-48|CYP3A4 inducers may decrease the|drug
DDI-DrugBank.d485.s21|68-84|ethinyl estradiol|group
DDI-DrugBank.d485.s22|25-41|aminoglutethimide|drug
DDI-DrugBank.d485.s22|44-56|carbamazepine|drug
DDI-DrugBank.d485.s22|59-67|nafcillin|drug
DDI-DrugBank.d485.s22|70-79|nevirapine|drug
DDI-DrugBank.d485.s22|82-94|phenobarbital|drug
DDI-DrugBank.d485.s22|97-105|phenytoin|drug
DDI-DrugBank.d485.s22|112-121|rifamycins|group
DDI-DrugBank.d485.s23|0-11|Griseofulvin|drug
DDI-DrugBank.d485.s23|14-25|Griseofulvin|drug
DDI-DrugBank.d485.s25|59-70|griseofulvin|drug
DDI-DrugBank.d485.s26|0-7|Morphine|drug
DDI-DrugBank.d485.s26|76-83|morphine|drug
DDI-DrugBank.d485.s27|0-46|Non-nucleoside reverse transcriptase inhibitors|group
DDI-DrugBank.d485.s27|58-67|Nevirapine|drug
DDI-DrugBank.d485.s29|12-22|delavirdine|drug
DDI-DrugBank.d485.s30|20-28|efavirenz|drug
DDI-DrugBank.d485.s31|0-11|Prednisolone|drug
DDI-DrugBank.d485.s31|14-30|Ethinyl estradiol|group
DDI-DrugBank.d485.s31|62-73|prednisolone|drug
DDI-DrugBank.d485.s32|0-7|Protease|drug
DDI-DrugBank.d485.s32|21-30|Amprenavir|drug
DDI-DrugBank.d485.s32|33-41|lopinavir|drug
DDI-DrugBank.d485.s32|44-53|nelfinavir|drug
DDI-DrugBank.d485.s32|60-68|ritonavir|drug
DDI-DrugBank.d485.s34|0-8|Indinavir|drug
DDI-DrugBank.d485.s35|12-21|saquinavir|drug
DDI-DrugBank.d485.s36|0-7|Rifampin|brand
DDI-DrugBank.d485.s36|10-17|Rifampin|brand
DDI-DrugBank.d485.s36|47-63|ethinyl estradiol|group
DDI-DrugBank.d485.s36|74-83|progestins|group
DDI-DrugBank.d485.s36|86-98|norethindrone|brand
DDI-DrugBank.d485.s38|0-13|Salicylic acid|drug
DDI-DrugBank.d485.s38|82-95|salicylic acid|drug
DDI-DrugBank.d485.s39|0-9|Selegiline|drug
DDI-DrugBank.d485.s39|65-69|serum|group
DDI-DrugBank.d485.s39|88-97|selegiline|drug
DDI-DrugBank.d485.s40|0-11|Theophylline|drug
DDI-DrugBank.d485.s40|14-30|Ethinyl estradiol|group
DDI-DrugBank.d485.s40|62-73|theophylline|drug
DDI-DrugBank.d485.s41|27-39|amitriptyline|drug
DDI-DrugBank.d485.s41|42-51|imipramine|drug
DDI-DrugBank.d485.s41|54-66|nortriptyline|drug
DDI-DrugBank.d485.s43|0-6|ETHANOL|drug
DDI-DrugBank.d485.s43|10-39|NUTRITION / HERB INTERACTIONS :|brand
DDI-DrugBank.d485.s43|22-45|HERB INTERACTIONS : Food :|brand
DDI-DrugBank.d485.s43|27-49|INTERACTIONS : Food : CNS|brand
DDI-DrugBank.d485.s43|41-44|Food|group
DDI-DrugBank.d485.s43|47-73|CNS effects of caffeine may|brand
DDI-DrugBank.d485.s43|62-69|caffeine|drug
DDI-DrugBank.d485.s43|153-160|caffeine|drug
DDI-DrugBank.d485.s44|0-9|Grapefruit|drug
DDI-DrugBank.d485.s44|27-43|ethinyl estradiol|group
DDI-DrugBank.d485.s44|94-105|progesterone|drug
DDI-DrugBank.d485.s46|124-130|enzymes|group
DDI-DrugBank.d485.s47|20-31|black cohosh|drug
DDI-DrugBank.d485.s48|6-17|saw palmetto|drug
DDI-DrugBank.d485.s48|20-29|red clover|brand
DDI-DrugBank.d485.s48|32-38|ginseng|drug
DDI-DrugBank.d119.s0|56-64|etomidate|drug
DDI-DrugBank.d119.s2|0-9|Probenecid|drug
DDI-DrugBank.d119.s2|34-42|etomidate|drug
DDI-DrugBank.d119.s3|0-8|Diazoxide|drug
DDI-DrugBank.d119.s4|0-9|Zimelidine|drug
DDI-DrugBank.d119.s5|7-16|analgesics|group
DDI-DrugBank.d119.s6|0-12|Aminophylline|drug
DDI-DrugBank.d119.s7|0-8|Midazolam|drug
DDI-DrugBank.d194.s0|47-55|ETOPOPHOS|brand
DDI-DrugBank.d194.s0|124-133|levamisole|drug
DDI-DrugBank.d194.s1|22-56|A resulting in concentrations above|brand
DDI-DrugBank.d194.s1|92-100|etoposide|drug
DDI-DrugBank.d194.s1|132-140|etoposide|drug
DDI-DrugBank.d194.s1|180-183|body|brand
DDI-DrugBank.d194.s1|198-206|etoposide|drug
DDI-DrugBank.d194.s1|220-228|etoposide|drug
DDI-DrugBank.d434.s1|67-74|Felbatol|brand
DDI-DrugBank.d434.s2|75-90|AED AED Felbatol|brand
DDI-DrugBank.d434.s2|79-90|AED Felbatol|brand
DDI-DrugBank.d434.s2|83-90|Felbatol|brand
DDI-DrugBank.d434.s4|0-8|Phenytoin|drug
DDI-DrugBank.d434.s6|0-12|Carbamazepine|drug
DDI-DrugBank.d434.s6|15-18|CBZ )|brand
DDI-DrugBank.d434.s7|1-11|CBZ epoxide|brand
DDI-DrugBank.d434.s8|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s9|47-59|carbamazepine|drug
DDI-DrugBank.d434.s11|20-27|Felbatol|brand
DDI-DrugBank.d434.s11|59-67|Phenytoin|drug
DDI-DrugBank.d434.s11|70-77|Felbatol|brand
DDI-DrugBank.d434.s11|115-123|phenytoin|drug
DDI-DrugBank.d434.s12|57-65|phenytoin|drug
DDI-DrugBank.d434.s12|98-106|phenytoin|drug
DDI-DrugBank.d434.s13|74-82|felbamate|drug
DDI-DrugBank.d434.s14|15-23|felbamate|drug
DDI-DrugBank.d434.s14|97-105|phenytoin|drug
DDI-DrugBank.d434.s15|12-19|maintain|brand
DDI-DrugBank.d434.s15|82-90|felbamate|drug
DDI-DrugBank.d434.s15|115-123|phenytoin|drug
DDI-DrugBank.d434.s16|55-63|phenytoin|drug
DDI-DrugBank.d434.s16|91-98|Felbatol|brand
DDI-DrugBank.d434.s16|121-129|phenytoin|drug
DDI-DrugBank.d434.s16|167-174|Felbatol|brand
DDI-DrugBank.d434.s17|0-12|Carbamazepine|drug
DDI-DrugBank.d434.s17|15-22|Felbatol|brand
DDI-DrugBank.d434.s17|63-75|carbamazepine|drug
DDI-DrugBank.d434.s17|135-147|carbamazepine|drug
DDI-DrugBank.d434.s18|3-38|nine otherwise healthy subjects with|drug
DDI-DrugBank.d434.s18|59-71|carbamazepine|drug
DDI-DrugBank.d434.s18|105-117|carbamazepine|drug
DDI-DrugBank.d434.s19|4-16|carbamazepine|drug
DDI-DrugBank.d434.s19|76-84|felbamate|drug
DDI-DrugBank.d434.s20|0-12|Carbamazepine|drug
DDI-DrugBank.d434.s20|128-136|felbamate|drug
DDI-DrugBank.d434.s21|39-51|carbamazepine|drug
DDI-DrugBank.d434.s21|57-69|carbamazepine|drug
DDI-DrugBank.d434.s22|11-18|Felbatol|brand
DDI-DrugBank.d434.s24|75-83|felbamate|drug
DDI-DrugBank.d434.s25|15-23|felbamate|drug
DDI-DrugBank.d434.s26|127-134|Felbatol|brand
DDI-DrugBank.d434.s27|163-170|Felbatol|brand
DDI-DrugBank.d434.s28|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s28|35-43|felbamate|drug
DDI-DrugBank.d434.s28|50-62|phenobarbital|drug
DDI-DrugBank.d434.s28|86-98|phenobarbital|drug
DDI-DrugBank.d434.s28|173-185|phenobarbital|drug
DDI-DrugBank.d434.s28|219-231|phenobarbital|drug
DDI-DrugBank.d434.s29|88-96|felbamate|drug
DDI-DrugBank.d434.s30|40-47|Felbatol|brand
DDI-DrugBank.d434.s30|61-69|Phenytoin|drug
DDI-DrugBank.d434.s30|122-129|Felbatol|brand
DDI-DrugBank.d434.s30|133-141|felbamate|drug
DDI-DrugBank.d434.s30|192-200|phenytoin|drug
DDI-DrugBank.d434.s30|282-289|Felbatol|brand
DDI-DrugBank.d434.s30|311-314|same|drug
DDI-DrugBank.d434.s30|324-331|Felbatol|brand
DDI-DrugBank.d434.s31|0-12|Carbamazepine|drug
DDI-DrugBank.d434.s31|15-27|Carbamazepine|drug
DDI-DrugBank.d434.s31|84-91|Felbatol|brand
DDI-DrugBank.d434.s31|142-154|carbamazepine|drug
DDI-DrugBank.d434.s31|240-247|Felbatol|brand
DDI-DrugBank.d434.s31|269-272|same|drug
DDI-DrugBank.d434.s31|282-289|Felbatol|brand
DDI-DrugBank.d434.s32|103-110|Felbatol|brand
DDI-DrugBank.d434.s32|225-232|Felbatol|brand
DDI-DrugBank.d434.s32|236-244|felbamate|drug
DDI-DrugBank.d434.s33|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s33|31-43|phenobarbital|drug
DDI-DrugBank.d434.s33|63-71|felbamate|drug
DDI-DrugBank.d434.s34|20-28|felbamate|drug
DDI-DrugBank.d434.s34|180-188|felbamate|drug
DDI-DrugBank.d434.s35|11-18|Antacids|group
DDI-DrugBank.d434.s35|23-30|Felbatol|brand
DDI-DrugBank.d434.s35|88-95|Felbatol|brand
DDI-DrugBank.d434.s35|172-179|antacids|group
DDI-DrugBank.d434.s36|11-22|Erythromycin|drug
DDI-DrugBank.d434.s36|27-34|Felbatol|brand
DDI-DrugBank.d434.s36|61-72|erythromycin|drug
DDI-DrugBank.d434.s36|160-177|AUC , CI/kg or tmax|brand
DDI-DrugBank.d434.s36|182-190|felbamate|drug
DDI-DrugBank.d434.s37|11-18|Felbatol|brand
DDI-DrugBank.d434.s37|65-88|A group of 24 nonsmoking|brand
DDI-DrugBank.d434.s37|160-166|regimen|brand
DDI-DrugBank.d434.s37|185-201|ethinyl estradiol|group
DDI-DrugBank.d434.s37|213-221|gestodene|drug
DDI-DrugBank.d434.s37|269-277|felbamate|drug
DDI-DrugBank.d434.s38|0-8|Felbamate|drug
DDI-DrugBank.d434.s38|54-62|gestodene|drug
DDI-DrugBank.d434.s38|158-174|ethinyl estradiol|group
DDI-DrugBank.d434.s39|110-118|felbamate|drug
DDI-DrugBank.d361.s0|172-182|Floxuridine|drug
DDI-DrugBank.d453.s0|0-7|Cytosine|group
DDI-DrugBank.d453.s0|78-87|antifungal|brand
DDI-DrugBank.d453.s0|101-111|flucytosine|drug
DDI-DrugBank.d453.s1|45-51|prolong|brand
DDI-DrugBank.d453.s1|81-91|flucytosine|drug
DDI-DrugBank.d453.s2|50-54|serum|group
DDI-DrugBank.d453.s2|124-130|Ancobon|brand
DDI-DrugBank.d453.s2|177-186|creatinine|drug
DDI-DrugBank.d453.s3|44-53|creatinine|drug
DDI-DrugBank.d526.s0|78-92|corticosteroids|group
DDI-DrugBank.d526.s1|0-13|Amphotericin B|drug
DDI-DrugBank.d526.s1|38-46|diuretics|group
DDI-DrugBank.d526.s1|49-65|benzothiadiazines|group
DDI-DrugBank.d526.s1|86-100|ethacrynic acid|brand
DDI-DrugBank.d526.s1|106-115|furosemide|drug
DDI-DrugBank.d526.s2|6-10|serum|group
DDI-DrugBank.d526.s3|4-12|potassium|drug
DDI-DrugBank.d526.s4|0-19|Digitalis glycosides|group
DDI-DrugBank.d526.s5|8-12|serum|group
DDI-DrugBank.d526.s6|4-12|potassium|drug
DDI-DrugBank.d526.s7|5-18|anticoagulants|group
DDI-DrugBank.d526.s7|30-40|prothrombin|drug
DDI-DrugBank.d526.s8|8-18|prothrombin|drug
DDI-DrugBank.d526.s9|36-42|insulin|group
DDI-DrugBank.d526.s12|0-6|Aspirin|brand
DDI-DrugBank.d526.s13|34-40|aspirin|brand
DDI-DrugBank.d526.s14|65-72|steroids|group
DDI-DrugBank.d526.s14|101-107|aspirin|brand
DDI-DrugBank.d526.s15|33-43|therapeutic|brand
DDI-DrugBank.d526.s15|62-68|aspirin|brand
DDI-DrugBank.d526.s17|0-11|Barbiturates|group
DDI-DrugBank.d526.s17|14-22|phenytoin|drug
DDI-DrugBank.d526.s17|28-35|rifampin|brand
DDI-DrugBank.d526.s17|70-84|fludrocortisone|drug
DDI-DrugBank.d526.s17|130-136|enzymes|group
DDI-DrugBank.d526.s19|0-16|Anabolic steroids|group
DDI-DrugBank.d526.s19|32-63|C-17 alkylated androgens such as|brand
DDI-DrugBank.d526.s19|47-55|androgens|group
DDI-DrugBank.d526.s19|65-76|oxymetholone|drug
DDI-DrugBank.d526.s19|79-118|methandrostenolone , norethandrolone , and|drug
DDI-DrugBank.d526.s19|99-113|norethandrolone|drug
DDI-DrugBank.d526.s21|0-7|Vaccines|group
DDI-DrugBank.d526.s22|29-59|corticosteroid-binding globulin|drug
DDI-DrugBank.d526.s23|60-74|corticosteroids|group
DDI-DrugBank.d526.s24|51-87|corticosteroid dosage may be required|drug
DDI-DrugBank.d526.s25|34-48|Corticosteroids|group
DDI-DrugBank.d529.s0|0-7|Antacids|group
DDI-DrugBank.d529.s0|28-39|flurbiprofen|drug
DDI-DrugBank.d529.s0|89-95|antacid|brand
DDI-DrugBank.d529.s0|124-128|serum|group
DDI-DrugBank.d529.s1|84-95|flurbiprofen|drug
DDI-DrugBank.d529.s2|0-13|Anticoagulants|group
DDI-DrugBank.d529.s2|16-27|Flurbiprofen|drug
DDI-DrugBank.d529.s3|52-63|flurbiprofen|drug
DDI-DrugBank.d529.s3|84-97|anticoagulants|group
DDI-DrugBank.d529.s4|0-6|Aspirin|brand
DDI-DrugBank.d529.s4|38-44|aspirin|brand
DDI-DrugBank.d529.s4|50-61|flurbiprofen|drug
DDI-DrugBank.d529.s4|85-89|serum|group
DDI-DrugBank.d529.s5|15-21|aspirin|brand
DDI-DrugBank.d529.s5|42-46|serum|group
DDI-DrugBank.d529.s5|174-182|arthritis|brand
DDI-DrugBank.d529.s6|18-29|flurbiprofen|drug
DDI-DrugBank.d529.s6|35-41|aspirin|brand
DDI-DrugBank.d529.s7|47-58|flurbiprofen|drug
DDI-DrugBank.d529.s7|63-67|blood|group
DDI-DrugBank.d529.s7|90-100|propranolol|drug
DDI-DrugBank.d529.s7|106-113|atenolol|drug
DDI-DrugBank.d529.s8|0-11|Flurbiprofen|drug
DDI-DrugBank.d529.s8|80-90|propranolol|drug
DDI-DrugBank.d529.s8|100-107|atenolol|drug
DDI-DrugBank.d529.s9|0-11|Flurbiprofen|drug
DDI-DrugBank.d529.s10|0-11|Flurbiprofen|drug
DDI-DrugBank.d529.s11|21-32|flurbiprofen|drug
DDI-DrugBank.d529.s12|0-9|Cimetidine|drug
DDI-DrugBank.d529.s12|12-21|Ranitidine|drug
DDI-DrugBank.d529.s12|70-79|cimetidine|drug
DDI-DrugBank.d529.s12|84-93|ranitidine|drug
DDI-DrugBank.d529.s12|110-121|flurbiprofen|drug
DDI-DrugBank.d529.s12|228-232|serum|group
DDI-DrugBank.d529.s12|257-268|flurbiprofen|drug
DDI-DrugBank.d529.s12|284-293|cimetidine|drug
DDI-DrugBank.d529.s13|0-6|Digoxin|drug
DDI-DrugBank.d529.s13|50-61|flurbiprofen|drug
DDI-DrugBank.d529.s13|67-73|digoxin|drug
DDI-DrugBank.d529.s13|140-144|serum|group
DDI-DrugBank.d529.s14|0-8|Diuretics|group
DDI-DrugBank.d529.s14|56-67|flurbiprofen|drug
DDI-DrugBank.d529.s14|152-161|furosemide|drug
DDI-DrugBank.d529.s16|114-147|thiazide diuretics in some studies|drug
DDI-DrugBank.d529.s16|123-131|diuretics|group
DDI-DrugBank.d529.s16|158-184|potassium-sparing diuretics|group
DDI-DrugBank.d529.s17|19-30|flurbiprofen|drug
DDI-DrugBank.d529.s17|36-45|furosemide|drug
DDI-DrugBank.d529.s17|56-64|diuretics|group
DDI-DrugBank.d529.s17|96-126|determine if the desired effect|drug
DDI-DrugBank.d529.s18|40-51|flurbiprofen|drug
DDI-DrugBank.d529.s18|109-117|glyburide|drug
DDI-DrugBank.d529.s18|126-134|metformin|drug
DDI-DrugBank.d529.s18|142-155|chlorpropamide|drug
DDI-DrugBank.d529.s18|162-171|phenformin|drug
DDI-DrugBank.d529.s18|183-191|glyburide|drug
DDI-DrugBank.d529.s18|198-207|phenformin|drug
DDI-DrugBank.d529.s19|41-45|blood|group
DDI-DrugBank.d529.s19|105-116|flurbiprofen|drug
DDI-DrugBank.d103.s0|115-120|relief|brand
DDI-DrugBank.d103.s0|159-168|formoterol|drug
DDI-DrugBank.d103.s1|48-54|control|brand
DDI-DrugBank.d103.s1|92-97|asthma|group
DDI-DrugBank.d103.s2|101-107|FORADIL|brand
DDI-DrugBank.d103.s3|0-16|Monoamine Oxidase|drug
DDI-DrugBank.d103.s3|60-66|FORADIL|brand
DDI-DrugBank.d103.s3|143-159|monoamine oxidase|drug
DDI-DrugBank.d103.s3|223-232|formoterol|drug
DDI-DrugBank.d103.s4|0-14|Corticosteroids|group
DDI-DrugBank.d103.s4|37-45|Diuretics|group
DDI-DrugBank.d103.s4|75-82|xanthine|drug
DDI-DrugBank.d103.s4|97-104|steroids|group
DDI-DrugBank.d103.s4|110-118|diuretics|group
DDI-DrugBank.d103.s6|83-89|FORADIL|brand
DDI-DrugBank.d103.s7|10-16|FORADIL|brand
DDI-DrugBank.d103.s7|85-93|eye drops|brand
DDI-DrugBank.d103.s8|26-34|quinidine|drug
DDI-DrugBank.d103.s8|37-48|disopyramide|drug
DDI-DrugBank.d103.s8|51-62|procainamide|drug
DDI-DrugBank.d103.s8|65-78|phenothiazines|group
DDI-DrugBank.d103.s9|0-28|INFORMATION TO BE PROVIDED TO|brand
DDI-DrugBank.d103.s9|12-32|TO BE PROVIDED TO THE|brand
DDI-DrugBank.d103.s9|15-40|BE PROVIDED TO THE PATIENT|brand
DDI-DrugBank.d103.s9|18-43|PROVIDED TO THE PATIENT OR|brand
DDI-DrugBank.d103.s9|27-52|TO THE PATIENT OR GUARDIAN|brand
DDI-DrugBank.d103.s9|30-56|THE PATIENT OR GUARDIAN See|brand
DDI-DrugBank.d103.s9|34-68|PATIENT OR GUARDIAN See illustrated|brand
DDI-DrugBank.d103.s9|42-80|OR GUARDIAN See illustrated Information|brand
DDI-DrugBank.d103.s9|45-52|GUARDIAN|brand
DDI-DrugBank.d103.s9|101-108|Guardian|brand
DDI-DrugBank.d103.s10|52-58|FORADIL|brand
DDI-DrugBank.d103.s10|62-71|formoterol|drug
DDI-DrugBank.d103.s10|187-192|asthma|group
DDI-DrugBank.d103.s10|197-228|COPD medications they are taking|brand
DDI-DrugBank.d103.s14|0-6|FORADIL|brand
DDI-DrugBank.d103.s14|38-43|asthma|group
DDI-DrugBank.d103.s14|48-76|COPD symptoms and extra doses|brand
DDI-DrugBank.d103.s14|106-112|purpose|brand
DDI-DrugBank.d103.s15|85-94|salbutamol|drug
DDI-DrugBank.d103.s17|130-135|asthma|group
DDI-DrugBank.d103.s20|0-6|FORADIL|brand
DDI-DrugBank.d103.s20|63-77|corticosteroids|group
DDI-DrugBank.d103.s21|184-190|FORADIL|brand
DDI-DrugBank.d103.s24|22-28|FORADIL|brand
DDI-DrugBank.d103.s26|47-53|FORADIL|brand
DDI-DrugBank.d103.s26|106-111|asthma|group
DDI-DrugBank.d103.s26|121-130|compliance|brand
DDI-DrugBank.d511.s0|0-29|A possible drug interaction of|brand
DDI-DrugBank.d511.s0|31-38|FOSCAVIR|brand
DDI-DrugBank.d511.s0|56-66|pentamidine|drug
DDI-DrugBank.d511.s1|66-73|FOSCAVIR|brand
DDI-DrugBank.d511.s1|91-101|pentamidine|drug
DDI-DrugBank.d511.s3|56-66|pentamidine|drug
DDI-DrugBank.d511.s4|69-76|FOSCAVIR|brand
DDI-DrugBank.d511.s4|171-184|amphotericin B|drug
DDI-DrugBank.d511.s4|202-212|pentamidine|drug
DDI-DrugBank.d511.s5|6-13|FOSCAVIR|brand
DDI-DrugBank.d511.s5|25-29|serum|group
DDI-DrugBank.d511.s5|57-63|calcium|drug
DDI-DrugBank.d511.s5|123-127|serum|group
DDI-DrugBank.d511.s6|0-10|Ganciclovir|group
DDI-DrugBank.d511.s6|37-45|foscarnet|drug
DDI-DrugBank.d511.s6|51-61|ganciclovir|group
DDI-DrugBank.d511.s6|180-191|CMV disease .|brand
DDI-DrugBank.d70.s0|0-10|Fulvestrant|drug
DDI-DrugBank.d70.s0|30-46|CYP 3A4 in vitro .|brand
DDI-DrugBank.d70.s0|34-46|3A4 in vitro .|drug
DDI-DrugBank.d70.s1|41-65|CYP 3A4 inhibitors on the|brand
DDI-DrugBank.d70.s1|45-82|3A4 inhibitors on the pharmacokinetics|drug
DDI-DrugBank.d70.s1|87-97|fulvestrant|drug
DDI-DrugBank.d70.s2|56-90|A two-year carcinogenesis study was|brand
DDI-DrugBank.d70.s3|135-157|AUC0-30 days ] ] achieved|brand
DDI-DrugBank.d70.s5|69-114|endocrine feedback alterations in gonadotropin|drug
DDI-DrugBank.d70.s6|0-10|Fulvestrant|drug
DDI-DrugBank.d70.s7|16-26|fulvestrant|drug
DDI-DrugBank.d70.s7|135-138|body|brand
DDI-DrugBank.d70.s7|154-164|BSA ] , for 2|brand
DDI-DrugBank.d70.s8|175-179|BSA ) .|brand
DDI-DrugBank.d70.s9|170-174|BSA ) .|brand
DDI-DrugBank.d70.s10|15-25|fulvestrant|drug
DDI-DrugBank.d70.s11|25-35|fulvestrant|drug
DDI-DrugBank.d70.s11|226-236|fulvestrant|drug
DDI-DrugBank.d70.s13|6-16|fulvestrant|drug
DDI-DrugBank.d70.s13|94-118|AUC0-30 days ] achieved in|brand
DDI-DrugBank.d70.s14|29-32|D : .|brand
DDI-DrugBank.d70.s15|53-55|IM ;|brand
DDI-DrugBank.d70.s16|67-70|body|brand
DDI-DrugBank.d70.s16|86-103|BSA ] ) , fulvestrant|brand
DDI-DrugBank.d70.s16|93-103|fulvestrant|drug
DDI-DrugBank.d70.s17|0-10|Fulvestrant|drug
DDI-DrugBank.d70.s17|120-122|IM ;|brand
DDI-DrugBank.d70.s18|24-51|BSA ) and non-ossification of|brand
DDI-DrugBank.d70.s18|90-98|the first|brand
DDI-DrugBank.d70.s18|143-172|IM ( approximately one-tenth of|brand
DDI-DrugBank.d70.s18|192-220|BSA ) when administered during|brand
DDI-DrugBank.d70.s19|18-25|maintain|brand
DDI-DrugBank.d70.s19|65-75|fulvestrant|drug
DDI-DrugBank.d70.s19|105-126|BSA ) during the period|brand
DDI-DrugBank.d70.s20|78-95|BSA ) , increases in|brand
DDI-DrugBank.d70.s21|0-10|Fulvestrant|drug
DDI-DrugBank.d70.s21|178-180|IM ;|brand
DDI-DrugBank.d70.s22|27-55|BSA ) when administered during|brand
DDI-DrugBank.d70.s23|49-54|rabbit|drug
DDI-DrugBank.d70.s23|75-85|fulvestrant|drug
DDI-DrugBank.d70.s23|148-182|define the possible adverse effects|drug
DDI-DrugBank.d70.s24|16-26|Fulvestrant|drug
DDI-DrugBank.d70.s26|19-29|fulvestrant|drug
DDI-DrugBank.d70.s27|111-118|FASLODEX|brand
DDI-DrugBank.d70.s28|41-48|FASLODEX|brand
DDI-DrugBank.d70.s29|216-223|FASLODEX|brand
DDI-DrugBank.d231.s0|0-9|Furosemide|drug
DDI-DrugBank.d231.s2|0-9|Furosemide|drug
DDI-DrugBank.d231.s2|49-63|ethacrynic acid|brand
DDI-DrugBank.d231.s3|33-43|salicylates|group
DDI-DrugBank.d231.s3|64-73|furosemide|drug
DDI-DrugBank.d231.s4|0-9|Furosemide|drug
DDI-DrugBank.d231.s4|53-58|muscle|brand
DDI-DrugBank.d231.s4|79-90|tubocurarine|drug
DDI-DrugBank.d231.s4|125-139|succinylcholine|drug
DDI-DrugBank.d231.s5|0-6|Lithium|brand
DDI-DrugBank.d231.s5|43-51|diuretics|group
DDI-DrugBank.d231.s5|121-127|lithium|brand
DDI-DrugBank.d231.s6|0-9|Furosemide|drug
DDI-DrugBank.d231.s6|40-50|therapeutic|brand
DDI-DrugBank.d231.s8|0-9|Furosemide|drug
DDI-DrugBank.d231.s8|51-64|norepinephrine|drug
DDI-DrugBank.d231.s9|9-22|norepinephrine|drug
DDI-DrugBank.d231.s10|39-48|sucralfate|drug
DDI-DrugBank.d231.s10|54-63|furosemide|drug
DDI-DrugBank.d231.s10|132-141|furosemide|drug
DDI-DrugBank.d231.s11|60-92|determine if the desired diuretic|drug
DDI-DrugBank.d231.s11|128-137|furosemide|drug
DDI-DrugBank.d231.s12|14-23|furosemide|drug
DDI-DrugBank.d231.s12|29-38|sucralfate|drug
DDI-DrugBank.d231.s13|29-36|Solution|brand
DDI-DrugBank.d231.s13|101-110|furosemide|drug
DDI-DrugBank.d231.s13|116-135|acetylsalicylic acid|drug
DDI-DrugBank.d231.s13|157-166|creatinine|drug
DDI-DrugBank.d231.s14|59-83|BUN , serum creatinine and|brand
DDI-DrugBank.d231.s14|64-68|serum|group
DDI-DrugBank.d231.s14|85-89|serum|group
DDI-DrugBank.d231.s14|130-139|furosemide|drug
DDI-DrugBank.d231.s15|53-64|indomethacin|drug
DDI-DrugBank.d231.s15|125-134|furosemide|drug
DDI-DrugBank.d231.s16|0-11|Indomethacin|drug
DDI-DrugBank.d231.s16|36-40|renin|drug
DDI-DrugBank.d231.s16|50-60|aldosterone|drug
DDI-DrugBank.d231.s16|77-81|renin|drug
DDI-DrugBank.d231.s17|24-35|indomethacin|drug
DDI-DrugBank.d231.s17|41-50|furosemide|drug
DDI-DrugBank.d231.s17|82-114|determine if the desired diuretic|drug
DDI-DrugBank.d231.s17|150-159|furosemide|drug
DDI-DrugBank.d161.s1|43-48|Gemzar|brand
DDI-DrugBank.d161.s1|54-62|cisplatin|drug
DDI-DrugBank.d161.s1|108-137|CLINICAL PHARMACOLOGY section .|brand
DDI-DrugBank.d161.s1|117-137|PHARMACOLOGY section .|brand
DDI-DrugBank.d488.s0|38-44|Heparin|drug
DDI-DrugBank.d488.s0|59-72|anticoagulants|group
DDI-DrugBank.d488.s0|75-81|Heparin|drug
DDI-DrugBank.d488.s0|94-100|prolong|brand
DDI-DrugBank.d488.s0|116-126|prothrombin|drug
DDI-DrugBank.d488.s1|16-22|heparin|drug
DDI-DrugBank.d488.s1|58-65|warfarin|drug
DDI-DrugBank.d488.s1|202-206|blood|group
DDI-DrugBank.d488.s1|228-238|prothrombin|drug
DDI-DrugBank.d488.s2|35-54|acetylsalicylic acid|drug
DDI-DrugBank.d488.s2|57-63|dextran|drug
DDI-DrugBank.d488.s2|66-79|phenylbutazone|drug
DDI-DrugBank.d488.s2|82-90|ibuprofen|drug
DDI-DrugBank.d488.s2|93-104|indomethacin|drug
DDI-DrugBank.d488.s2|107-118|dipyridamole|drug
DDI-DrugBank.d488.s2|121-138|hydroxychloroquine|drug
DDI-DrugBank.d488.s2|330-336|heparin|drug
DDI-DrugBank.d488.s3|28-34|heparin|drug
DDI-DrugBank.d488.s3|77-92|antithrombin III|group
DDI-DrugBank.d488.s3|130-145|antithrombin III|group
DDI-DrugBank.d488.s4|51-57|heparin|drug
DDI-DrugBank.d488.s4|96-111|antithrombin III|group
DDI-DrugBank.d488.s6|17-23|Heparin|drug
DDI-DrugBank.d488.s6|44-56|tetracyclines|group
DDI-DrugBank.d488.s6|59-66|nicotine|drug
DDI-DrugBank.d488.s6|140-146|heparin|drug
DDI-DrugBank.d488.s7|0-6|Heparin|drug
DDI-DrugBank.d488.s7|50-60|doxorubicin|drug
DDI-DrugBank.d488.s7|63-72|droperidol|drug
DDI-DrugBank.d488.s7|75-87|ciprofloxacin|drug
DDI-DrugBank.d488.s7|93-104|mitoxantrone|drug
DDI-DrugBank.d488.s7|173-179|heparin|drug
DDI-DrugBank.d488.s8|88-103|aminotransferase|drug
DDI-DrugBank.d488.s8|106-121|SGOT [ S-AST ] and|brand
DDI-DrugBank.d488.s8|112-128|S-AST ] and SGPT [|brand
DDI-DrugBank.d488.s8|123-135|SGPT [ S-ALT ] )|brand
DDI-DrugBank.d488.s8|129-147|S-ALT ] ) levels have|brand
DDI-DrugBank.d488.s8|232-238|heparin|drug
DDI-DrugBank.d488.s9|6-21|aminotransferase|drug
DDI-DrugBank.d488.s9|181-187|heparin|drug
DDI-DrugBank.d16.s0|41-51|hydroxyurea|drug
DDI-DrugBank.d16.s1|18-28|hydroxyurea|drug
DDI-DrugBank.d16.s1|40-62|myelosuppressive agents|group
DDI-DrugBank.d16.s2|6-16|hydroxyurea|drug
DDI-DrugBank.d16.s2|32-36|serum|group
DDI-DrugBank.d415.s0|14-27|Anticoagulants|group
DDI-DrugBank.d415.s0|89-97|ibuprofen|drug
DDI-DrugBank.d415.s0|122-132|prothrombin|drug
DDI-DrugBank.d415.s0|229-242|anticoagulants|group
DDI-DrugBank.d415.s1|49-57|ibuprofen|drug
DDI-DrugBank.d415.s1|63-105|other nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d415.s1|159-172|anticoagulants|group
DDI-DrugBank.d415.s1|227-235|ibuprofen|drug
DDI-DrugBank.d415.s1|252-265|anticoagulants|group
DDI-DrugBank.d415.s2|0-6|Aspirin|brand
DDI-DrugBank.d415.s2|35-41|aspirin|brand
DDI-DrugBank.d415.s2|67-90|anti-inflammatory agents|group
DDI-DrugBank.d415.s2|103-111|ibuprofen|drug
DDI-DrugBank.d415.s2|179-183|blood|group
DDI-DrugBank.d415.s2|199-209|non-aspirin|brand
DDI-DrugBank.d415.s3|91-97|aspirin|brand
DDI-DrugBank.d415.s3|102-110|ibuprofen|drug
DDI-DrugBank.d415.s5|0-11|Methotrexate|drug
DDI-DrugBank.d415.s5|14-22|Ibuprofen|drug
DDI-DrugBank.d415.s5|122-133|methotrexate|drug
DDI-DrugBank.d415.s5|164-169|rabbit|drug
DDI-DrugBank.d415.s6|23-31|ibuprofen|drug
DDI-DrugBank.d415.s6|63-74|methotrexate|drug
DDI-DrugBank.d415.s7|26-34|ibuprofen|drug
DDI-DrugBank.d415.s7|71-82|methotrexate|drug
DDI-DrugBank.d415.s8|0-26|H-2 Antagonists : In studies|brand
DDI-DrugBank.d415.s8|72-81|cimetidine|drug
DDI-DrugBank.d415.s8|86-95|ranitidine|drug
DDI-DrugBank.d415.s8|102-110|ibuprofen|drug
DDI-DrugBank.d415.s8|141-149|ibuprofen|drug
DDI-DrugBank.d415.s9|0-9|Furosemide|drug
DDI-DrugBank.d415.s9|78-86|ibuprofen|drug
DDI-DrugBank.d415.s9|125-134|furosemide|drug
DDI-DrugBank.d415.s9|140-148|thiazides|group
DDI-DrugBank.d415.s11|32-40|ibuprofen|drug
DDI-DrugBank.d415.s12|0-6|Lithium|brand
DDI-DrugBank.d415.s12|9-17|Ibuprofen|drug
DDI-DrugBank.d415.s12|51-57|lithium|brand
DDI-DrugBank.d415.s12|91-97|lithium|brand
DDI-DrugBank.d415.s13|17-23|lithium|brand
DDI-DrugBank.d415.s13|80-86|lithium|brand
DDI-DrugBank.d415.s14|82-90|ibuprofen|drug
DDI-DrugBank.d415.s15|11-19|ibuprofen|drug
DDI-DrugBank.d415.s15|25-31|lithium|brand
DDI-DrugBank.d415.s15|115-121|lithium|brand
DDI-DrugBank.d415.s16|20-26|lithium|brand
DDI-DrugBank.d527.s0|0-28|A number of substances affect|brand
DDI-DrugBank.d527.s0|30-36|glucose|group
DDI-DrugBank.d527.s0|65-71|insulin|group
DDI-DrugBank.d527.s1|157-185|ACE inhibitors , disopyramide ,|brand
DDI-DrugBank.d527.s1|173-184|disopyramide|drug
DDI-DrugBank.d527.s1|197-206|fluoxetine|drug
DDI-DrugBank.d527.s1|209-237|MAO inhibitors , propoxyphene ,|brand
DDI-DrugBank.d527.s1|225-236|propoxyphene|brand
DDI-DrugBank.d527.s1|239-249|salicylates|group
DDI-DrugBank.d527.s1|252-263|somatostatin|drug
DDI-DrugBank.d527.s1|279-288|octreotide|drug
DDI-DrugBank.d527.s2|94-100|insulin|group
DDI-DrugBank.d527.s2|103-117|corticosteroids|group
DDI-DrugBank.d527.s2|120-126|danazol|drug
DDI-DrugBank.d527.s2|129-137|diuretics|group
DDI-DrugBank.d527.s2|170-180|epinephrine|drug
DDI-DrugBank.d527.s2|183-191|albuterol|brand
DDI-DrugBank.d527.s2|194-204|terbutaline|drug
DDI-DrugBank.d527.s2|208-216|isoniazid|drug
DDI-DrugBank.d527.s2|219-231|phenothiazine|drug
DDI-DrugBank.d527.s2|258-264|thyroid|brand
DDI-DrugBank.d527.s2|276-284|estrogens|group
DDI-DrugBank.d527.s3|15-23|clonidine|drug
DDI-DrugBank.d527.s3|26-32|lithium|brand
DDI-DrugBank.d527.s3|45-51|alcohol|brand
DDI-DrugBank.d527.s3|122-128|insulin|group
DDI-DrugBank.d527.s4|0-10|Pentamidine|drug
DDI-DrugBank.d527.s5|92-100|clonidine|drug
DDI-DrugBank.d527.s5|103-114|guanethidine|drug
DDI-DrugBank.d527.s5|121-129|reserpine|drug
DDI-DrugBank.d51.s0|0-7|ATROVENT|brand
DDI-DrugBank.d51.s0|138-145|steroids|group
DDI-DrugBank.d51.s1|22-30|albuterol|brand
DDI-DrugBank.d51.s1|105-112|ATROVENT|brand
DDI-DrugBank.d51.s2|0-21|Anticholinergic agents|group
DDI-DrugBank.d51.s2|33-43|ipratropium|drug
DDI-DrugBank.d51.s3|56-63|ATROVENT|brand
DDI-DrugBank.d279.s0|23-31|CAMPTOSAR|brand
DDI-DrugBank.d279.s0|118-138|antineoplastic agents|group
DDI-DrugBank.d279.s1|149-157|CAMPTOSAR|brand
DDI-DrugBank.d279.s2|33-41|CAMPTOSAR|brand
DDI-DrugBank.d279.s3|56-64|CAMPTOSAR|brand
DDI-DrugBank.d279.s3|113-125|dexamethasone|drug
DDI-DrugBank.d279.s5|59-67|CAMPTOSAR|brand
DDI-DrugBank.d279.s6|62-78|diabetes mellitus|group
DDI-DrugBank.d279.s6|95-101|glucose|group
DDI-DrugBank.d279.s6|142-150|CAMPTOSAR|brand
DDI-DrugBank.d279.s7|20-32|dexamethasone|drug
DDI-DrugBank.d279.s8|115-130|prochlorperazine|drug
DDI-DrugBank.d279.s8|156-159|same|drug
DDI-DrugBank.d279.s8|168-176|CAMPTOSAR|brand
DDI-DrugBank.d279.s9|82-97|prochlorperazine|drug
DDI-DrugBank.d279.s10|26-33|laxative|brand
DDI-DrugBank.d279.s10|59-67|CAMPTOSAR|brand
DDI-DrugBank.d279.s11|94-102|CAMPTOSAR|brand
DDI-DrugBank.d279.s11|140-148|diuretics|group
DDI-DrugBank.d279.s11|169-177|CAMPTOSAR|brand
DDI-DrugBank.d279.s12|74-82|CAMPTOSAR|brand
DDI-DrugBank.d55.s0|0-12|Isoproterenol|brand
DDI-DrugBank.d55.s0|42-52|epinephrine|drug
DDI-DrugBank.d55.s0|134-143|stimulants|group
DDI-DrugBank.d55.s2|0-6|ISUPREL|brand
DDI-DrugBank.d55.s2|73-83|anesthetics|group
DDI-DrugBank.d55.s2|93-101|halothane|drug
DDI-DrugBank.d55.s2|195-200|amines|group
DDI-DrugBank.d57.s0|71-81|penicillins|group
DDI-DrugBank.d57.s0|86-99|cephalosporins|group
DDI-DrugBank.d57.s1|134-138|serum|group
DDI-DrugBank.d57.s1|150-157|or serum|brand
DDI-DrugBank.d499.s0|50-59|ketoprofen|drug
DDI-DrugBank.d499.s1|131-140|ketoprofen|drug
DDI-DrugBank.d499.s3|0-7|Antacids|group
DDI-DrugBank.d499.s3|40-48|magnesium|drug
DDI-DrugBank.d499.s3|64-81|aluminum hydroxide|drug
DDI-DrugBank.d499.s3|147-156|ketoprofen|drug
DDI-DrugBank.d499.s5|0-6|Aspirin|brand
DDI-DrugBank.d499.s5|9-18|Ketoprofen|drug
DDI-DrugBank.d499.s5|35-41|aspirin|brand
DDI-DrugBank.d499.s6|72-78|aspirin|brand
DDI-DrugBank.d499.s6|90-99|ketoprofen|drug
DDI-DrugBank.d499.s6|131-140|ketoprofen|drug
DDI-DrugBank.d499.s6|184-190|aspirin|brand
DDI-DrugBank.d499.s6|212-218|aspirin|brand
DDI-DrugBank.d499.s8|29-35|aspirin|brand
DDI-DrugBank.d499.s8|41-50|ketoprofen|drug
DDI-DrugBank.d499.s10|10-28|Hydrochlorothiazide|drug
DDI-DrugBank.d499.s10|56-65|ketoprofen|drug
DDI-DrugBank.d499.s10|100-108|potassium|drug
DDI-DrugBank.d499.s10|145-163|hydrochlorothiazide|drug
DDI-DrugBank.d499.s11|16-24|diuretics|group
DDI-DrugBank.d499.s11|109-113|blood|group
DDI-DrugBank.d499.s13|0-6|Digoxin|drug
DDI-DrugBank.d499.s13|71-80|ketoprofen|drug
DDI-DrugBank.d499.s13|86-92|digoxin|drug
DDI-DrugBank.d499.s13|127-136|ketoprofen|drug
DDI-DrugBank.d499.s13|156-160|serum|group
DDI-DrugBank.d499.s13|172-178|digoxin|drug
DDI-DrugBank.d499.s15|0-7|Warfarin|drug
DDI-DrugBank.d499.s15|68-77|ketoprofen|drug
DDI-DrugBank.d499.s15|130-137|warfarin|drug
DDI-DrugBank.d499.s15|142-152|prothrombin|drug
DDI-DrugBank.d499.s16|57-64|warfarin|drug
DDI-DrugBank.d499.s16|80-108|GI bleeding a complication of|brand
DDI-DrugBank.d499.s16|110-119|ketoprofen|drug
DDI-DrugBank.d499.s17|64-73|ketoprofen|drug
DDI-DrugBank.d499.s17|142-151|ketoprofen|drug
DDI-DrugBank.d499.s17|157-164|warfarin|drug
DDI-DrugBank.d499.s19|0-9|Probenecid|drug
DDI-DrugBank.d499.s19|12-21|Probenecid|drug
DDI-DrugBank.d499.s19|53-62|ketoprofen|drug
DDI-DrugBank.d499.s19|100-109|ketoprofen|drug
DDI-DrugBank.d499.s20|30-39|ketoprofen|drug
DDI-DrugBank.d499.s20|45-54|probenecid|drug
DDI-DrugBank.d499.s22|0-11|Methotrexate|drug
DDI-DrugBank.d499.s22|14-23|Ketoprofen|drug
DDI-DrugBank.d499.s22|85-96|methotrexate|drug
DDI-DrugBank.d499.s22|118-122|serum|group
DDI-DrugBank.d499.s24|0-6|Lithium|brand
DDI-DrugBank.d499.s24|22-45|anti-inflammatory agents|group
DDI-DrugBank.d499.s24|97-103|lithium|brand
DDI-DrugBank.d499.s25|30-36|lithium|brand
DDI-DrugBank.d499.s25|63-72|ketoprofen|drug
DDI-DrugBank.d499.s25|97-103|lithium|brand
DDI-DrugBank.d499.s26|0-40|DRUG/LABORATORY TEST INTERACTIONS : EFFECT|brand
DDI-DrugBank.d499.s26|16-43|TEST INTERACTIONS : EFFECT ON|brand
DDI-DrugBank.d499.s26|21-49|INTERACTIONS : EFFECT ON BLOOD|brand
DDI-DrugBank.d499.s26|35-72|EFFECT ON BLOOD COAGULATION Ketoprofen|brand
DDI-DrugBank.d499.s26|42-82|ON BLOOD COAGULATION Ketoprofen decreases|brand
DDI-DrugBank.d499.s26|45-49|BLOOD|group
DDI-DrugBank.d499.s26|63-72|Ketoprofen|drug
DDI-DrugBank.d499.s27|18-24|prolong|brand
DDI-DrugBank.d499.s27|77-92|baseline values .|drug
DDI-DrugBank.d499.s28|50-60|prothrombin|drug
DDI-DrugBank.d499.s28|100-107|thrombin|drug
DDI-DrugBank.d92.s0|37-49|glutamic acid|drug
DDI-DrugBank.d66.s0|6-19|growth hormone|group
DDI-DrugBank.d66.s0|42-52|L-glutamine|drug
DDI-DrugBank.d66.s0|64-77|growth hormone|group
DDI-DrugBank.d66.s1|0-10|L-glutamine|drug
DDI-DrugBank.d66.s2|0-11|Indomethacin|drug
DDI-DrugBank.d66.s2|34-44|L-glutamine|drug
DDI-DrugBank.d66.s2|50-61|indomethacin|drug
DDI-DrugBank.d66.s2|122-133|indomethacin|drug
DDI-DrugBank.d66.s3|27-37|L-glutamine|drug
DDI-DrugBank.d66.s4|9-19|misoprostol|drug
DDI-DrugBank.d66.s5|0-11|Methotrexate|drug
DDI-DrugBank.d66.s5|40-51|methotrexate|drug
DDI-DrugBank.d66.s5|109-119|L-glutamine|drug
DDI-DrugBank.d66.s6|19-50|nine patients with breast cancer|drug
DDI-DrugBank.d66.s6|150-160|L-glutamine|drug
DDI-DrugBank.d66.s7|0-9|Paclitaxel|drug
DDI-DrugBank.d66.s7|28-38|L-glutamine|drug
DDI-DrugBank.d66.s7|112-121|paclitaxel|drug
DDI-DrugBank.d66.s7|136-142|prevent|brand
DDI-DrugBank.d66.s7|208-217|paclitaxel|drug
DDI-DrugBank.d412.s0|39-47|labetalol|drug
DDI-DrugBank.d412.s0|162-170|labetalol|drug
DDI-DrugBank.d412.s4|0-9|Cimetidine|drug
DDI-DrugBank.d412.s4|61-69|labetalol|drug
DDI-DrugBank.d412.s5|105-113|labetalol|drug
DDI-DrugBank.d412.s5|128-131|care|brand
DDI-DrugBank.d412.s5|186-190|blood|group
DDI-DrugBank.d412.s5|201-207|control|brand
DDI-DrugBank.d412.s6|33-41|halothane|drug
DDI-DrugBank.d412.s6|85-93|labetalol|drug
DDI-DrugBank.d412.s7|47-55|labetalol|drug
DDI-DrugBank.d412.s7|81-89|halothane|drug
DDI-DrugBank.d412.s7|129-137|halothane|drug
DDI-DrugBank.d412.s7|170-175|degree|brand
DDI-DrugBank.d412.s8|68-76|labetalol|drug
DDI-DrugBank.d412.s9|0-8|Labetalol|drug
DDI-DrugBank.d412.s9|56-68|nitroglycerin|drug
DDI-DrugBank.d412.s10|3-11|labetalol|drug
DDI-DrugBank.d412.s10|30-42|nitroglycerin|drug
DDI-DrugBank.d412.s11|0-3|Care|brand
DDI-DrugBank.d412.s11|24-32|labetalol|drug
DDI-DrugBank.d412.s11|61-67|calcium|drug
DDI-DrugBank.d412.s11|88-96|verapamil|drug
DDI-DrugBank.d412.s12|130-138|allergens|group
DDI-DrugBank.d412.s12|218-228|therapeutic|brand
DDI-DrugBank.d412.s13|56-66|epinephrine|drug
DDI-DrugBank.d412.s14|50-58|labetalol|drug
DDI-DrugBank.d412.s14|79-105|urine may result in falsely|drug
DDI-DrugBank.d412.s14|134-147|catecholamines|group
DDI-DrugBank.d412.s14|150-199|metanephrine , normetanephrine and vanillylmandelic|drug
DDI-DrugBank.d412.s14|164-209|normetanephrine and vanillylmandelic acid when|drug
DDI-DrugBank.d412.s15|84-92|labetalol|drug
DDI-DrugBank.d412.s15|209-241|J Chromatogr 385:241,1987 ) should|brand
DDI-DrugBank.d412.s15|280-293|catecholamines|group
DDI-DrugBank.d412.s16|0-8|Labetalol|drug
DDI-DrugBank.d412.s16|74-84|amphetamine|drug
DDI-DrugBank.d412.s16|101-125|urine for the presence of|drug
DDI-DrugBank.d412.s16|189-224|A ( thin-layer chromatographic assay|brand
DDI-DrugBank.d412.s17|33-41|labetalol|drug
DDI-DrugBank.d412.s17|59-90|urine test for amphetamine using|drug
DDI-DrugBank.d412.s17|74-84|amphetamine|drug
DDI-DrugBank.d71.s0|0-9|Lamivudine|drug
DDI-DrugBank.d71.s0|14-50|predominantly eliminated in the urine|drug
DDI-DrugBank.d71.s0|46-77|urine by active organic cationic|drug
DDI-DrugBank.d71.s1|222-233|trimethoprim|drug
DDI-DrugBank.d71.s3|48-57|lamivudine|drug
DDI-DrugBank.d71.s3|95-120|TMP/SMX such as those used|brand
DDI-DrugBank.d71.s4|118-127|lamivudine|drug
DDI-DrugBank.d71.s5|0-9|Lamivudine|drug
DDI-DrugBank.d71.s5|15-25|zalcitabine|drug
DDI-DrugBank.d71.s6|18-27|lamivudine|drug
DDI-DrugBank.d71.s6|49-59|zalcitabine|drug
DDI-DrugBank.d189.s0|29-32|Date|drug
DDI-DrugBank.d189.s0|116-124|captopril|drug
DDI-DrugBank.d189.s0|142-151|felodipine|drug
DDI-DrugBank.d189.s0|154-160|digoxin|drug
DDI-DrugBank.d189.s0|163-170|warfarin|drug
DDI-DrugBank.d189.s0|173-182|isosorbide|drug
DDI-DrugBank.d189.s0|197-206|carvedilol|drug
DDI-DrugBank.d189.s0|209-215|ethanol|drug
DDI-DrugBank.d189.s0|220-231|itraconazole|drug
DDI-DrugBank.d411.s1|22-28|thyroid|brand
DDI-DrugBank.d411.s1|81-89|on target|brand
DDI-DrugBank.d411.s1|149-159|therapeutic|brand
DDI-DrugBank.d411.s1|169-181|levothyroxine|drug
DDI-DrugBank.d411.s2|0-12|Levothyroxine|drug
DDI-DrugBank.d411.s2|90-102|levothyroxine|drug
DDI-DrugBank.d411.s2|163-176|cholestyramine|drug
DDI-DrugBank.d411.s2|185-194|colestipol|drug
DDI-DrugBank.d411.s2|211-225|ferrous sulfate|drug
DDI-DrugBank.d411.s2|228-233|sodium|group
DDI-DrugBank.d411.s2|258-264|soybean|drug
DDI-DrugBank.d411.s2|296-305|sucralfate|drug
DDI-DrugBank.d411.s3|11-15|Serum|group
DDI-DrugBank.d411.s3|67-79|levothyroxine|drug
DDI-DrugBank.d411.s3|99-103|serum|group
DDI-DrugBank.d411.s3|145-149|serum|group
DDI-DrugBank.d411.s3|159-166|proteins|group
DDI-DrugBank.d411.s3|169-177|androgens|group
DDI-DrugBank.d411.s3|200-207|hormones|group
DDI-DrugBank.d411.s3|210-221|asparaginase|group
DDI-DrugBank.d411.s3|224-233|clofibrate|drug
DDI-DrugBank.d411.s3|236-244|estrogens|group
DDI-DrugBank.d411.s3|281-294|5-fluorouracil|drug
DDI-DrugBank.d411.s3|297-306|furosemide|drug
DDI-DrugBank.d411.s3|309-323|glucocorticoids|group
DDI-DrugBank.d411.s3|326-342|meclofenamic acid|drug
DDI-DrugBank.d411.s3|345-353|mefenamic|brand
DDI-DrugBank.d411.s3|361-369|methadone|drug
DDI-DrugBank.d411.s3|372-383|perphenazine|drug
DDI-DrugBank.d411.s3|386-399|phenylbutazone|drug
DDI-DrugBank.d411.s3|402-410|phenytoin|drug
DDI-DrugBank.d411.s3|413-423|salicylates|group
DDI-DrugBank.d411.s3|426-434|tamoxifen|drug
DDI-DrugBank.d411.s4|0-6|Thyroid|brand
DDI-DrugBank.d411.s4|51-57|thyroid|brand
DDI-DrugBank.d411.s4|70-93|TSH levels , generally by|brand
DDI-DrugBank.d411.s4|106-112|thyroid|brand
DDI-DrugBank.d411.s4|213-245|TSH secretion : aminoglutethimide ,|brand
DDI-DrugBank.d411.s4|228-244|aminoglutethimide|drug
DDI-DrugBank.d411.s4|270-279|amiodarone|drug
DDI-DrugBank.d411.s4|282-290|androgens|group
DDI-DrugBank.d411.s4|313-320|hormones|group
DDI-DrugBank.d411.s4|331-336|anions|group
DDI-DrugBank.d411.s4|352-362|perchlorate|drug
DDI-DrugBank.d411.s4|430-442|carbamazepine|drug
DDI-DrugBank.d411.s4|445-459|chloral hydrate|drug
DDI-DrugBank.d411.s4|462-469|diazepam|drug
DDI-DrugBank.d411.s4|472-479|dopamine|drug
DDI-DrugBank.d411.s4|485-492|dopamine|drug
DDI-DrugBank.d411.s4|504-514|ethionamide|drug
DDI-DrugBank.d411.s4|517-531|glucocorticoids|group
DDI-DrugBank.d411.s4|534-540|heparin|drug
DDI-DrugBank.d411.s4|568-574|insulin|group
DDI-DrugBank.d411.s4|640-647|levodopa|drug
DDI-DrugBank.d411.s4|650-659|lovastatin|drug
DDI-DrugBank.d411.s4|662-668|lithium|brand
DDI-DrugBank.d411.s4|671-712|6-mercaptopurine , metoclopramide , mitotane|drug
DDI-DrugBank.d411.s4|689-702|metoclopramide|drug
DDI-DrugBank.d411.s4|705-712|mitotane|drug
DDI-DrugBank.d411.s4|715-727|nitroprusside|drug
DDI-DrugBank.d411.s4|730-742|phenobarbital|drug
DDI-DrugBank.d411.s4|745-753|phenytoin|drug
DDI-DrugBank.d411.s4|756-765|resorcinol|drug
DDI-DrugBank.d411.s4|768-775|rifampin|brand
DDI-DrugBank.d411.s4|778-789|somatostatin|drug
DDI-DrugBank.d411.s4|800-811|sulfonamides|group
DDI-DrugBank.d411.s4|814-826|sulfonylureas|group
DDI-DrugBank.d411.s4|829-847|thiazide diuretics .|drug
DDI-DrugBank.d411.s4|838-846|diuretics|group
DDI-DrugBank.d411.s5|174-180|thyroid|brand
DDI-DrugBank.d411.s6|0-9|Amiodarone|drug
DDI-DrugBank.d411.s6|12-21|Amiodarone|drug
DDI-DrugBank.d411.s7|0-13|Anticoagulants|group
DDI-DrugBank.d411.s7|57-70|anticoagulants|group
DDI-DrugBank.d411.s8|21-27|Insulin|group
DDI-DrugBank.d411.s8|30-42|Sulfonylureas|group
DDI-DrugBank.d411.s8|63-69|insulin|group
DDI-DrugBank.d411.s8|143-159|diabetes mellitus|group
DDI-DrugBank.d411.s8|214-220|thyroid|brand
DDI-DrugBank.d411.s10|0-8|Cytokines|group
DDI-DrugBank.d411.s10|11-20|interferon|drug
DDI-DrugBank.d411.s10|37-45|Cytokines|group
DDI-DrugBank.d411.s11|0-19|Digitalis Glycosides|group
DDI-DrugBank.d411.s11|22-32|Therapeutic|brand
DDI-DrugBank.d411.s11|45-64|digitalis glycosides|group
DDI-DrugBank.d411.s12|0-4|Serum|group
DDI-DrugBank.d411.s13|0-7|Ketamine|drug
DDI-DrugBank.d411.s13|115-127|levothyroxine|drug
DDI-DrugBank.d411.s13|140-147|ketamine|drug
DDI-DrugBank.d411.s14|0-10|Maprotiline|drug
DDI-DrugBank.d411.s15|0-5|Sodium|group
DDI-DrugBank.d411.s15|15-29|123I and 131I ) ,|drug
DDI-DrugBank.d411.s15|24-50|131I ) , Sodium Pertechnetate|drug
DDI-DrugBank.d411.s15|31-36|Sodium|group
DDI-DrugBank.d411.s15|52-80|Tc99m : Uptake of radiolabeled|drug
DDI-DrugBank.d411.s15|82-85|ions|group
DDI-DrugBank.d411.s16|49-55|thyroid|brand
DDI-DrugBank.d411.s17|67-74|somatrem|drug
DDI-DrugBank.d411.s18|0-11|Theophylline|drug
DDI-DrugBank.d411.s18|14-25|Theophylline|drug
DDI-DrugBank.d411.s19|59-69|therapeutic|brand
DDI-DrugBank.d411.s19|130-155|catecholamine sensitivity .|drug
DDI-DrugBank.d130.s0|0-9|Lincomycin|drug
DDI-DrugBank.d130.s0|105-133|neuromuscular blocking agents|group
DDI-DrugBank.d130.s2|19-28|lincomycin|drug
DDI-DrugBank.d130.s2|34-45|erythromycin|drug
DDI-DrugBank.d158.s0|0-24|Urinary acidifying agents|group
DDI-DrugBank.d158.s0|40-56|ammonium chloride|drug
DDI-DrugBank.d158.s0|59-64|sodium|group
DDI-DrugBank.d158.s0|71-79|phosphate|brand
DDI-DrugBank.d158.s0|145-155|amphetamine|drug
DDI-DrugBank.d158.s1|28-32|blood|group
DDI-DrugBank.d158.s1|57-68|amphetamines|group
DDI-DrugBank.d158.s2|57-68|amphetamines|group
DDI-DrugBank.d158.s3|27-38|Amphetamines|group
DDI-DrugBank.d158.s4|0-46|d-amphetamine with desipramine or protriptyline|drug
DDI-DrugBank.d158.s4|19-29|desipramine|drug
DDI-DrugBank.d158.s4|34-46|protriptyline|drug
DDI-DrugBank.d158.s4|141-167|d-amphetamine in the brain ;|drug
DDI-DrugBank.d158.s6|0-35|MAO inhibitors MAOI antidepressants ,|brand
DDI-DrugBank.d158.s6|15-43|MAOI antidepressants , as well|brand
DDI-DrugBank.d158.s6|64-75|furazolidone|drug
DDI-DrugBank.d158.s6|83-93|amphetamine|drug
DDI-DrugBank.d158.s7|25-36|amphetamines|group
DDI-DrugBank.d158.s7|70-76|release|brand
DDI-DrugBank.d158.s7|81-94|norepinephrine|drug
DDI-DrugBank.d158.s9|0-30|A variety of toxic neurological|brand
DDI-DrugBank.d158.s10|16-27|Amphetamines|group
DDI-DrugBank.d158.s11|19-30|Amphetamines|group
DDI-DrugBank.d158.s12|0-13|Chlorpromazine|drug
DDI-DrugBank.d158.s12|16-29|Chlorpromazine|drug
DDI-DrugBank.d158.s12|38-45|dopamine|drug
DDI-DrugBank.d158.s12|51-64|norepinephrine|drug
DDI-DrugBank.d158.s12|126-137|amphetamines|group
DDI-DrugBank.d158.s12|164-174|amphetamine|drug
DDI-DrugBank.d158.s13|0-11|Ethosuximide|drug
DDI-DrugBank.d158.s13|14-25|Amphetamines|group
DDI-DrugBank.d158.s13|62-73|ethosuximide|drug
DDI-DrugBank.d158.s14|0-10|Haloperidol|drug
DDI-DrugBank.d158.s14|13-23|Haloperidol|drug
DDI-DrugBank.d158.s14|32-39|dopamine|drug
DDI-DrugBank.d158.s14|101-112|amphetamines|group
DDI-DrugBank.d158.s15|0-6|Lithium|brand
DDI-DrugBank.d158.s15|60-71|amphetamines|group
DDI-DrugBank.d158.s15|93-99|lithium|brand
DDI-DrugBank.d158.s16|0-9|Meperidine|drug
DDI-DrugBank.d158.s16|12-23|Amphetamines|group
DDI-DrugBank.d158.s16|40-48|analgesic|brand
DDI-DrugBank.d158.s16|60-69|meperidine|drug
DDI-DrugBank.d158.s17|0-10|Methenamine|drug
DDI-DrugBank.d158.s17|41-52|amphetamines|group
DDI-DrugBank.d158.s17|95-111|acidifying agents|group
DDI-DrugBank.d158.s17|121-131|methenamine|drug
DDI-DrugBank.d158.s18|0-13|Norepinephrine|drug
DDI-DrugBank.d158.s18|16-27|Amphetamines|group
DDI-DrugBank.d158.s18|62-75|norepinephrine|drug
DDI-DrugBank.d158.s19|0-12|Phenobarbital|drug
DDI-DrugBank.d158.s19|15-26|Amphetamines|group
DDI-DrugBank.d158.s19|63-75|phenobarbital|drug
DDI-DrugBank.d158.s20|21-33|phenobarbital|drug
DDI-DrugBank.d158.s21|0-8|Phenytoin|drug
DDI-DrugBank.d158.s21|11-22|Amphetamines|group
DDI-DrugBank.d158.s21|59-67|phenytoin|drug
DDI-DrugBank.d158.s22|21-29|phenytoin|drug
DDI-DrugBank.d158.s23|0-11|Propoxyphene|brand
DDI-DrugBank.d158.s23|26-37|propoxyphene|brand
DDI-DrugBank.d158.s23|51-61|amphetamine|drug
DDI-DrugBank.d158.s24|0-17|Veratrum alkaloids|group
DDI-DrugBank.d158.s24|20-31|Amphetamines|group
DDI-DrugBank.d158.s24|67-84|veratrum alkaloids|group
DDI-DrugBank.d158.s25|35-46|Amphetamines|group
DDI-DrugBank.d158.s25|92-113|corticosteroid levels .|drug
DDI-DrugBank.d158.s27|0-11|Amphetamines|group
DDI-DrugBank.d258.s0|0-9|Loratadine|drug
DDI-DrugBank.d258.s0|59-69|therapeutic|brand
DDI-DrugBank.d258.s0|80-91|erythromycin|drug
DDI-DrugBank.d258.s0|94-103|cimetidine|drug
DDI-DrugBank.d258.s0|110-121|ketoconazole|drug
DDI-DrugBank.d258.s1|42-57|AUC 0-24 hrs ) of|brand
DDI-DrugBank.d258.s1|59-68|loratadine|drug
DDI-DrugBank.d258.s1|77-141|descarboethoxyloratadine were observed following coadministration|drug
DDI-DrugBank.d258.s1|146-155|loratadine|drug
DDI-DrugBank.d258.s1|294-303|loratadine|drug
DDI-DrugBank.d258.s3|39-48|cimetidine|drug
DDI-DrugBank.d258.s3|53-64|ketoconazole|drug
DDI-DrugBank.d258.s4|23-38|AUC 0-24 hrs ) of|brand
DDI-DrugBank.d258.s4|40-51|erythromycin|drug
DDI-DrugBank.d258.s4|92-101|loratadine|drug
DDI-DrugBank.d258.s4|134-145|erythromycin|drug
DDI-DrugBank.d258.s6|39-46|TABLE 1 .|brand
DDI-DrugBank.d258.s7|0-24|TABLE 1 Effects on Plasma|brand
DDI-DrugBank.d258.s7|42-57|AUC 0-24 hrs ) of|brand
DDI-DrugBank.d258.s7|59-68|Loratadine|drug
DDI-DrugBank.d258.s7|74-114|Descarboethoxyloratadine After 10 Days of|drug
DDI-DrugBank.d258.s7|134-143|Loratadine|drug
DDI-DrugBank.d258.s8|0-9|Loratadine|drug
DDI-DrugBank.d258.s9|0-11|Erythromycin|drug
DDI-DrugBank.d258.s9|21-30|q8h ) + 40 %|drug
DDI-DrugBank.d258.s10|0-9|Cimetidine|drug
DDI-DrugBank.d258.s11|0-11|Ketoconazole|drug
DDI-DrugBank.d258.s11|21-35|q12h ) +307 % +73|drug
DDI-DrugBank.d258.s12|107-116|loratadine|drug
DDI-DrugBank.d504.s0|122-129|loxapine|drug
DDI-DrugBank.d504.s0|135-143|lorazepam|drug
DDI-DrugBank.d504.s1|18-25|loxapine|drug
DDI-DrugBank.d504.s2|67-74|loxapine|drug
DDI-DrugBank.d716.s0|16-23|mazindol|drug
DDI-DrugBank.d716.s0|45-61|monoamine oxidase|drug
DDI-DrugBank.d716.s0|74-100|MAOI ) such as isocarboxazid|brand
DDI-DrugBank.d716.s0|88-100|isocarboxazid|drug
DDI-DrugBank.d716.s0|103-109|Marplan|brand
DDI-DrugBank.d716.s0|113-127|tranylcypromine|drug
DDI-DrugBank.d716.s0|130-136|Parnate|brand
DDI-DrugBank.d716.s0|143-152|phenelzine|drug
DDI-DrugBank.d716.s0|155-160|Nardil|brand
DDI-DrugBank.d716.s1|11-17|insulin|group
DDI-DrugBank.d716.s1|92-99|mazindol|drug
DDI-DrugBank.d716.s2|0-7|Mazindol|drug
DDI-DrugBank.d716.s2|35-46|guanethidine|drug
DDI-DrugBank.d716.s2|49-55|Ismelin|brand
DDI-DrugBank.d716.s3|34-38|blood|group
DDI-DrugBank.d716.s4|35-46|guanethidine|drug
DDI-DrugBank.d716.s5|101-113|amitriptyline|drug
DDI-DrugBank.d716.s5|116-121|Elavil|brand
DDI-DrugBank.d716.s5|125-133|amoxapine|drug
DDI-DrugBank.d716.s5|146-152|doxepin|drug
DDI-DrugBank.d716.s5|155-162|Sinequan|brand
DDI-DrugBank.d716.s5|166-178|nortriptyline|drug
DDI-DrugBank.d716.s5|181-187|Pamelor|brand
DDI-DrugBank.d716.s5|191-200|imipramine|drug
DDI-DrugBank.d716.s5|203-210|Tofranil|brand
DDI-DrugBank.d716.s5|214-225|clomipramine|drug
DDI-DrugBank.d716.s5|228-236|Anafranil|brand
DDI-DrugBank.d716.s5|240-252|protriptyline|drug
DDI-DrugBank.d716.s5|255-262|Vivactil|brand
DDI-DrugBank.d716.s5|269-279|desipramine|drug
DDI-DrugBank.d716.s5|282-290|Norpramin|brand
DDI-DrugBank.d716.s6|40-47|mazindol|drug
DDI-DrugBank.d623.s0|58-74|depo-subQ provera|brand
DDI-DrugBank.d623.s1|0-16|Aminoglutethimide|drug
DDI-DrugBank.d623.s1|50-66|depo-subQ provera|brand
DDI-DrugBank.d623.s1|103-107|serum|group
DDI-DrugBank.d623.s1|127-130|MPA .|brand
DDI-DrugBank.d623.s3|46-79|endocrine and liver function tests|drug
DDI-DrugBank.d623.s3|60-73|liver function|group
DDI-DrugBank.d623.s3|86-90|blood|group
DDI-DrugBank.d623.s3|200-211|progesterone|drug
DDI-DrugBank.d623.s3|214-222|estradiol|drug
DDI-DrugBank.d623.s3|239-250|testosterone|drug
DDI-DrugBank.d623.s3|253-262|cortisol ) .|drug
DDI-DrugBank.d623.s4|64-72|LH , FSH ) .|brand
DDI-DrugBank.d623.s4|68-72|FSH ) .|brand
DDI-DrugBank.d623.s5|4-37|SHBG concentrations are decreased .|brand
DDI-DrugBank.d623.s8|4-22|Sulfobromophthalein|drug
DDI-DrugBank.d623.s8|34-47|liver function|group
DDI-DrugBank.d597.s0|0-34|ACE inhibitors Reports suggest that|brand
DDI-DrugBank.d597.s0|87-115|angiotensin-converting enzyme|drug
DDI-DrugBank.d597.s0|118-133|ACE ) inhibitors .|brand
DDI-DrugBank.d597.s1|92-106|ACE inhibitors .|brand
DDI-DrugBank.d597.s2|0-6|Aspirin|brand
DDI-DrugBank.d597.s2|39-45|aspirin|brand
DDI-DrugBank.d597.s2|56-81|TID ) to healthy volunteers|brand
DDI-DrugBank.d597.s2|106-114|AUC ( 10 % )|brand
DDI-DrugBank.d597.s2|134-142|meloxicam|drug
DDI-DrugBank.d597.s4|61-69|meloxicam|drug
DDI-DrugBank.d597.s4|75-81|aspirin|brand
DDI-DrugBank.d597.s5|39-45|aspirin|brand
DDI-DrugBank.d597.s5|52-56|MOBIC|brand
DDI-DrugBank.d597.s5|93-128|GI ulceration or other complications|brand
DDI-DrugBank.d597.s5|150-154|MOBIC|brand
DDI-DrugBank.d597.s6|0-4|MOBIC|brand
DDI-DrugBank.d597.s6|30-36|aspirin|brand
DDI-DrugBank.d597.s7|0-13|Cholestyramine|drug
DDI-DrugBank.d597.s7|48-61|cholestyramine|drug
DDI-DrugBank.d597.s7|104-112|meloxicam|drug
DDI-DrugBank.d597.s8|91-94|AUC .|brand
DDI-DrugBank.d597.s9|59-67|meloxicam|drug
DDI-DrugBank.d597.s11|0-9|Cimetidine|drug
DDI-DrugBank.d597.s11|49-58|cimetidine|drug
DDI-DrugBank.d597.s11|120-128|meloxicam|drug
DDI-DrugBank.d597.s12|0-6|Digoxin|drug
DDI-DrugBank.d597.s12|9-17|Meloxicam|drug
DDI-DrugBank.d597.s12|97-103|digoxin|drug
DDI-DrugBank.d597.s13|67-73|digoxin|drug
DDI-DrugBank.d597.s13|79-87|meloxicam|drug
DDI-DrugBank.d597.s14|0-9|Furosemide|drug
DDI-DrugBank.d597.s14|130-139|furosemide|drug
DDI-DrugBank.d597.s14|145-179|thiazide diuretics in some patients|drug
DDI-DrugBank.d597.s14|154-162|diuretics|group
DDI-DrugBank.d597.s16|13-22|furosemide|drug
DDI-DrugBank.d597.s16|35-43|meloxicam|drug
DDI-DrugBank.d597.s17|0-9|Furosemide|drug
DDI-DrugBank.d597.s17|113-121|meloxicam|drug
DDI-DrugBank.d597.s18|46-55|furosemide|drug
DDI-DrugBank.d597.s18|61-65|MOBIC|brand
DDI-DrugBank.d597.s19|0-6|Lithium|brand
DDI-DrugBank.d597.s19|73-79|lithium|brand
DDI-DrugBank.d597.s19|113-119|lithium|brand
DDI-DrugBank.d597.s20|56-62|lithium|brand
DDI-DrugBank.d597.s20|82-105|AUC were increased by 21|brand
DDI-DrugBank.d597.s20|130-136|lithium|brand
DDI-DrugBank.d597.s20|172-195|BID with meloxicam 15 mg|brand
DDI-DrugBank.d597.s20|181-189|meloxicam|drug
DDI-DrugBank.d597.s20|197-222|QD as compared to subjects|brand
DDI-DrugBank.d597.s20|234-240|lithium|brand
DDI-DrugBank.d597.s21|85-89|MOBIC|brand
DDI-DrugBank.d597.s22|12-18|lithium|brand
DDI-DrugBank.d597.s22|63-67|MOBIC|brand
DDI-DrugBank.d597.s23|0-11|Methotrexate|drug
DDI-DrugBank.d597.s23|14-37|A study in 13 rheumatoid|brand
DDI-DrugBank.d597.s23|39-47|arthritis|brand
DDI-DrugBank.d597.s23|50-51|RA|drug
DDI-DrugBank.d597.s23|106-114|meloxicam|drug
DDI-DrugBank.d597.s23|143-154|methotrexate|drug
DDI-DrugBank.d597.s24|0-8|Meloxicam|drug
DDI-DrugBank.d597.s24|87-98|methotrexate|drug
DDI-DrugBank.d597.s25|10-21|methotrexate|drug
DDI-DrugBank.d597.s25|40-48|meloxicam|drug
DDI-DrugBank.d597.s25|65-69|serum|group
DDI-DrugBank.d597.s26|0-7|Warfarin|drug
DDI-DrugBank.d597.s26|70-78|the first|brand
DDI-DrugBank.d597.s26|118-122|MOBIC|brand
DDI-DrugBank.d597.s26|154-161|warfarin|drug
DDI-DrugBank.d597.s27|14-22|meloxicam|drug
DDI-DrugBank.d597.s27|55-62|warfarin|drug
DDI-DrugBank.d597.s27|132-139|warfarin|drug
DDI-DrugBank.d597.s27|158-192|INR ( International Normalized Ratio|brand
DDI-DrugBank.d597.s28|19-27|meloxicam|drug
DDI-DrugBank.d597.s28|43-50|warfarin|drug
DDI-DrugBank.d597.s28|109-116|warfarin|drug
DDI-DrugBank.d597.s28|135-145|prothrombin|drug
DDI-DrugBank.d597.s29|43-61|INR from 1.5 to 2.1|brand
DDI-DrugBank.d597.s30|42-46|MOBIC|brand
DDI-DrugBank.d597.s30|53-60|warfarin|drug
DDI-DrugBank.d597.s30|80-87|warfarin|drug
DDI-DrugBank.d597.s30|115-139|INR and an increased risk|brand
DDI-DrugBank.d585.s0|92-101|amantadine|drug
DDI-DrugBank.d585.s0|104-124|antiarrhythmic agents|group
DDI-DrugBank.d585.s0|135-152|I ( e.g. , quinidine|brand
DDI-DrugBank.d585.s0|144-152|quinidine|drug
DDI-DrugBank.d585.s0|172-191|antipsychotic agents|group
DDI-DrugBank.d585.s0|200-213|phenothiazines|group
DDI-DrugBank.d585.s0|234-268|MAO inhibitors , narcotic analgesics|brand
DDI-DrugBank.d585.s0|259-268|analgesics|group
DDI-DrugBank.d585.s0|277-286|meperidine|drug
DDI-DrugBank.d585.s0|290-297|nitrates|group
DDI-DrugBank.d585.s0|303-310|nitrites|group
DDI-DrugBank.d585.s1|43-61|antiglaucoma agents|group
DDI-DrugBank.d585.s2|133-147|corticosteroids|group
DDI-DrugBank.d585.s3|0-21|Anticholinergic agents|group
DDI-DrugBank.d585.s3|122-128|digoxin|drug
DDI-DrugBank.d585.s4|10-14|serum|group
DDI-DrugBank.d585.s5|104-117|metoclopramide|drug
DDI-DrugBank.d585.s6|8-15|antacids|group
DDI-DrugBank.d585.s6|54-75|anticholinergic agents|group
DDI-DrugBank.d585.s7|59-75|hydrochloric acid|drug
DDI-DrugBank.d703.s0|23-44|Central Nervous System|group
DDI-DrugBank.d703.s0|59-68|MEPERIDINE|drug
DDI-DrugBank.d703.s0|77-102|BE USED WITH GREAT CAUTION|brand
DDI-DrugBank.d703.s0|80-106|USED WITH GREAT CAUTION AND|brand
DDI-DrugBank.d703.s0|85-109|WITH GREAT CAUTION AND IN|brand
DDI-DrugBank.d703.s0|90-117|GREAT CAUTION AND IN REDUCED|brand
DDI-DrugBank.d703.s0|96-124|CAUTION AND IN REDUCED DOSAGE|brand
DDI-DrugBank.d703.s0|104-127|AND IN REDUCED DOSAGE IN|brand
DDI-DrugBank.d703.s0|108-136|IN REDUCED DOSAGE IN PATIENTS|brand
DDI-DrugBank.d703.s0|111-140|REDUCED DOSAGE IN PATIENTS WHO|brand
DDI-DrugBank.d703.s0|119-144|DOSAGE IN PATIENTS WHO ARE|brand
DDI-DrugBank.d703.s0|126-157|IN PATIENTS WHO ARE CONCURRENTLY|brand
DDI-DrugBank.d703.s0|129-167|PATIENTS WHO ARE CONCURRENTLY RECEIVING|brand
DDI-DrugBank.d703.s0|138-173|WHO ARE CONCURRENTLY RECEIVING OTHER|brand
DDI-DrugBank.d703.s0|142-182|ARE CONCURRENTLY RECEIVING OTHER NARCOTIC|brand
DDI-DrugBank.d703.s0|146-193|CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS|brand
DDI-DrugBank.d703.s0|159-194|RECEIVING OTHER NARCOTIC ANALGESICS ,|brand
DDI-DrugBank.d703.s0|169-202|OTHER NARCOTIC ANALGESICS , GENERAL|brand
DDI-DrugBank.d703.s0|175-214|NARCOTIC ANALGESICS , GENERAL ANESTHETICS|brand
DDI-DrugBank.d703.s0|184-193|ANALGESICS|group
DDI-DrugBank.d703.s0|196-231|GENERAL ANESTHETICS , PHENOTHIAZINES ,|brand
DDI-DrugBank.d703.s0|204-214|ANESTHETICS|group
DDI-DrugBank.d703.s0|217-230|PHENOTHIAZINES|group
DDI-DrugBank.d703.s0|233-273|OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS (|brand
DDI-DrugBank.d703.s0|239-282|TRANQUILIZERS , SEDATIVE-HYPNOTICS ( INCLUDING|brand
DDI-DrugBank.d703.s0|254-296|SEDATIVE-HYPNOTICS ( INCLUDING BARBITURATES )|brand
DDI-DrugBank.d703.s0|274-307|INCLUDING BARBITURATES ) , TRICYCLIC|brand
DDI-DrugBank.d703.s0|284-295|BARBITURATES|group
DDI-DrugBank.d703.s0|299-337|TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS|brand
DDI-DrugBank.d703.s0|309-349|ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS|brand
DDI-DrugBank.d703.s0|325-351|AND OTHER CNS DEPRESSANTS (|brand
DDI-DrugBank.d703.s0|329-360|OTHER CNS DEPRESSANTS ( INCLUDING|brand
DDI-DrugBank.d703.s0|335-368|CNS DEPRESSANTS ( INCLUDING ALCOHOL|brand
DDI-DrugBank.d703.s0|339-369|DEPRESSANTS ( INCLUDING ALCOHOL )|brand
DDI-DrugBank.d703.s0|352-370|INCLUDING ALCOHOL ) .|brand
DDI-DrugBank.d703.s0|362-368|ALCOHOL|brand
DDI-DrugBank.d703.s1|0-35|RESPIRATORY DEPRESSION , HYPOTENSION ,|brand
DDI-DrugBank.d703.s1|12-39|DEPRESSION , HYPOTENSION , AND|brand
DDI-DrugBank.d703.s1|24-57|HYPOTENSION , AND PROFOUND SEDATION|brand
DDI-DrugBank.d703.s1|37-65|AND PROFOUND SEDATION OR COMA|brand
DDI-DrugBank.d703.s1|41-69|PROFOUND SEDATION OR COMA MAY|brand
DDI-DrugBank.d703.s1|50-76|SEDATION OR COMA MAY RESULT|brand
DDI-DrugBank.d703.s1|59-77|OR COMA MAY RESULT .|brand
DDI-DrugBank.d703.s1|62-77|COMA MAY RESULT .|brand
DDI-DrugBank.d703.s1|67-77|MAY RESULT .|brand
DDI-DrugBank.d703.s1|71-77|RESULT .|brand
DDI-DrugBank.d634.s0|0-13|Anticoagulants|group
DDI-DrugBank.d634.s0|44-57|anticoagulants|group
DDI-DrugBank.d634.s0|119-129|methimazole|drug
DDI-DrugBank.d634.s2|0-34|A dose reduction of beta-adrenergic|brand
DDI-DrugBank.d634.s3|0-19|Digitalis glycosides|group
DDI-DrugBank.d634.s3|22-26|Serum|group
DDI-DrugBank.d634.s3|121-127|regimen|brand
DDI-DrugBank.d634.s4|18-37|digitalis glycosides|group
DDI-DrugBank.d634.s5|0-11|Theophylline|drug
DDI-DrugBank.d634.s5|14-25|Theophylline|drug
DDI-DrugBank.d634.s5|89-100|theophylline|drug
DDI-DrugBank.d634.s6|18-29|theophylline|drug
DDI-DrugBank.d578.s1|78-95|methylprednisolone|drug
DDI-DrugBank.d578.s3|54-71|methylprednisolone|drug
DDI-DrugBank.d578.s4|26-32|enzymes|group
DDI-DrugBank.d578.s4|42-54|phenobarbital|drug
DDI-DrugBank.d578.s4|57-65|phenytoin|drug
DDI-DrugBank.d578.s4|72-79|rifampin|brand
DDI-DrugBank.d578.s4|111-128|methylprednisolone|drug
DDI-DrugBank.d578.s4|159-176|methylprednisolone|drug
DDI-DrugBank.d578.s5|14-27|troleandomycin|drug
DDI-DrugBank.d578.s5|33-44|ketoconazole|drug
DDI-DrugBank.d578.s5|76-93|methylprednisolone|drug
DDI-DrugBank.d578.s6|23-40|methylprednisolone|drug
DDI-DrugBank.d578.s7|0-17|Methylprednisolone|drug
DDI-DrugBank.d578.s7|67-73|aspirin|brand
DDI-DrugBank.d578.s8|40-44|serum|group
DDI-DrugBank.d578.s8|102-119|methylprednisolone|drug
DDI-DrugBank.d578.s9|0-6|Aspirin|brand
DDI-DrugBank.d578.s9|54-68|corticosteroids|group
DDI-DrugBank.d578.s10|14-31|methylprednisolone|drug
DDI-DrugBank.d578.s10|41-54|anticoagulants|group
DDI-DrugBank.d578.s11|106-120|corticosteroids|group
DDI-DrugBank.d578.s12|54-61|maintain|brand
DDI-DrugBank.d678.s0|16-24|pituitary|group
DDI-DrugBank.d678.s0|68-98|corticosteroid therapy , must be|drug
DDI-DrugBank.d678.s0|146-155|Metopirone|brand
DDI-DrugBank.d678.s1|18-27|Metopirone|brand
DDI-DrugBank.d678.s1|47-55|phenytoin|drug
DDI-DrugBank.d678.s2|68-76|phenytoin|drug
DDI-DrugBank.d678.s4|0-9|Metopirone|brand
DDI-DrugBank.d678.s4|43-55|acetaminophen|drug
DDI-DrugBank.d678.s4|87-99|acetaminophen|drug
DDI-DrugBank.d603.s0|37-46|ProAmatine|brand
DDI-DrugBank.d603.s0|52-69|cardiac glycosides|group
DDI-DrugBank.d603.s0|111-114|A.V .|brand
DDI-DrugBank.d603.s2|66-78|phenylephrine|drug
DDI-DrugBank.d603.s2|81-95|pseudoephedrine|drug
DDI-DrugBank.d603.s2|98-106|ephedrine|drug
DDI-DrugBank.d603.s2|109-127|phenylpropanolamine|drug
DDI-DrugBank.d603.s2|132-148|dihydroergotamine|drug
DDI-DrugBank.d603.s2|200-209|ProAmatine|brand
DDI-DrugBank.d603.s2|254-263|ProAmatine|brand
DDI-DrugBank.d603.s2|321-336|vasoconstriction|group
DDI-DrugBank.d603.s3|0-9|ProAmatine|brand
DDI-DrugBank.d603.s3|105-119|fludrocortisone|drug
DDI-DrugBank.d603.s4|18-56|supine hypertension should be carefully|drug
DDI-DrugBank.d603.s4|138-152|fludrocortisone|drug
DDI-DrugBank.d603.s5|0-9|ProAmatine|brand
DDI-DrugBank.d603.s5|54-61|prazosin|drug
DDI-DrugBank.d603.s5|64-72|terazosin|drug
DDI-DrugBank.d603.s5|79-87|doxazosin|drug
DDI-DrugBank.d603.s5|120-129|ProAmatine|brand
DDI-DrugBank.d603.s5|274-297|desglymidodrine ( a base )|drug
DDI-DrugBank.d603.s5|415-423|metformin|drug
DDI-DrugBank.d603.s5|426-435|cimetidine|drug
DDI-DrugBank.d603.s5|438-447|ranitidine|drug
DDI-DrugBank.d603.s5|450-461|procainamide|drug
DDI-DrugBank.d603.s5|464-474|triamterene|drug
DDI-DrugBank.d603.s5|477-486|flecainide|drug
DDI-DrugBank.d603.s5|493-501|quinidine|drug
DDI-DrugBank.d573.s0|17-28|Guanethidine|drug
DDI-DrugBank.d573.s0|40-48|minoxidil|drug
DDI-DrugBank.d573.s0|146-157|guanethidine|drug
DDI-DrugBank.d573.s1|19-30|guanethidine|drug
DDI-DrugBank.d573.s1|67-75|minoxidil|drug
DDI-DrugBank.d573.s2|28-36|minoxidil|drug
DDI-DrugBank.d700.s0|0-7|Antacids|group
DDI-DrugBank.d700.s0|41-48|Myfortic|brand
DDI-DrugBank.d700.s0|163-170|antacids|group
DDI-DrugBank.d700.s0|199-213|AUC ( 0-t ) values|brand
DDI-DrugBank.d700.s0|219-234|MPA were 25 % and|brand
DDI-DrugBank.d700.s0|271-278|Myfortic|brand
DDI-DrugBank.d700.s1|23-30|Myfortic|brand
DDI-DrugBank.d700.s1|36-43|antacids|group
DDI-DrugBank.d700.s2|0-11|Cyclosporine|drug
DDI-DrugBank.d700.s2|64-75|cyclosporine|drug
DDI-DrugBank.d700.s2|78-108|USP ( MODIFIED ) pharmacokinetics|brand
DDI-DrugBank.d700.s2|83-124|MODIFIED ) pharmacokinetics were unaffected|brand
DDI-DrugBank.d700.s2|152-159|Myfortic|brand
DDI-DrugBank.d700.s3|0-34|Acyclovir/Ganciclovir : may be taken|drug
DDI-DrugBank.d700.s3|41-48|Myfortic|brand
DDI-DrugBank.d700.s4|67-71|blood|group
DDI-DrugBank.d700.s5|5-53|acyclovir/ganciclovir and MPAG concentrations are|drug
DDI-DrugBank.d700.s5|31-66|MPAG concentrations are increased in|brand
DDI-DrugBank.d700.s6|47-58|azathioprine|drug
DDI-DrugBank.d700.s6|64-84|mycophenolate mofetil|drug
DDI-DrugBank.d700.s6|94-110|purine metabolism|drug
DDI-DrugBank.d700.s6|136-143|Myfortic|brand
DDI-DrugBank.d700.s6|184-195|azathioprine|drug
DDI-DrugBank.d700.s6|200-220|mycophenolate mofetil|drug
DDI-DrugBank.d700.s7|0-13|Cholestyramine|drug
DDI-DrugBank.d700.s7|40-44|Acids|group
DDI-DrugBank.d700.s7|108-144|MPA exposure when coadministered with|brand
DDI-DrugBank.d700.s7|146-166|mycophenolate mofetil|drug
DDI-DrugBank.d700.s8|29-36|Myfortic|brand
DDI-DrugBank.d700.s8|43-56|cholestyramine|drug
DDI-DrugBank.d700.s8|154-158|acids|group
DDI-DrugBank.d700.s8|204-221|activated charcoal|drug
DDI-DrugBank.d700.s8|275-282|Myfortic|brand
DDI-DrugBank.d700.s9|55-62|Myfortic|brand
DDI-DrugBank.d700.s10|48-83|levonorgesterol AUC was decreased by|drug
DDI-DrugBank.d700.s10|64-86|AUC was decreased by 15|brand
DDI-DrugBank.d700.s10|114-134|mycophenolate mofetil|drug
DDI-DrugBank.d700.s11|80-87|Myfortic|brand
DDI-DrugBank.d700.s11|123-129|control|brand
DDI-DrugBank.d700.s12|0-12|Live Vaccines|group
DDI-DrugBank.d700.s12|37-44|Myfortic|brand
DDI-DrugBank.d700.s12|74-81|vaccines|group
DDI-DrugBank.d700.s15|62-69|Myfortic|brand
DDI-DrugBank.d700.s16|16-42|MPAG hydrolysis may lead to|brand
DDI-DrugBank.d700.s16|49-77|MPA available for absorption .|brand
DDI-DrugBank.d552.s0|0-7|Nabilone|drug
DDI-DrugBank.d552.s0|100-133|CNS depressants , including alcohol|brand
DDI-DrugBank.d552.s0|127-133|alcohol|brand
DDI-DrugBank.d552.s0|136-147|barbiturates|group
DDI-DrugBank.d552.s0|162-171|analgesics|group
DDI-DrugBank.d552.s0|265-277|schizophrenia|group
DDI-DrugBank.d552.s1|0-7|Nabilone|drug
DDI-DrugBank.d552.s1|44-75|CNS depressant effect when given|brand
DDI-DrugBank.d552.s1|89-96|diazepam|drug
DDI-DrugBank.d552.s1|113-118|sodium|group
DDI-DrugBank.d552.s1|121-127|alcohol|brand
DDI-DrugBank.d552.s1|132-138|codeine|drug
DDI-DrugBank.d204.s0|112-122|Anesthetics|group
DDI-DrugBank.d204.s0|185-195|anesthetics|group
DDI-DrugBank.d204.s1|36-42|insulin|group
DDI-DrugBank.d204.s3|37-45|reserpine|drug
DDI-DrugBank.d204.s5|149-157|allergens|group
DDI-DrugBank.d204.s5|237-247|therapeutic|brand
DDI-DrugBank.d204.s6|56-66|epinephrine|drug
DDI-DrugBank.d340.s0|0-9|Nelfinavir|drug
DDI-DrugBank.d340.s0|30-54|CYP3A ( cytochrome P450 3A|drug
DDI-DrugBank.d340.s0|37-51|cytochrome P450|drug
DDI-DrugBank.d340.s1|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s1|64-91|CYP3A ( e.g. , dihydropyridine|drug
DDI-DrugBank.d340.s1|77-117|dihydropyridine calcium channel blockers )|drug
DDI-DrugBank.d340.s1|93-99|calcium|drug
DDI-DrugBank.d340.s1|206-212|prolong|brand
DDI-DrugBank.d340.s1|223-233|therapeutic|brand
DDI-DrugBank.d340.s2|0-9|Nelfinavir|drug
DDI-DrugBank.d340.s2|38-43|C.P.A .|brand
DDI-DrugBank.d340.s3|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s3|51-86|CYP3A may decrease nelfinavir plasma|drug
DDI-DrugBank.d340.s3|70-79|nelfinavir|drug
DDI-DrugBank.d340.s3|118-128|therapeutic|brand
DDI-DrugBank.d340.s4|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s4|52-87|CYP3A may increase nelfinavir plasma|drug
DDI-DrugBank.d340.s4|71-80|nelfinavir|drug
DDI-DrugBank.d340.s5|101-108|VIRACEPT|brand
DDI-DrugBank.d340.s5|114-120|dapsone|drug
DDI-DrugBank.d340.s5|123-181|trimethoprim/sulfamethoxazole , clarithromycin , erythromycin|drug
DDI-DrugBank.d340.s5|154-167|clarithromycin|drug
DDI-DrugBank.d340.s5|170-181|erythromycin|drug
DDI-DrugBank.d340.s5|184-195|itraconazole|drug
DDI-DrugBank.d340.s5|200-210|fluconazole|drug
DDI-DrugBank.d340.s6|45-52|VIRACEPT|brand
DDI-DrugBank.d340.s6|71-80|amiodarone|drug
DDI-DrugBank.d340.s6|83-91|quinidine|drug
DDI-DrugBank.d340.s6|109-118|astemizole|drug
DDI-DrugBank.d340.s6|121-131|terfenadine|drug
DDI-DrugBank.d340.s6|191-198|rifampin|brand
DDI-DrugBank.d340.s6|216-224|midazolam|drug
DDI-DrugBank.d340.s6|227-235|triazolam|drug
DDI-DrugBank.d340.s6|257-265|cisapride|drug
DDI-DrugBank.d340.s7|61-68|VIRACEPT|brand
DDI-DrugBank.d340.s7|96-104|rifabutin|drug
DDI-DrugBank.d340.s8|37-44|VIRACEPT|brand
DDI-DrugBank.d340.s8|84-93|nelfinavir|drug
DDI-DrugBank.d340.s10|0-10|Terfenadine|drug
DDI-DrugBank.d340.s10|31-41|terfenadine|drug
DDI-DrugBank.d340.s10|48-55|VIRACEPT|brand
DDI-DrugBank.d340.s10|97-107|terfenadine|drug
DDI-DrugBank.d340.s11|11-18|VIRACEPT|brand
DDI-DrugBank.d340.s11|65-75|terfenadine|drug
DDI-DrugBank.d340.s12|41-48|VIRACEPT|brand
DDI-DrugBank.d340.s12|100-109|astemizole|drug
DDI-DrugBank.d340.s13|9-16|Protease|drug
DDI-DrugBank.d340.s14|0-8|Indinavir|drug
DDI-DrugBank.d340.s14|31-39|indinavir|drug
DDI-DrugBank.d340.s14|46-53|VIRACEPT|brand
DDI-DrugBank.d340.s14|86-95|nelfinavir|drug
DDI-DrugBank.d340.s14|104-116|AUC and a 51 %|brand
DDI-DrugBank.d340.s14|130-138|indinavir|drug
DDI-DrugBank.d340.s14|147-150|A.C .|brand
DDI-DrugBank.d340.s16|0-8|Ritonavir|drug
DDI-DrugBank.d340.s16|31-39|ritonavir|drug
DDI-DrugBank.d340.s16|46-53|VIRACEPT|brand
DDI-DrugBank.d340.s16|86-95|nelfinavir|drug
DDI-DrugBank.d340.s16|104-129|AUC and very little change|brand
DDI-DrugBank.d340.s16|134-142|ritonavir|drug
DDI-DrugBank.d340.s16|151-154|A.C .|brand
DDI-DrugBank.d340.s18|0-9|Saquinavir|drug
DDI-DrugBank.d340.s18|32-41|saquinavir|drug
DDI-DrugBank.d340.s18|102-111|saquinavir|drug
DDI-DrugBank.d340.s18|126-133|VIRACEPT|brand
DDI-DrugBank.d340.s18|166-175|nelfinavir|drug
DDI-DrugBank.d340.s18|184-208|AUC and a 4-fold increase|brand
DDI-DrugBank.d340.s18|213-222|saquinavir|drug
DDI-DrugBank.d340.s18|231-234|A.C .|brand
DDI-DrugBank.d340.s19|28-37|saquinavir|drug
DDI-DrugBank.d340.s19|44-50|gelatin|drug
DDI-DrugBank.d340.s21|0-9|Antifungal|brand
DDI-DrugBank.d340.s22|0-11|Ketoconazole|drug
DDI-DrugBank.d340.s22|34-45|ketoconazole|drug
DDI-DrugBank.d340.s22|52-59|VIRACEPT|brand
DDI-DrugBank.d340.s22|91-100|nelfinavir|drug
DDI-DrugBank.d340.s22|109-112|A.C .|brand
DDI-DrugBank.d340.s23|92-103|ketoconazole|drug
DDI-DrugBank.d340.s23|109-116|VIRACEPT|brand
DDI-DrugBank.d340.s24|9-29|Reverse Transcriptase|drug
DDI-DrugBank.d340.s25|0-9|Didanosine|drug
DDI-DrugBank.d340.s25|35-44|didanosine|drug
DDI-DrugBank.d340.s26|11-20|nelfinavir|drug
DDI-DrugBank.d340.s26|51-54|food|group
DDI-DrugBank.d340.s26|102-111|didanosine|drug
DDI-DrugBank.d340.s27|0-23|A dose adjustment is not|brand
DDI-DrugBank.d340.s27|37-46|zidovudine|drug
DDI-DrugBank.d340.s27|69-76|VIRACEPT|brand
DDI-DrugBank.d340.s28|77-84|VIRACEPT|brand
DDI-DrugBank.d340.s28|110-119|lamivudine|drug
DDI-DrugBank.d340.s28|124-132|stavudine|drug
DDI-DrugBank.d340.s30|0-8|Rifabutin|drug
DDI-DrugBank.d340.s30|31-39|rifabutin|drug
DDI-DrugBank.d340.s30|45-52|VIRACEPT|brand
DDI-DrugBank.d340.s30|84-93|nelfinavir|drug
DDI-DrugBank.d340.s30|102-115|AUC and a 207 %|brand
DDI-DrugBank.d340.s30|129-137|rifabutin|drug
DDI-DrugBank.d340.s30|146-149|A.C .|brand
DDI-DrugBank.d340.s31|35-43|rifabutin|drug
DDI-DrugBank.d340.s31|106-113|VIRACEPT|brand
DDI-DrugBank.d340.s32|0-7|Rifampin|brand
DDI-DrugBank.d340.s32|30-37|rifampin|brand
DDI-DrugBank.d340.s32|43-50|VIRACEPT|brand
DDI-DrugBank.d340.s32|83-92|nelfinavir|drug
DDI-DrugBank.d340.s32|101-104|A.C .|brand
DDI-DrugBank.d340.s33|0-7|VIRACEPT|brand
DDI-DrugBank.d340.s33|13-20|rifampin|brand
DDI-DrugBank.d340.s35|0-16|Ethinyl Estradiol|group
DDI-DrugBank.d340.s35|22-34|Norethindrone|brand
DDI-DrugBank.d340.s35|57-64|VIRACEPT|brand
DDI-DrugBank.d340.s35|71-95|OVCON-35 resulted in a 47|brand
DDI-DrugBank.d340.s35|110-126|ethinyl estradiol|group
DDI-DrugBank.d340.s35|151-163|norethindrone|brand
DDI-DrugBank.d340.s36|82-89|VIRACEPT|brand
DDI-DrugBank.d330.s0|174-181|neomycin|drug
DDI-DrugBank.d330.s1|86-95|polymyxins|group
DDI-DrugBank.d330.s1|122-129|neomycin|drug
DDI-DrugBank.d330.s1|182-189|neomycin|drug
DDI-DrugBank.d330.s2|5-12|neomycin|drug
DDI-DrugBank.d330.s2|58-83|penicillin V , oral vitamin|drug
DDI-DrugBank.d330.s2|69-88|V , oral vitamin B-12|brand
DDI-DrugBank.d330.s2|85-121|B-12 , methotrexate and 5-fluorouracil|brand
DDI-DrugBank.d330.s2|91-102|methotrexate|drug
DDI-DrugBank.d330.s2|108-121|5-fluorouracil|drug
DDI-DrugBank.d330.s3|35-41|digoxin|drug
DDI-DrugBank.d330.s4|11-17|digoxin|drug
DDI-DrugBank.d330.s5|5-12|neomycin|drug
DDI-DrugBank.d330.s5|48-55|coumarin|drug
DDI-DrugBank.d330.s5|60-73|anticoagulants|group
DDI-DrugBank.d330.s5|89-97|vitamin K|group
DDI-DrugBank.d276.s0|0-7|Antacids|group
DDI-DrugBank.d276.s0|20-28|magnesium|drug
DDI-DrugBank.d276.s0|80-93|nitrofurantoin|drug
DDI-DrugBank.d276.s1|47-56|adsorption|group
DDI-DrugBank.d276.s1|61-74|nitrofurantoin|drug
DDI-DrugBank.d276.s1|96-104|magnesium|drug
DDI-DrugBank.d276.s2|26-35|probenecid|drug
DDI-DrugBank.d276.s2|41-54|sulfinpyrazone|drug
DDI-DrugBank.d276.s2|96-109|nitrofurantoin|drug
DDI-DrugBank.d276.s3|26-39|nitrofurantoin|drug
DDI-DrugBank.d276.s3|155-167|antibacterial|brand
DDI-DrugBank.d276.s4|65-78|nitrofurantoin|drug
DDI-DrugBank.d276.s4|111-117|glucose|group
DDI-DrugBank.d276.s4|126-141|urine may occur .|drug
DDI-DrugBank.d276.s5|53-61|solutions|group
DDI-DrugBank.d276.s5|80-86|glucose|group
DDI-DrugBank.d217.s0|26-37|theophylline|drug
DDI-DrugBank.d217.s0|75-88|quinolone use .|drug
DDI-DrugBank.d217.s1|101-111|norfloxacin|drug
DDI-DrugBank.d217.s1|117-128|theophylline|drug
DDI-DrugBank.d217.s2|25-36|theophylline|drug
DDI-DrugBank.d217.s2|87-98|theophylline|drug
DDI-DrugBank.d217.s3|9-13|serum|group
DDI-DrugBank.d217.s3|25-36|cyclosporine|drug
DDI-DrugBank.d217.s3|81-92|cyclosporine|drug
DDI-DrugBank.d217.s3|99-109|norfloxacin|drug
DDI-DrugBank.d217.s4|11-22|cyclosporine|drug
DDI-DrugBank.d217.s4|73-84|cyclosporine|drug
DDI-DrugBank.d217.s5|0-9|Quinolones|group
DDI-DrugBank.d217.s5|22-32|norfloxacin|drug
DDI-DrugBank.d217.s5|67-80|anticoagulants|group
DDI-DrugBank.d217.s5|93-100|warfarin|drug
DDI-DrugBank.d217.s6|52-62|prothrombin|drug
DDI-DrugBank.d217.s7|34-43|quinolones|group
DDI-DrugBank.d217.s7|55-65|norfloxacin|drug
DDI-DrugBank.d217.s7|72-80|glyburide|drug
DDI-DrugBank.d217.s8|25-29|blood|group
DDI-DrugBank.d217.s9|32-42|norfloxacin|drug
DDI-DrugBank.d217.s9|103-112|probenecid|drug
DDI-DrugBank.d217.s9|118-128|norfloxacin|drug
DDI-DrugBank.d217.s10|23-36|nitrofurantoin|drug
DDI-DrugBank.d217.s10|63-76|nitrofurantoin|drug
DDI-DrugBank.d217.s10|97-109|antibacterial|brand
DDI-DrugBank.d217.s10|121-131|Norfloxacin|drug
DDI-DrugBank.d217.s11|0-12|Multivitamins|brand
DDI-DrugBank.d217.s11|44-47|iron|drug
DDI-DrugBank.d217.s11|52-55|zinc|drug
DDI-DrugBank.d217.s11|58-65|antacids|group
DDI-DrugBank.d217.s11|70-79|sucralfate|drug
DDI-DrugBank.d217.s11|172-182|norfloxacin|drug
DDI-DrugBank.d217.s11|247-251|serum|group
DDI-DrugBank.d217.s11|257-284|urine levels of norfloxacin .|drug
DDI-DrugBank.d217.s11|273-283|norfloxacin|drug
DDI-DrugBank.d217.s12|0-4|Videx|brand
DDI-DrugBank.d217.s12|7-16|Didanosine|drug
DDI-DrugBank.d217.s12|78-85|solution|brand
DDI-DrugBank.d217.s12|178-188|norfloxacin|drug
DDI-DrugBank.d217.s12|263-267|serum|group
DDI-DrugBank.d217.s12|273-300|urine levels of norfloxacin .|drug
DDI-DrugBank.d217.s12|289-299|norfloxacin|drug
DDI-DrugBank.d217.s13|5-14|quinolones|group
DDI-DrugBank.d217.s13|73-80|caffeine|drug
DDI-DrugBank.d217.s14|38-45|caffeine|drug
DDI-DrugBank.d747.s0|0-11|Tetracycline|drug
DDI-DrugBank.d747.s0|31-40|antibiotic|brand
DDI-DrugBank.d747.s0|85-116|penicillin and concurrent use of|drug
DDI-DrugBank.d728.s1|48-55|ELOXATIN|brand
DDI-DrugBank.d728.s1|72-96|5-FU has been observed in|brand
DDI-DrugBank.d728.s2|13-55|5-FU plasma concentrations by approximately|brand
DDI-DrugBank.d728.s2|104-111|ELOXATIN|brand
DDI-DrugBank.d728.s3|6-13|platinum|drug
DDI-DrugBank.d758.s0|4-38|CNS depressant effects of oxycodone|brand
DDI-DrugBank.d758.s0|30-38|oxycodone|drug
DDI-DrugBank.d758.s0|89-105|CNS depressants ..|brand
DDI-DrugBank.d665.s0|63-74|erythromycin|drug
DDI-DrugBank.d665.s0|77-88|tetracycline|drug
DDI-DrugBank.d665.s0|132-142|penicillins|group
DDI-DrugBank.d665.s5|97-109|antibacterial|brand
DDI-DrugBank.d665.s5|132-163|penicillin therapy first , should|drug
DDI-DrugBank.d665.s6|0-29|Penicillin blood levels may be|drug
DDI-DrugBank.d665.s6|11-15|blood|group
DDI-DrugBank.d665.s6|73-82|probenecid|drug
DDI-DrugBank.d665.s6|128-138|penicillins|group
DDI-DrugBank.d665.s7|16-53|penicillin from plasma protein binding|drug
DDI-DrugBank.d665.s7|92-115|penicillin in the serum .|drug
DDI-DrugBank.d665.s7|110-114|serum|group
DDI-DrugBank.d628.s0|35-42|DIPRIVAN|brand
DDI-DrugBank.d628.s0|158-166|narcotics|group
DDI-DrugBank.d628.s0|173-180|morphine|drug
DDI-DrugBank.d628.s0|183-192|meperidine|drug
DDI-DrugBank.d628.s0|199-206|fentanyl|drug
DDI-DrugBank.d628.s1|20-26|opioids|group
DDI-DrugBank.d628.s1|64-75|barbiturates|group
DDI-DrugBank.d628.s1|78-92|chloral hydrate|drug
DDI-DrugBank.d628.s1|95-104|droperidol|drug
DDI-DrugBank.d628.s2|30-39|anesthetic|brand
DDI-DrugBank.d628.s2|64-71|DIPRIVAN|brand
DDI-DrugBank.d628.s3|58-65|DIPRIVAN|brand
DDI-DrugBank.d628.s3|229-237|analgesic|brand
DDI-DrugBank.d628.s3|251-263|nitrous oxide|drug
DDI-DrugBank.d628.s3|268-274|opioids|group
DDI-DrugBank.d628.s4|65-74|isoflurane|drug
DDI-DrugBank.d628.s4|77-85|enflurane|drug
DDI-DrugBank.d628.s4|92-100|halothane|drug
DDI-DrugBank.d628.s4|127-134|DIPRIVAN|brand
DDI-DrugBank.d628.s5|63-72|anesthetic|brand
DDI-DrugBank.d628.s5|119-126|DIPRIVAN|brand
DDI-DrugBank.d628.s6|0-7|DIPRIVAN|brand
DDI-DrugBank.d628.s6|140-168|neuromuscular blocking agents|group
DDI-DrugBank.d628.s6|175-189|succinylcholine|drug
DDI-DrugBank.d628.s6|211-216|muscle|brand
DDI-DrugBank.d628.s7|136-141|muscle|brand
DDI-DrugBank.d628.s7|175-183|analgesic|brand
DDI-DrugBank.d628.s7|203-212|anesthetic|brand
DDI-DrugBank.d710.s0|0-9|Cimetidine|drug
DDI-DrugBank.d710.s0|35-44|cimetidine|drug
DDI-DrugBank.d710.s0|71-81|rimantadine|drug
DDI-DrugBank.d710.s1|29-39|rimantadine|drug
DDI-DrugBank.d710.s1|95-104|Cimetidine|drug
DDI-DrugBank.d710.s1|152-162|rimantadine|drug
DDI-DrugBank.d710.s1|270-280|rimantadine|drug
DDI-DrugBank.d710.s1|299-302|same|drug
DDI-DrugBank.d710.s1|331-340|cimetidine|drug
DDI-DrugBank.d710.s2|0-12|Acetaminophen|drug
DDI-DrugBank.d710.s2|15-25|Rimantadine|drug
DDI-DrugBank.d710.s3|11-23|acetaminophen|drug
DDI-DrugBank.d710.s4|24-34|rimantadine|drug
DDI-DrugBank.d710.s5|22-34|acetaminophen|drug
DDI-DrugBank.d710.s5|71-99|AUC values for rimantadine by|brand
DDI-DrugBank.d710.s5|86-96|rimantadine|drug
DDI-DrugBank.d710.s6|0-6|Aspirin|brand
DDI-DrugBank.d710.s6|9-19|Rimantadine|drug
DDI-DrugBank.d710.s7|11-17|aspirin|brand
DDI-DrugBank.d710.s8|24-34|rimantadine|drug
DDI-DrugBank.d710.s9|31-61|AUC of rimantadine were reduced|brand
DDI-DrugBank.d710.s9|38-48|rimantadine|drug
DDI-DrugBank.d710.s9|100-106|aspirin|brand
DDI-DrugBank.d591.s0|0-10|Ropivacaine|drug
DDI-DrugBank.d591.s0|74-84|anesthetics|group
DDI-DrugBank.d591.s0|137-147|anesthetics|group
DDI-DrugBank.d591.s1|11-36|P4501A2 is involved in the|drug
DDI-DrugBank.d591.s1|61-71|ropivacaine|drug
DDI-DrugBank.d591.s1|78-82|major|brand
DDI-DrugBank.d591.s2|33-43|ropivacaine|drug
DDI-DrugBank.d591.s2|91-101|fluvoxamine|drug
DDI-DrugBank.d591.s2|150-166|CYP1A2 inhibitor .|drug
DDI-DrugBank.d591.s3|37-64|P4501A2 , such as fluvoxamine|drug
DDI-DrugBank.d591.s3|54-64|fluvoxamine|drug
DDI-DrugBank.d591.s3|112-122|Ropivacaine|drug
DDI-DrugBank.d591.s3|143-153|Ropivacaine|drug
DDI-DrugBank.d591.s3|176-186|ropivacaine|drug
DDI-DrugBank.d591.s4|33-69|CYP1A2 inhibitors are coadministered .|drug
DDI-DrugBank.d591.s5|60-97|CYP1A2 via competitive inhibition such|drug
DDI-DrugBank.d591.s5|102-113|theophylline|drug
DDI-DrugBank.d591.s5|119-128|imipramine|drug
DDI-DrugBank.d591.s6|56-80|CYP3A4 , ketoconazole ( 100|drug
DDI-DrugBank.d591.s6|64-75|ketoconazole|drug
DDI-DrugBank.d591.s6|105-115|ropivacaine|drug
DDI-DrugBank.d591.s6|152-163|ketoconazole|drug
DDI-DrugBank.d591.s6|220-230|ropivacaine|drug
DDI-DrugBank.d576.s0|0-10|Salicylates|group
DDI-DrugBank.d576.s1|0-6|ASPIRIN|brand
DDI-DrugBank.d576.s1|12-41|OTHER SALICYLATE DRUGS WILL BE|brand
DDI-DrugBank.d576.s1|18-50|SALICYLATE DRUGS WILL BE ADDITIVE|brand
DDI-DrugBank.d576.s1|29-53|DRUGS WILL BE ADDITIVE TO|brand
DDI-DrugBank.d576.s1|35-62|WILL BE ADDITIVE TO DISALCID|brand
DDI-DrugBank.d576.s1|40-66|BE ADDITIVE TO DISALCID AND|brand
DDI-DrugBank.d576.s1|43-70|ADDITIVE TO DISALCID AND MAY|brand
DDI-DrugBank.d576.s1|52-79|TO DISALCID AND MAY INCREASE|brand
DDI-DrugBank.d576.s1|55-62|DISALCID|brand
DDI-DrugBank.d576.s1|68-104|MAY INCREASE PLASMA CONCENTRATIONS OF|brand
DDI-DrugBank.d576.s1|72-114|INCREASE PLASMA CONCENTRATIONS OF SALICYLIC|brand
DDI-DrugBank.d576.s1|81-119|PLASMA CONCENTRATIONS OF SALICYLIC ACID|brand
DDI-DrugBank.d576.s1|88-122|CONCENTRATIONS OF SALICYLIC ACID TO|brand
DDI-DrugBank.d576.s1|103-128|OF SALICYLIC ACID TO TOXIC|brand
DDI-DrugBank.d576.s1|106-119|SALICYLIC ACID|drug
DDI-DrugBank.d576.s1|124-136|TOXIC LEVELS .|brand
DDI-DrugBank.d576.s1|130-136|LEVELS .|brand
DDI-DrugBank.d576.s2|27-54|urine pH will increase renal|drug
DDI-DrugBank.d576.s2|33-34|pH|drug
DDI-DrugBank.d576.s2|91-104|salicylic acid|drug
DDI-DrugBank.d576.s4|0-10|Salicylates|group
DDI-DrugBank.d576.s4|61-92|predispose to systemic bleeding .|drug
DDI-DrugBank.d576.s5|0-10|Salicylates|group
DDI-DrugBank.d576.s6|78-110|penicillin , thiopental , thyroxine|drug
DDI-DrugBank.d576.s6|90-99|thiopental|drug
DDI-DrugBank.d576.s6|102-139|thyroxine , triiodothyronine , phenytoin|drug
DDI-DrugBank.d576.s6|113-128|triiodothyronine|group
DDI-DrugBank.d576.s6|131-139|phenytoin|drug
DDI-DrugBank.d576.s6|142-155|sulfinpyrazone|drug
DDI-DrugBank.d576.s6|158-165|naproxen|drug
DDI-DrugBank.d576.s6|168-175|warfarin|drug
DDI-DrugBank.d576.s6|178-189|methotrexate|drug
DDI-DrugBank.d576.s6|205-219|corticosteroids|group
DDI-DrugBank.d576.s7|60-66|thyroid|brand
DDI-DrugBank.d576.s7|98-105|proteins|group
DDI-DrugBank.d576.s7|153-177|T4 value in some patients|drug
DDI-DrugBank.d576.s8|0-6|thyroid|brand
DDI-DrugBank.d599.s0|83-85|GH .|brand
DDI-DrugBank.d599.s1|14-46|ACTH deficiency should have their|brand
DDI-DrugBank.d599.s2|11-18|Nutropin|brand
DDI-DrugBank.d599.s3|78-85|Nutropin|brand
DDI-DrugBank.d599.s5|51-58|Nutropin|brand
DDI-DrugBank.d599.s6|37-74|GH treatment increases cytochrome P450|brand
DDI-DrugBank.d599.s6|60-74|cytochrome P450|drug
DDI-DrugBank.d599.s6|77-112|CP450 ) mediated antipyrine clearance|drug
DDI-DrugBank.d599.s6|93-102|antipyrine|drug
DDI-DrugBank.d599.s7|24-54|GH administration may alter the|brand
DDI-DrugBank.d599.s7|106-130|CP450 liver enzymes ( e.g.|drug
DDI-DrugBank.d599.s7|118-124|enzymes|group
DDI-DrugBank.d599.s7|133-147|corticosteroids|group
DDI-DrugBank.d599.s7|154-161|steroids|group
DDI-DrugBank.d599.s7|164-178|anticonvulsants|group
DDI-DrugBank.d599.s8|37-69|GH is administered in combination|brand
DDI-DrugBank.d599.s8|115-134|CP450 liver enzymes .|drug
DDI-DrugBank.d599.s8|127-133|enzymes|group
DDI-DrugBank.d602.s0|42-48|NEXAVAR|brand
DDI-DrugBank.d602.s0|97-131|predominantly by the UGT1A1 pathway|drug
DDI-DrugBank.d602.s0|118-137|UGT1A1 pathway ( e.g .|drug
DDI-DrugBank.d602.s0|139-148|irinotecan|drug
DDI-DrugBank.d602.s1|27-33|NEXAVAR|brand
DDI-DrugBank.d602.s1|69-87|AUC of doxorubicin .|brand
DDI-DrugBank.d602.s1|76-86|doxorubicin|drug
DDI-DrugBank.d602.s2|42-52|doxorubicin|drug
DDI-DrugBank.d602.s2|59-65|NEXAVAR|brand
DDI-DrugBank.d602.s3|0-8|Sorafenib|drug
DDI-DrugBank.d602.s3|19-44|CYP2B6 and CYP2C8 in vitro|drug
DDI-DrugBank.d602.s3|30-52|CYP2C8 in vitro with Ki|drug
DDI-DrugBank.d602.s3|75-90|M , respectively .|brand
DDI-DrugBank.d602.s4|35-63|CYP2B6 and CYP2C8 is expected|drug
DDI-DrugBank.d602.s4|46-75|CYP2C8 is expected to increase|drug
DDI-DrugBank.d602.s4|103-109|NEXAVAR|brand
DDI-DrugBank.d602.s5|56-85|CYP2B6 and CYP2C8 with NEXAVAR|drug
DDI-DrugBank.d602.s5|67-86|CYP2C8 with NEXAVAR .|drug
DDI-DrugBank.d602.s5|79-85|NEXAVAR|brand
DDI-DrugBank.d732.s0|0-5|CHEMET|brand
DDI-DrugBank.d732.s0|59-62|iron|drug
DDI-DrugBank.d732.s2|30-35|CHEMET|brand
DDI-DrugBank.d732.s2|82-105|EDTA is not recommended .|brand
DDI-DrugBank.d732.s3|35-42|Succimer|drug
DDI-DrugBank.d732.s3|63-67|serum|group
DDI-DrugBank.d732.s4|28-35|succimer|drug
DDI-DrugBank.d732.s4|73-79|ketones|group
DDI-DrugBank.d732.s4|84-122|urine using nitroprusside reagents such|drug
DDI-DrugBank.d732.s4|96-108|nitroprusside|drug
DDI-DrugBank.d732.s4|177-181|serum|group
DDI-DrugBank.d732.s4|197-200|CPK .|brand
DDI-DrugBank.d693.s0|22-31|folic acid|drug
DDI-DrugBank.d693.s0|37-43|digoxin|drug
DDI-DrugBank.d693.s0|119-131|sulfasalazine|drug
DDI-DrugBank.d693.s1|20-32|sulfasalazine|drug
DDI-DrugBank.d693.s1|58-69|methotrexate|drug
DDI-DrugBank.d693.s1|115-123|arthritis|brand
DDI-DrugBank.d693.s2|15-27|sulfasalazine|drug
DDI-DrugBank.d693.s2|67-78|methotrexate|drug
DDI-DrugBank.d693.s2|163-171|arthritis|brand
DDI-DrugBank.d693.s4|51-63|sulfasalazine|drug
DDI-DrugBank.d693.s4|87-90|body|brand
DDI-DrugBank.d693.s5|0-22|REFERENCES 7.Farr M , et|brand
DDI-DrugBank.d693.s5|18-26|M , et al .|brand
DDI-DrugBank.d693.s6|35-82|sulphasalazine therapy in inflammatory arthritis|drug
DDI-DrugBank.d693.s6|74-82|arthritis|brand
DDI-DrugBank.d743.s0|0-11|Ketoconazole|drug
DDI-DrugBank.d743.s0|82-93|ketoconazole|drug
DDI-DrugBank.d743.s0|121-131|terfenadine|drug
DDI-DrugBank.d743.s0|145-177|QT interval prolongation and rare|brand
DDI-DrugBank.d743.s1|0-4|death|drug
DDI-DrugBank.d743.s2|35-46|ketoconazole|drug
DDI-DrugBank.d743.s2|84-94|terfenadine|drug
DDI-DrugBank.d743.s2|126-136|terfenadine|drug
DDI-DrugBank.d743.s3|22-32|terfenadine|drug
DDI-DrugBank.d743.s3|99-119|QT and QTc intervals .|brand
DDI-DrugBank.d743.s4|30-41|ketoconazole|drug
DDI-DrugBank.d743.s4|47-57|terfenadine|drug
DDI-DrugBank.d743.s5|0-11|Itraconazole|drug
DDI-DrugBank.d743.s5|54-64|terfenadine|drug
DDI-DrugBank.d743.s5|118-128|terfenadine|drug
DDI-DrugBank.d743.s5|134-145|itraconazole|drug
DDI-DrugBank.d743.s5|169-180|itraconazole|drug
DDI-DrugBank.d743.s6|4-8|death|drug
DDI-DrugBank.d743.s7|30-41|itraconazole|drug
DDI-DrugBank.d743.s7|47-57|terfenadine|drug
DDI-DrugBank.d743.s8|51-60|antifungal|brand
DDI-DrugBank.d743.s8|80-90|fluconazole|drug
DDI-DrugBank.d743.s8|93-105|metronidazole|drug
DDI-DrugBank.d743.s8|112-121|miconazole|drug
DDI-DrugBank.d743.s8|127-138|ketoconazole|drug
DDI-DrugBank.d743.s8|145-156|itraconazole|drug
DDI-DrugBank.d743.s8|198-208|terfenadine|drug
DDI-DrugBank.d743.s9|0-9|Macrolides|group
DDI-DrugBank.d743.s9|60-71|erythromycin|drug
DDI-DrugBank.d743.s9|77-90|clarithromycin|drug
DDI-DrugBank.d743.s9|115-125|terfenadine|drug
DDI-DrugBank.d743.s9|185-196|ketoconazole|drug
DDI-DrugBank.d743.s10|9-20|erythromycin|drug
DDI-DrugBank.d743.s10|64-74|terfenadine|drug
DDI-DrugBank.d743.s10|110-120|terfenadine|drug
DDI-DrugBank.d743.s11|0-28|A few spontaneous accounts of|brand
DDI-DrugBank.d743.s11|30-70|QT interval prolongation with ventricular|brand
DDI-DrugBank.d743.s11|155-166|erythromycin|drug
DDI-DrugBank.d743.s11|171-184|troleandomycin|drug
DDI-DrugBank.d743.s12|30-40|terfenadine|drug
DDI-DrugBank.d743.s12|47-60|clarithromycin|drug
DDI-DrugBank.d743.s12|63-74|erythromycin|drug
DDI-DrugBank.d743.s12|80-93|troleandomycin|drug
DDI-DrugBank.d743.s12|202-212|terfenadine|drug
DDI-DrugBank.d743.s12|258-269|azithromycin|drug
DDI-DrugBank.d743.s13|46-56|terfenadine|drug
DDI-DrugBank.d743.s13|63-74|azithromycin|drug
DDI-DrugBank.d721.s0|23-28|SKELID|brand
DDI-DrugBank.d721.s0|50-56|calcium|drug
DDI-DrugBank.d721.s0|64-70|calcium|drug
DDI-DrugBank.d721.s0|76-81|SKELID|brand
DDI-DrugBank.d721.s0|107-110|same|drug
DDI-DrugBank.d721.s0|168-175|antacids|group
DDI-DrugBank.d721.s0|210-215|SKELID|brand
DDI-DrugBank.d721.s1|0-6|Aspirin|brand
DDI-DrugBank.d721.s1|40-45|SKELID|brand
DDI-DrugBank.d721.s1|85-90|SKELID|brand
DDI-DrugBank.d721.s2|23-28|SKELID|brand
DDI-DrugBank.d721.s2|55-66|indomethacin|drug
DDI-DrugBank.d721.s2|124-133|diclofenac|drug
DDI-DrugBank.d721.s3|34-40|digoxin|drug
DDI-DrugBank.d721.s3|76-81|SKELID|brand
DDI-DrugBank.d721.s4|27-64|tiludronate does not displace warfarin|drug
DDI-DrugBank.d721.s4|57-64|warfarin|drug
DDI-DrugBank.d751.s0|0-8|AGGRASTAT|brand
DDI-DrugBank.d751.s0|46-52|aspirin|brand
DDI-DrugBank.d751.s0|58-64|heparin|drug
DDI-DrugBank.d751.s1|11-19|AGGRASTAT|brand
DDI-DrugBank.d751.s1|42-48|heparin|drug
DDI-DrugBank.d751.s1|54-60|aspirin|brand
DDI-DrugBank.d751.s1|124-130|heparin|drug
DDI-DrugBank.d751.s1|136-142|aspirin|brand
DDI-DrugBank.d774.s0|0-9|Trilostane|drug
DDI-DrugBank.d774.s0|29-45|aminoglutethimide|drug
DDI-DrugBank.d774.s0|50-57|mitotane|drug
DDI-DrugBank.d263.s0|0-9|Zidovudine|drug
DDI-DrugBank.d263.s0|72-100|ZDV and zalcitabine which has|brand
DDI-DrugBank.d263.s0|80-90|zalcitabine|drug
DDI-DrugBank.d263.s1|0-10|Zalcitabine|drug
DDI-DrugBank.d263.s1|83-98|ZDV , as shown in|brand
DDI-DrugBank.d263.s1|120-124|blood|group
DDI-DrugBank.d263.s1|172-188|U937 and Molt-4 ) .|drug
DDI-DrugBank.d263.s2|7-10|same|drug
DDI-DrugBank.d263.s2|36-45|didanosine|drug
DDI-DrugBank.d263.s2|51-59|stavudine|drug
DDI-DrugBank.d263.s2|127-137|zalcitabine|drug
DDI-DrugBank.d263.s2|153-157|blood|group
DDI-DrugBank.d263.s3|0-9|Lamivudine|drug
DDI-DrugBank.d263.s3|43-47|blood|group
DDI-DrugBank.d263.s3|68-97|U937 and Molt-4 cells revealed|drug
DDI-DrugBank.d263.s3|104-113|lamivudine|drug
DDI-DrugBank.d263.s3|139-149|zalcitabine|drug
DDI-DrugBank.d263.s4|129-139|zalcitabine|drug
DDI-DrugBank.d263.s4|188-198|zalcitabine|drug
DDI-DrugBank.d263.s5|0-10|Zalcitabine|drug
DDI-DrugBank.d263.s5|22-31|lamivudine|drug
DDI-DrugBank.d263.s6|78-87|lamivudine|drug
DDI-DrugBank.d263.s6|135-144|lamivudine|drug
DDI-DrugBank.d263.s6|180-192|deoxycytidine|group
DDI-DrugBank.d263.s6|206-216|zalcitabine|drug
DDI-DrugBank.d263.s7|66-76|zalcitabine|drug
DDI-DrugBank.d263.s7|82-91|lamivudine|drug
DDI-DrugBank.d263.s7|173-183|zalcitabine|drug
DDI-DrugBank.d263.s7|241-251|zalcitabine|drug
DDI-DrugBank.d263.s9|19-29|zalcitabine|drug
DDI-DrugBank.d263.s9|35-44|lamivudine|drug
DDI-DrugBank.d263.s10|0-9|Saquinavir|drug
DDI-DrugBank.d263.s10|31-35|HIVID|brand
DDI-DrugBank.d263.s10|38-47|saquinavir|drug
DDI-DrugBank.d263.s10|54-75|ZDV has been studied (|brand
DDI-DrugBank.d263.s12|68-72|HIVID|brand
DDI-DrugBank.d263.s13|104-118|chloramphenicol|drug
DDI-DrugBank.d263.s13|121-129|cisplatin|drug
DDI-DrugBank.d263.s13|132-138|dapsone|drug
DDI-DrugBank.d263.s13|141-150|disulfiram|drug
DDI-DrugBank.d263.s13|153-163|ethionamide|drug
DDI-DrugBank.d263.s13|166-177|glutethimide|drug
DDI-DrugBank.d263.s13|180-183|gold|group
DDI-DrugBank.d263.s13|186-196|hydralazine|drug
DDI-DrugBank.d263.s13|211-219|isoniazid|drug
DDI-DrugBank.d263.s13|222-234|metronidazole|drug
DDI-DrugBank.d263.s13|237-250|nitrofurantoin|drug
DDI-DrugBank.d263.s13|253-261|phenytoin|drug
DDI-DrugBank.d263.s13|264-272|ribavirin|drug
DDI-DrugBank.d263.s13|279-289|vincristine|drug
DDI-DrugBank.d263.s14|19-23|HIVID|brand
DDI-DrugBank.d263.s14|30-39|didanosine|drug
DDI-DrugBank.d263.s15|12-22|Pentamidine|drug
DDI-DrugBank.d263.s15|40-44|HIVID|brand
DDI-DrugBank.d263.s16|0-4|Death|drug
DDI-DrugBank.d263.s16|68-78|pentamidine|drug
DDI-DrugBank.d263.s16|84-88|HIVID|brand
DDI-DrugBank.d263.s17|15-25|pentamidine|drug
DDI-DrugBank.d263.s17|95-99|HIVID|brand
DDI-DrugBank.d263.s18|14-22|Foscarnet|drug
DDI-DrugBank.d263.s18|74-82|foscarnet|drug
DDI-DrugBank.d263.s18|247-257|zalcitabine|drug
DDI-DrugBank.d263.s19|56-60|HIVID|brand
DDI-DrugBank.d263.s20|0-9|Probenecid|drug
DDI-DrugBank.d263.s20|14-23|Cimetidine|drug
DDI-DrugBank.d263.s20|56-65|probenecid|drug
DDI-DrugBank.d263.s20|70-79|cimetidine|drug
DDI-DrugBank.d263.s20|110-120|zalcitabine|drug
DDI-DrugBank.d263.s20|179-189|zalcitabine|drug
DDI-DrugBank.d263.s21|51-61|zalcitabine|drug
DDI-DrugBank.d263.s21|121-131|zalcitabine|drug
DDI-DrugBank.d263.s22|30-36|Antacid|brand
DDI-DrugBank.d263.s22|62-72|zalcitabine|drug
DDI-DrugBank.d263.s22|171-177|antacid|brand
DDI-DrugBank.d263.s23|64-74|zalcitabine|drug
DDI-DrugBank.d263.s23|160-167|antacids|group
DDI-DrugBank.d263.s24|0-13|Metoclopramide|drug
DDI-DrugBank.d263.s24|75-85|zalcitabine|drug
DDI-DrugBank.d263.s24|91-104|metoclopramide|drug
DDI-DrugBank.d263.s25|0-10|Doxorubicin|drug
DDI-DrugBank.d263.s25|13-23|Doxorubicin|drug
DDI-DrugBank.d263.s25|46-56|zalcitabine|drug
DDI-DrugBank.d263.s25|100-108|phosphate|brand
DDI-DrugBank.d263.s26|32-42|zalcitabine|drug
